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ABSTRACT 
 
Ovarian stimulation plays a pivotal role in assisted reproductive therapies, to 
increase the number of embryos available for treatment; however, there is no 
clear consensus from meta-analyses in the literature which, if any, of the 
preparations in use are superior in terms of clinical outcomes. The aim of this 
thesis was to examine the effect of common human gonadotrophin 
preparations with different half lives and LH activity (hMG, rFSH and 
Pergoveris) on embryo quality and resulting offspring, compared to non-
stimulated negative controls and positive PMSG treated controls, using the 
mouse model. The studies in this thesis indicated that an LH ceiling threshold 
is evident during folliculogenesis, where the use of long acting LH 
preparations resulted in higher numbers of fragmented oocytes, absent of 
cumulus cells (P<0.001), reduced expression of the pro and anti-angiogenic 
factors, MYHII and PEDF in cumulus cells (P<0.05), increased embryonic 
developmental arrest (P<0.001) and perturbed IGF2 (P<0.05) and VEGFA 
gene expression in resulting blastocysts (P<0.01), compared to negative 
controls. Use of preparations containing LH bioactivity resulted in offspring 
with altered total body weight trajectories and internal organ weight 
abnormalities (P<0.05), which were, in some instances, compounded by in 
vitro culture. In addition, we elucidated a relationship between FSH half life 
differences between urinary and recombinant preparations and embryo 
quality. The urinary human gonadotrophin preparation, hMG, could yield 
developmentally competent embryos at lower concentrations, than the 
recombinant Pergoveris treatment. In addition to FSH, these preparations 
contain LH and both low doses of preparations composed of short half life 
rFSH and rLH and high doses of preparations containing long acting LH 
bioactivity, resulted in the highest rates of developmental arrest. These 
groups were observed to have complete absence of H19 expression. The 
results of this thesis provide clear evidence that ovarian stimulation does 
negatively impact the embryo and subsequent offspring and provides support 
for an LH ceiling threshold, above which detrimental effects occur, both on in 
vitro embryo development and in vivo foetal development, which later effects 
postnatal growth. 
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CHAPTER 1: LITERATURE REVIEW 
 
1.1 THE IMPORTANCE OF OVARIAN STIMULATION 
The use of controlled ovarian stimulation (COS) plays a pivotal role in 
assisted reproductive therapies (ART) to increase the number of embryos 
available for treatment of couples unable to conceive by conventional 
means. Infertility is defined as the inability of a couple to spontaneously 
conceive following one year of regular unprotected sexual intercourse 
(Frey and Patel, 2004). Infertility is escalating at an unprecedented rate 
with a current estimate of 1 in 6 UK couples encountering problems 
conceiving (Kamel, 2010). A wide variety of options are now available for 
the clinical management of infertility. Routine treatments include intra-
uterine insemination (IUI), in vitro fertilisation (IVF) and intra-cytoplasmic 
sperm injection (ICSI) and more recently pre-implantation genetic 
diagnosis/screening (PGD/PGS). The number of ART procedures annually 
undertaken is increasing with an uptake of 5.8% from 2006-2007 (HFEA, 
2009). Thus it is imperative to continually refine and advance techniques 
such as the super-ovulatory regimes employed to improve the outcomes 
of treatment.  
 
The first successful IVF birth resulted from a single oocyte aspirated 
during a natural menstrual cycle, soon after the luteinising hormone (LH) 
surge. Following the transfer of 32 cleavage stage embryos to recipient 
mothers, only four patients achieved pregnancy, of which three 
miscarried. One went to full term to become Louise Brown (Edwards et 
al., 1980). It was logically deduced, therefore, that stimulating the ovaries 
would enable a greater number of mature follicles from the developing 
cohort to be retrieved, permitting several embryos to be transferred in 
order to increase success rates (Wood et al., 1985). Edwards and Steptoe 
had considered this and originally used human menopausal gonadotrophin 
(hMG) and human chorionic gonadotrophin (hCG) in a COS regime 
discussed in more detail in section 1.6.1. However, after repeated failures 
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they reverted back to natural cycle IVF under the assumption that the 
observed shortening of the luteal phase of stimulated women may be 
having an adverse effect on the pregnancy rates (Beall and DeCherney, 
2012). Superovulation protocols, whereby exogenous gonadotrophins are 
utilised to promote follicle growth whilst LH or hCG are administered for 
the final follicular maturation and rupture, were refined by Carl Wood and 
Alan Trounson in Melbourne Australia during the late 1970s and the first 
baby born to a patient following ovarian stimulation, Candice Reed, was 
born in Canada in 1980 (Challoner, 1999;  Martín-Coello et al., 2008).  
 
Despite the benefit of superovulation significantly increasing the oocyte 
yield per cycle, it is not without its disadvantages. In mice, superovulation 
with PMSG has been associated with delayed embryonic development to 
blastocyst in vitro and in vivo, abnormal pre-implantation development, a 
40% reduction in foetal growth and increased numbers of re-sorption sites 
(Van der Auwera and D'Hooghe, 2001). Adverse effects on embryo 
viability were exacerbated when higher doses of PMSG were used, 
possibly due to nutritional deficiency as a consequence of overcrowded 
uteri (Edgar et al., 1987;  Evans et al., 1981). PMSG is no longer used in 
patient treatment and the few studies on the effects of human 
gonadotrophins on embryo development in mice are contradictory, due to 
strain and method variances (Brooke et al., 2007;  Calongos et al., 2008;  
Muñoz et al., 1995;  Edirisinghe et al., 1986). The effects of COS on 
human embryos are sparse due to ethical and moral limitations, however 
there are reports suggesting human singleton conceptions generated 
through IVF display more peri-natal complications than their naturally 
conceived counterparts (Jackson et al., 2004;  Helmerhorst et al., 2004;  
Basatemur and Sutcliffe, 2008). The putative origins of the negative 
effects reported after COS could potentially occur at multiple stages 
during folliculogenesis and may alter the uterine environment and 
endometrial receptivity, which consequently may affect foetal 
development. 
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In this chapter I will provide an overview of normal physiology in mice and 
humans; covering oogenesis and folliculogenesis, embryo development, 
implantation and foetal development, before introducing the rationale for 
ovarian stimulation, the history behind the current preparations in clinical 
use and a summary of previously published findings on the negative 
consequences of ovarian stimulation. The literature review will provide the 
background for the following experiments which assess the effect of 
human gonadotrophin preparations on oocyte and embryo quality, 
genetics of cumulus and trophectoderm cells from blastocysts and 
ultimately postnatal growth of offspring, in comparison to non-stimulated 
and PMSG treated controls.    
 
1.2 OOGENESIS AND FOLLICULOGENESIS 
1.2.1 Primordial follicle formation 
Oogenesis begins with the formation of primordial germ cells (PGCs) from 
the proximal epiblast from day 8 in mice and is thought to be controlled 
by the bone morphogenetic proteins; BMP2, BMP4 and BMP8b signalling 
from the extra-embryonic tissue (Oktem and Urman, 2010). These 
pluripotent cells chemotactically home to the future gonads and after 
colonisation is complete at approximately 9.5-11.5 days post coitum (dpc) 
the PGCs differentiate into oogonia, undergoing several rounds of mitotic 
divisions before entering meiosis and arresting at the diplotene phase of 
prophase I (Richards and Pangas, 2010). In mice, formation of these 
primordial follicles is thought to occur during the first few days post 
partum and are fully formed by day 3 (McGee and Hsueh, 2000). The 
female gametes are then stored in a quiescent state until sequentially 
recruited to enter the growing follicle pool (Oktem and Urman, 2010). The 
first wave of follicles to reach the antral stage occurs by week 3 post 
partum in the mouse (McGee and Hsueh, 2000).  
 
Follicular endowment, in the human, commences pre-natally and it is a 
widely accepted doctrine in reproductive biology that females at birth are 
provisioned with the entire complement of oocytes to last their 
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reproductive life span (Zuckerman, 1951). PGCs are estimated to form 
between the third and fourth week of human gestation and reside within 
the future gonads by seven weeks. Primordial follicles are estimated to 
form around mid-gestation (Fulton et al., 2005). Unlike mice, the female 
gametes in humans are suggested to be recruited to enter the growing 
follicle pool from as early as 15-16 weeks gestation. This continues 
postnatally until the ovarian follicular reserve is depleted (Knight and 
Glister, 2006). In contrast however, it has recently been proposed that 
new primordial follicles can form in the ovaries throughout early life in the 
mouse and the putative origin of these germ cells is the bone marrow 
(Johnson et al., 2004;  Johnson et al., 2005). Implications of this 
observation remain to be determined but women still run out of oocytes.    
 
1.2.2 Gonadotrophin independent follicles 
Follicular development has three distinct phases classified according to the 
morphological appearance of the follicle and dependence on pituitary 
gonadotrophins for successive growth. The first stage, the gonadotrophin 
independent stage is where irreversible recruitment from the resting 
primordial follicles is initiated. Diplotene oocytes within primordial follicles 
are encased in flattened pre-granulosa cells that undergo a squamous-to-
cuboidal transition to form granulosa cells. The zona pellucida is also 
acquired during this transition from primordial to the primary follicle 
stage, the earliest form of a committed follicle (Oktem and Urman, 2010).  
 
As follicles further increase in size and develop into secondary and then 
tertiary follicles, the single granulosa cell layer becomes multi-layered 
through mitotic expansion and the basal lamina and theca cell layer are 
formed from differentiation of the surrounding stromal cells (Knight and 
Glister, 2006). This incessant phase of folliculogenesis initiates 15-16 
weeks into gestation and continues throughout post-natal development 
and adulthood until the ovary is depleted of its stockpile and the woman 
enters the menopause. These early gonadotrophin independent stages of 
follicle growth are controlled by the co-ordinated and synergistic actions of 
an extensive array of cytokines and growth factors from various signal 
                                               Chapter 1: Literature Review 
5 
 
transduction pathways including the transforming growth factor beta 
(TGFβ) super-family as summarised in Figure 1.1 (Oktem and Urman, 
2010;  Knight and Glister, 2006). Ovarian stimulation is assumed to have 
no effect on these early stages of folliculogenesis and therefore they will 
not be discussed in further detail.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: An extensive array of growth and cytokine factors acting at the 
paracrine and autocrine level are known to play a role in folliculogenesis from 
primordial follicle formation to the pre-antral stage. (Adapted from Oktem and 
Urman 2010). 
 
1.2.3 Gonadotrophin responsive follicles 
As the gonadotrophin independent tertiary follicles develop into small 
antral follicles, they become responsive to gonadotrophins. FSH receptors 
become detectable in follicles with only two layers of granulosa cells  and 
are constitutively expressed from the primary to antral stage of 
folliculogenesis (Webb and Campbell, 2007). Although follicle growth can 
occur in the absence of FSH (Picton et al., 1990),  the proliferative effects 
of FSH on the granulosa cells means that at high levels it can accelerate 
follicle growth from the tertiary stage upwards in vivo (Campbell et al., 
2004). In vitro, these tertiary and small antral follicles produce a 
measurable steroid response to FSH and LH (McNatty et al., 2010). 
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Although FSH is not obligatory for growth, it is conceivable that optimal 
oocyte quality may only be obtainable when they are present (Cortvrindt 
et al., 1997).  
 
During the early antral stages fluid-filled pockets begin to form in the 
granulosa cell layers that eventually coalesce to form the antral cavity 
which separates the cumulus cells from the mural granulosa. Continued 
proliferation of the theca and granulosa cells occurs throughout this stage, 
in addition to vascularisation of the theca cell layer. It is from this pool of 
antral gonadotrophin responsive follicles that a cohort is cyclically 
recruited to further grow in order to select a single dominant follicle 
(Oktem and Urman, 2010). Studies where FSH levels are suppressed with 
gonadotrophin releasing hormone (GnRH) agonists, show follicles stop 
developing at the small antral stage in the absence of gonadotrophins 
(Picton et al., 1990). The antral follicle stage marks the transition from a 
proliferative to differentiated follicle, where marked changes in gene 
expression occur, specifically those involved in steroidogenesis (Webb and 
Campbell, 2007;  Webb et al., 1999).  
 
1.2.4 Gonadotrophin dependant follicles  
Follicle dependence on gonadotrophins in mice has been suggested to 
coincide with antrum formation, with each small antral follicle, possessing 
a unique FSH threshold (estimated to be at least 30% over the basal FSH 
value), which must be exceeded for continued pre-ovulatory development 
and inhibition of atresia (Figure 1.2) (Craig et al., 2007;  Messinis et al., 
2010). Follicles of this size do not occur unless critical threshold 
concentrations of pituitary gonadotrophins are maintained (Campbell., 
2009).  It is in the later gonadotrophin dependent stage of folliculogenesis 
that the oocyte completes cytoplasmic and nuclear maturation rendering it 
competent to resume meiosis. Development of the antrum is concomitant 
with maturation  of the follicle, whereby the mural granulosa and theca 
cells differentiate into steroidogenic cells (Campbell et al., 2007). 
Granulosa cells surrounding the oocyte produce and release oestrogen 
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into the systemic circulation through the aromatic conversion of the theca 
cell derived substrate, androstenedione (Knight and Glister, 2001). 
Gonadotrophin dependent follicles each have their own micro-environment 
which will transduce gonadotrophic signals differently (Webb and 
Campbell, 2007).  
 
Figure 1.2: Advancement through folliculogenesis in mice is accompanied by 
altering dependence on gonadotrophins for further growth. During the 
gonadotrophin responsive stage, development can continue in the absence of FSH 
and LH but their presence can have an effect on development. The oocyte is 
arrested in meiosis I throughout follicular development and only resumes after 
antrum formation prior to ovulation.  
 
1.2.5 Mouse folliculogenesis 
Mouse folliculogenesis follows an analogous pathway to ovulation but 
takes a much shorter time period to complete than in humans, 
approximately 2-3 weeks from initiation of growth to ovulation (Pedersen, 
1969). Differences only occur during formation of the initial PGCs. 
Cytokinesis during PGC proliferation is incomplete in the mouse meaning 
oogonia may remain inter-connected by cytoplasmic bridges forming a 
syncitium. It is the breakdown of these nests which leads to the formation 
of primordial follicles. This occurs immediately postpartum in the mouse 
whilst in the human it is completed in the second trimester of foetal 
development (Hunt and Hassold, 2008). The inappropriate breakdown of 
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germ cell syncitia generates polyovular follicles (contain more than one 
oocyte) which are common in some mouse strains with TGFβ super-family 
mutations. Whilst these polyovular follicles have been observed in human 
ovaries at birth, they are rarely found in the adult (Richards and Pangas, 
2010). 
 
Cyclic recruitment of early antral follicles is analogous in rodents with the 
exception that multiple follicles become dominant, proposed to be due to 
differing threshold levels for negative feedback between mono and poly-
ovulatory species (Spearow, 1986). In hypo-gonadal and hypo-
physectomised mice and rats, follicle development can progress to the 
early antral stage in the absence of gonadotrophins (Halpin et al., 1986;  
Hirshfield, 1985). Prior to this stage, as with humans, mouse follicles have 
been shown to respond to gonadotrophins through cell divisions and 
differentiation, although the studies are conflicting (McGee and Hsueh, 
2000). 
 
Gene knockout (KO) studies in mice provide further support for the 
similarity between human and mice in the role played by gonadotrophins 
in regulating follicle development. FSHǃ subunit KO mice were generated 
with no biological FSH activity. KO females were infertile, with decreased 
ovarian size and complete absence of antral follicles and corpora lutea 
(Kumar et al., 1997). The morphology of primordial and pre-antral follicles 
appeared normal and antral follicle development could be stimulated by 
the pharmacological administration of PMSG and hCG (Kumar, 2009). FSH 
receptor KO mice also demonstrated small ovaries and a block in antral 
follicle formation (Dierich et al., 1998), indicating that dependence on 
gonadotrophins becomes apparent at this stage. Complete loss of FSH 
function in humans displays analogous phenotypes to these mouse models 
and patients can respond to high doses of exogenous gonadotrophins 
(Beau et al., 1998).   
 
Ovarian histological analysis of infertile LHǃ KO mice showed normal 
primary and secondary follicles but the majority of the antral follicles were 
abnormal containing degenerating oocytes and there were no pre-
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ovulatory follicles or corpora lutea (Ma et al., 2004). This could be 
overcome short term by administrating hCG (Ma et al., 2004). Similar 
arrested folliculogenesis and small ovary phenotypes were observed in LH 
receptor KO mice (Lei et al., 2001;  Zhang et al., 2001). This distinct LH 
KO phenotype compared with FSH KO mice provides genetic evidence for 
the distinct roles of the LH and FSH gonadotrophins during folliculogenesis 
(Kumar, 2009). Ovarian histology of women with LH receptor mutations 
show all stages of folliculogenesis except pre-ovulatory follicles and 
corpora lutea (Toledo et al., 1996). These observations in the human and 
mouse support the role of FSH and LH in the final stages of 
folliculogenesis and the necessity of LH for the final follicular maturation 
and ovulation during a normal cycle (Zhang et al., 2001).  
 
1.2.6 Endocrinology of folliculogenesis 
Ovarian follicle development is regulated by highly orchestrated endocrine 
events. Human folliculogenesis is a lengthy process taking approximately 
120-180 days for a follicle to evolve from the primordial to the pre-
ovulatory stage (Gougeon, 1986). The monthly cyclic selection of a cohort 
of follicles from the gonadotrophin responsive pool to progress past the 
small antral stage is governed by the hypothalamic pituitary ovarian axis. 
Defined as a hormone secreted from the pituitary that exerts its actions 
on the functioning of the gonads, the gonadotrophins are key organisers 
of the recurring menstrual cycle.   
 
The hypothalamus forms the ventral part of the diencephalon in the brain. 
It links the central nervous and endocrine systems (i.e. hypophysis) by 
the controlled emission of gonadotrophins from the anterior pituitary 
through pulsatile secretion of the paracrine deca-peptide, gonadotrophin 
releasing hormone (GnRH) (Knight and Glister, 2001). FSH and LH exert 
their function on the ovaries, which produce steroids and gonadotrophin 
modulating factors, such as inhibin and activin, in response to attenuate 
or enhance the initial pulsatile secretion of GnRH, thereby synchronizing 
the oestrus cycle (Richards and Pangas, 2010). The continuation of 
folliculogenesis is dependent on the ability of the follicle to respond to the 
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gonadotrophin cues through the presence of gonadotrophin receptors. The 
LH and FSH receptors belong to the G-protein coupled transmembrane 
family and are differentially expressed throughout folliculogenesis (Jia et 
al., 1991). FSH receptors are constitutively expressed on granulosa cells 
from the primary to the pre-ovulatory stage of follicular development 
(McNatty et al., 1999).  As the pre-antral follicle grows the proportion of 
FSH receptors exponentially increases with granulosa cell proliferation and 
immediately prior to antrum formation at the tertiary stage theca cells 
begin to express LH receptors (McNatty et al., 1999;  Richards, 2001). In 
large antral follicles granulosa cells also have LH receptors on their cell 
surfaces where they contribute to the production of progesterone and 
oestrogen  (Webb et al., 1999).  
 
1.2.6.1 Follicular phase 
At the luteo-follicular transition in humans, FSH levels rise due to a 
reduction in the negative feedback instigators oestradiol, inhibin A and the 
corpus luteum (CL) from the previous cycle regresses (Macklon et al., 
2006a). This transient increase in FSH synchronously recruits for growth a 
group of gonadotrophin responsive small antral follicles. The 
gonadotrophin responsive follicles with higher degrees of FSH sensitivity 
respond to the FSH increment and diverge from the pool of follicles during 
this cyclic recruitment (McGee and Hsueh, 2000). The continued growth 
and survival of this recruited follicular cohort is critically dependent on 
continued stimulation by gonadotrophins.  
 
Oestrogen is thought to be produced by granulosa cells in response to FSH 
and LH during the gonadotrophin dependant stage of folliculogenesis by 
the P450 aromatase conversion of the theca cell derived substrate 
androstenedione (McNatty et al., 1999). Through stimulation by LH, theca 
cells convert cholesterol into androstenedione and testosterone by 
cytochrome P450 side chain cleavage oxidases and 3 beta hydroxysteroid 
dehydrogenase respectively. FSH induced aromatase in granulosa cells 
subsequently converts androstenedione and testosterone into oestrogens, 
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such as oestradiol-17ǃ and oestrone (Macklon et al., 2006b). The actions 
of the gonadotrophins is proposed to be further mediated by the 
disulphide linked dimeric glycol-proteins inhibin and activin, which belong 
to the TGFǃ super family (Knight and Glister, 2006). Activin in vitro has 
been shown to stimulate expression of FSH receptors (Xiao et al., 1992), 
which through the binding of the FSH ligand may promote granulosa cell 
proliferation as shown in rat and human cell cultures (Li et al., 1995;  Miró 
and Hillier, 1992). Further, activin can potentially induce activation of 
aromatase observed in primates, rats and bovine granulosa cells (Hillier 
and Miró, 1993;  Miró et al., 1991;  Shukovski et al., 1993). Inhibin A, a 
product secreted from granulosa cells, has been shown in vitro to sensitise 
the neighbouring theca cells to the androgen production stimulatory 
effects of LH in human, rat and bovine (Hillier, 1991;  Hsueh et al., 1987;  
Wrathall and Knight, 1995). Inhibin A also effects FSH induced aromatase 
activity (Campbell et al., 1996). 
 
Collectively the hypothesised actions of activin, inhibin and other local 
factors and the known involvement of LH and FSH leads to an increase in 
serum oestrogen levels during the late follicular phase which suppresses 
the release of FSH from the pituitary gland (Knight and Glister, 2001). 
Only the dominant follicle with the greatest sensitivity to FSH is able to 
survive these declining levels (Baird, 1987). FSH and oestradiol are 
thought to induce LH receptors on granulosa cells and in combination with 
the constitutively expressed receptors on theca cells may enable 
continued development by switching gonadotrophin dependence from FSH 
to LH (Huirne et al., 2004;  Campbell et al., 1999;  Webb et al., 1999). In 
addition, high circulating oestrogen levels cause intense proliferation of 
the endometrium, in anticipation of embryo implantation (Lessey, 2010).   
 
1.2.6.2 Ovulation 
LH is required to stimulate production of steroid hormones during various 
phases: follicular development, resumption of meiosis, cumulus 
expansion, rupture of the dominant follicle and luteinisation of theca and 
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granulosa cells. This generates the CL required for providing support in 
early pregnancy (Huirne et al., 2004;  Yamashita and Shimada, 2012). 
Persistently high levels of oestrogen produced from growing antral follicles 
in the follicular phase, in conjunction with elevated progesterone, 
concomitantly increases the quantity of GnRH produced and released 
whilst sensitising the pituitary to its actions, giving rise to the LH surge 
resulting in ovulation (Huirne et al., 2004;  Clarke, 1995).  
 
In response to this peak in LH, cumulus cells surrounding the oocyte 
undergo expansion through the synthesis and secretion of hyaluronic acid 
(Yokoo et al., 2008). The hyaluronan is bound to the cell surfaces by 
hyaluronan binding proteins (linker proteins) resulting in a sticky matrix 
forming in the extracellular spaces between the cumulus cells, driving the 
expansion (Eppig, 2001). Therefore a direct relationship exists between 
the level of hyaluronic acid synthesis and the extent of cumulus 
expansion. It is hypothesised that the transient peak in LH production is 
terminated by gonadotrophin surge attenuating factor (GnSAF), which 
antagonises the sensitising effect of oestrogen on the pituitary, thus 
regulating the amplitude and duration of the LH surge (Messinis, 2006). 
Subsequent to ovulation, there is a rapid growth of blood vessels invading 
the granulosa cells and the ovulated follicle is converted into the corpus 
luteum (termed luteinisation) and the luteal phase begins (Phan et al., 
2006).  
 
1.2.6.3 Luteal phase 
Following the LH surge in humans, there is an incremental increase in 
progesterone levels (P4) that remain high during the luteal phase to 
maintain the developing CL and initial stages of pregnancy and prevent 
further ovulations (Stouffer, 2003). Progesterone transforms the 
oestrogen primed endometrium from a proliferative to a secretive tissue 
during the luteal phase, establishing embryo receptivity around a timed 
implantation window (Lessey, 2010). In mice the structure and function of 
the CL is only maintained for two days if mating has not occurred, or until 
day 10-12 of pregnancy as demonstrated in sterile mated pseudo-
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pregnant mice, after which the placenta takes over (Hilliard, 1973). In 
rodents however, luteinisation also requires surges of prolactin secretion 
induced by cervical stimuli, which increases the lifespan of the CL and 
enables sufficient amount of P4 to be produced to maintain pregnancy 
(Gunnet and Freeman, 1983). Unlike humans, mice express the enzyme 
20Į hydroxysteroid dehydrogenase (20Į-HSD) which is involved in 
progesterone catabolism. Prolactin represses this enzyme and has been 
shown to upregulate LH receptor expression which collectively explains 
the increase in P4 during luteolysis in the mouse (Albarracin et al., 1994;  
Gibori and Richards, 1978).  
 
1.2.7 Oogenesis and oocyte maturation 
Oogenesis, is defined as the acquisition of the developing oocyte encased 
in the follicle to resume meiosis upon fertilisation and to progress through 
the pre-implantation development stages prior to zygotic gene activation 
(ZGA). Oogenesis occurs concomitantly with folliculogenesis (Pesty et al., 
2007). The acquisition of fertilising ability begins at primordial follicle 
activation but is only completed 1-2 days prior to ovulation. Oocytes must 
develop a number of competencies in order to successfully fertilise and 
instigate a pregnancy to term. The three aspects of oocyte maturation 
are: nuclear, cytoplasmic and molecular (Wassarman and Kinloch, 1992).  
 
Nuclear maturation is the development of meiotic competence, i.e. the 
ability of the oocyte to overcome the meiotic block. In the mouse, it is 
acquired at the pre-antral to antral follicle transition as demonstrated by 
spontaneous resumption of meiosis when the oocyte is removed from the 
follicle. In humans, nuclear maturation is correlated with oocyte diameter 
and the ability to resume meiosis significantly increases when a diameter 
of 90-120µm is achieved (Mehlmann, 2005).  This size is related to follicle 
diameter and fertilisation rates are progressively enhanced with increasing 
size (Trounson et al., 2001). The first meiotic division is triggered at the 
time of ovulation and arrested in metaphase. Completion of the second 
meiotic division and expulsion of the second polar body occurs upon 
successful fertilisation and activation of the oocyte by a spermatozoon.  
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Resumption of meiosis is not a guarantee of full developmental 
competence. In addition to nuclear maturation, cytoplasmic competence is 
established through the complex processes involving changes in 
distribution, function and organisation of organelles, the most 
characterised being the cortical granule exocytosis that defends against 
polyspermy (Fulka et al., 1998).  Redistribution of mitochondria has also 
been implicated in this maturation event but many of the mechanisms 
have not been fully elucidated (Aerts and Bols, 2010). 
 
As the oocyte grows it synthesises and stores large quantities of RNA, 
ribosomes and proteins, termed molecular maturation. At the time of the 
LH surge, the accumulated mRNA is rapidly translated into proteins vital 
for completion of fertilisation and the initial cell divisions prior to 
activation of the zygotic genome (Fair et al., 2004). This aspect of 
maturation has been termed by some as oocyte capacitation as it 
reflects the intrinsic capacity of the oocyte to continue development (Fulka 
et al., 1998). These oocyte maturation events occur cumulatively from the 
beginning of folliculogenesis. 
   
1.2.8 Factors involved in folliculogenesis and oogenesis 
The development of the germ cells is reliant upon bi-directional paracrine 
communication between the oocyte and surrounding cumulus granulosa 
somatic cells via transzonal projections (Matzuk et al., 2002). The 
cumulus granulosa cells are closely associated with the oocyte in what is 
termed the cumulus oocyte complex (COC) (Carabatsos et al., 2000). The 
gap junctions span from the cumulus cells through the zona pellucida to 
the oocyte and consist of six connexion protein subunits. These subunits 
join together to form the complete channel, termed the connexon on 
individual cell membranes, which then subsequently align to form the gap 
junction (Bruzzone et al., 1996). These junctions permit passage of small 
molecular molecules such as pyruvate, amino acids, ions and signalling 
molecules (Wang et al., 2009). 
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Disruption of this coupling between cumulus granulosa cells and the 
oocyte leads to sterility if the oocytes fail to become meiotically 
competent (Carabatsos et al., 2000). Most of the oocyte metabolic needs 
required to sustain its growth and regulate its cell cycle are obtained 
through these gap junctions. In response, the oocyte directs the 
proliferation, differentiation and function of granulosa cells whilst also 
preventing premature luteinisation (Krysko et al., 2008). The cumulus 
cells are vital orchestrators of oocyte maturation and development, which 
is why these outer cells remain in close proximity to the oocyte until the 
completion of fertilisation (McKenzie et al., 2004). The oocyte also plays 
an active role in its development by secreting paracrine factors that 
influence gene expression and protein synthesis in granulosa and cumulus 
cells, whilst also maintaining an optimum microenvironment for the 
acquisition of developmental competence (Devjak et al., 2012).   
 
Although the importance of bi-directional communication in the acquisition 
of developmentally competent oocytes has been proven in rodents, it has 
yet to be confirmed in the human. There are several observations in the 
literature that suggest a role for paracrine factors in human fertility. For 
example, diminished levels of growth differentiation factor 9 (GDF-9) 
mRNA has been associated with polycystic ovarian disease, indicating a 
potential role in folliculogenesis (Teixeira Filho et al., 2002). Mutations in 
both GDF-9 and bone morphogenetic protein 15 (BMP-15) have been 
shown to be indicators of premature ovarian failure (Laissue et al., 2006). 
Furthermore, there is evidence to suggest the level of connexion 43 
(CX43) expression (gap junction connexin encoding gene) and the 
strength of gap junction apposition between cumulus granulosa cells is 
positively correlated with IVF success in terms of pregnancy rate (Wang et 
al., 2009). In spite of a lack of direct evidence, it can be assumed 
paracrine factors play parallel roles in humans as their homologous 
counterparts do in the mouse.  
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1.2.9 Angiogenesis in folliculogenesis and oogenesis 
Angiogenesis is the formation of new blood vessels by intussusceptions 
and sprouting from pre-existing vasculature. Through a cascade of events 
starting with capillary proliferation, it culminates in the formation of a new 
microcirculation composed of arterioles, capillaries and venules (Redmer 
and Reynolds, 1996). Angiogenesis is an essential mechanism required for 
folliculogenesis and oogenesis. Angiogenesis is critical for development of 
ovarian follicles and has been proposed to be implemented in oocyte 
maturation, specifically the renin angiotensin system (RAS, discussed in 
section 1.5.3) which appears to be controlled by LH (Zhang et al., 2010a). 
In addition, after ovulation angiogenesis is essential to support the 
developing CL (Chuderland et al., 2012). The female reproductive organs, 
namely the uterus and ovary, undergo cyclic angiogenesis which is a pre-
requisite for their optimal functionality (Reynolds et al., 2002). Down 
regulation during COS has been shown to significantly reduce the 
vascularity of the ovary. However, despite this not being a factor in the 
number of oocytes retrieved, the effect of vascularity at the individual 
follicle level and subsequent embryo development and pregnancy rates 
was not analysed (Jayaprakasan et al., 2008).  
 
Vascularisation of follicles has been examined as a marker of oocyte and 
embryo quality. Early studies using doppler imaging of the ovary found 
that oocytes collected from poorly vascularised follicles developed into 
embryos of inferior quality compared to those with greater vascularisation 
(Nargund et al., 1996).  Several studies have shown that greater blood 
flow, specifically in the wall of the pre-ovulatory follicle may improve 
fertilisation rates and embryo development in IVF patients (Bhal et al., 
1999;  Coulam et al., 1999;  Huey et al., 1999;  Du et al., 2006;  
Shrestha et al., 2006). The association between increased angiogenic 
indices of the follicle and retrieval rate of mature oocytes, improved 
embryo development and increased pregnancy rates have also been 
observed in mares and heifers (Silva et al., 2005;  Siddiqui et al., 2009a;  
Siddiqui et al., 2009b).   
 
                                               Chapter 1: Literature Review 
17 
 
Several studies have shown a positive correlation between follicle 
vascularisation and pregnancy rate (Chui et al., 1997;  Van Blerkom et 
al., 1997;  Borini et al., 2005). Furthermore, there were higher incidences 
of aneuploidy and spindle defects in oocytes derived from poorly 
vascularised follicles, potentially due to the hypoxic conditions hindering 
oxidative metabolism and consequently lowering the intracellular pH (Chui 
et al., 1997;  Van Blerkom et al., 1997). Hypoxia leads to the formation of 
reactive oxygen species (ROS) which causes lipid peroxidation, 
inactivation of enzymes and damages both cumulus cells and the oocyte, 
leading to apoptosis (van Montfoort et al., 2008). The concentration of 
ROS in follicular fluid has also been negatively correlated with embryonic 
development and pregnancy outcome (Das et al., 2006). One study did 
not find this positive association between follicle vascularity and 
pregnancy rates after IVF; however this study did not match the infertility 
pathology and combined both IVF and ICSI cycles (Ng et al., 2006). In 
addition, analysis of oocytes retrieved when no stimulation was used is 
lacking in the literature, so the effect of COS on the vascularity of the 
follicle is lacking and requires further investigation. A common response to 
hypoxia is angiogenesis. With our advancements in genetic understanding 
of cellular and molecular processes, studies are now analysing the 
correlation of angiogenic factors and embryo quality.  
 
1.3 Embryo development  
In mice mature metaphase II oocytes are released at ovulation in a single 
cumulus mass from the ovary and encounter spermatozoa in the swollen 
ampulla region of the oviduct (Nagy et al., 2003). After 2 hours the 
second polar body is extruded closely followed by formation of the two 
pronuclei (PN) after 4-8 hours and eventually the first cleavage division 
18-22 hours post insemination (Howlett and Bolton, 1985). The maternal 
to embryonic genomic switch occurs at the 2 cell stage in mice in contrast 
to humans when it occurs later at the 4-8 cell stage (Lane and Gardner, 
2005;  Braude et al., 1988). The time period required for the embryo to 
develop into an expanded blastocyst is also extended in the human 
requiring approximately 50 hours longer in comparison to the mouse 
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(Taft, 2008). In parallel the time from fertilisation to implantation is also 
adjusted taking a mere 4 days in the mouse versus 9 days in the human 
(Fujimori, 2010). In spite of these species-specific differences mouse pre-
implantation embryo development is morphologically similar to humans 
from the 1 cell zygote to the blastocyst (Figure 1.3). The subsequent 
three rounds of cell division occur asynchronomously resulting in spherical 
shaped blastomeres that are easily discernible until the 8 cell stage when 
they increase their contact and adhesion with neighbouring cells and form 
tight junctions (Fujimori, 2010). This process is mediated by uvomorulin, 
a calcium dependant trans-membrane adhesion molecule that belongs to 
the cadherin family (Nagy et al., 2003). 
 
After the fifth cell division, at the 32 cell stage, small individual fluid filled 
cavities form at multiple cell-cell boundaries and eventually converge to 
form the blastocyst cavity (blastocoel) (Kurotaki et al., 2007). The 
regulated active transport of ions and water by the trophectoderm TEAD4-
Yap system aids cavity formation and acts as a cue to activate the 
trophectoderm (TE) cell developmental program (Fujimori, 2010). TEAD4 
is the earliest gene identified that is required for specification of the TE 
lineage. Ablation of the TEAD4 gene in the mouse generates a pre-
implantation lethal phenotype due to failure to form a blastocoel cavity 
and TE, therefore preventing implantation into the endometrium (Yagi et 
al., 2007).  
 
The blastocyst is the first developmental stage where cell lineage is 
visually distinguishable with the outer TE cells contributing to extra-
embryonic tissues such as the placenta and the internal inner cell mass 
(ICM) going on to form the embryo proper. The lineages are discernible at 
the molecular level also, with caudal-like transcriptional factor with 
homeo-domain (Cdx2) and Oct4 marking TE and ICM cells respectively. 
Cdx2 is required to maintain TE lineage differentiation, which provides 
extra-embryonic tissue (e.g. placenta) and acts as a signalling source to 
pattern the embryo before gastrulation (Jedrusik et al., 2010). Four days 
after fertilisation the embryo hatches out of its protein cocoon, the zona 
pellucida (ZP), and directly interacts with the uterine epithelium to initiate 
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implantation (Fujimori, 2010). There are no preformed implantation sites 
in the mouse uteri but peristaltic movement evenly spaces the litters in 
the uterine horns (Nagy et al., 2003) 
Figure 1.3: (A) After fertilisation the male and female pronuclei form (2PN) and 
the second polar body is extruded (2PB). (B) Following completion of syngamy 
the zygote divides. (C) Until the 8 cell stage the individual blastomeres are 
distinguishable. (D) During compaction tight junctions form and the embryo 
becomes a tight ball of cells called the morula. (E) Fluid is actively pumped into 
the embryo to form the blastocoel cavity that continues to expand. The blastocyst 
has two distinct cell types, the inner cell mass (ICM) that will form the future 
embryo and the trophectoderm (TE) that will develop into the placenta. (F) When 
the blastocyst is fully expanded it hatches out of the zona pellucida (ZP) in order 
to implant in the uterine endometrium. (Information sourced from Braude et al 
2002).   
 
1.4 Epigenetics in gametogenesis and 
embryogenesis 
Epigenetics is the reversible extrinsic modification of DNA that results in 
altered gene expression with no change to the underlying DNA sequence 
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(Jurkowska and Jeltsch, 2013).  This is achievable through DNA 
methylation, histone tail modification (acetylation/deacetylation, 
methylation, ubiquitination), antisense RNA and modifications in 
chromatin structure (Fauque et al., 2007). Genomic imprinting is an 
epigenetic mechanism that differentially marks maternally and paternally 
inherited alleles at key regulatory sequences termed differentially 
methylated regions (DMRs), also referred to as imprinting control regions 
(ICRs), which mediate mono-allelic parent of origin dependant gene 
expression (Stouder et al., 2009). Epigenetic DNA methylation patterns 
originate from the male and female germ lines by the action of DNA 
methyl transferase 3 (Dnmt3). There are various isoforms of this enzyme 
but Dnmt3L in collaboration with Dnmt3a, are hypothesised to be the 
main DNA methyl-transferases involved in maternal imprint acquisition in 
the oocyte as they are expressed during gametogenesis (Pradhan and 
Esteve, 2003).  
 
In order to ensure appropriate sex specific imprint composition the 
genome undergoes widespread reprogramming during oocyte maturation 
and is analogous in the human and mouse (Figure 1.4). Pre-existing DNA 
methylation is erased during gametogenesis of PGCs with new imprints 
established in the germ line in an asynchronous manner during the oocyte 
growth phase of gametogenesis. This mechanism of erasure and 
reprogramming ensures abnormal epigenetic states (epi-mutations) are 
not transferred to the next generation. Epigenetic modifications are 
completed coincidently with the first meiotic division in the ovulatory 
follicle and are maintained throughout the rest of development (Obata and 
Kono, 2002). Therefore disruption in epigenetic reprogramming through 
the use of exogenous gonadotrophins may manifest later in gestation or 
after birth with life-long altercations for the individual (Khosla et al., 
2001).  
 
Once established, imprints are somatically maintained through pre and 
post-implantation development with the aid of DNA methyl-transferase 1 
(Dnmt1) (Latham, 1999). An oocyte specific transcript of this enzyme has 
been identified in the mouse termed Dnmt1o which is a truncated version 
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of the somatic isoform. This mRNA transcript is translated to protein and 
acts as a maternal store during embryogenesis to maintain methylation 
imprints until the embryonic genome is activated (Mertineit et al., 1998). 
  
Figure 1.4: Imprinting reprogramming is achieved through the 
erasure/acquisition of sex specific imprints during oogenesis and is important for 
subsequent development. After fertilisation the paternal (blue) and maternal 
(pink) genomes are de-methylated by an active and passive mechanism 
respectively. Re-methylation (purple) begins from the 8 cell stage to the 
blastocyst parallel to lineage restriction. Methylated imprinted genes (green) do 
not de-methylate (Adapted from Reik et al 2001 and Dean 2003).  
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Whilst epigenetic imprints are sustained, global DNA de-methylation is 
initiated at fertilisation with paternal methylation actively removed and 
the maternal passively lost upon subsequent cell divisions (Figure 1.4) 
(Mayer et al., 2000). Non-imprinted de novo tissue specific methylation is 
established by Dnmt3b upon lineage differentiation in the inner cell mass 
(ICM) at blastocyst formation (Reik et al., 2001). During this period of 
dynamic epigenetic alterations, environmental factors such as ovarian 
stimulation and embryo culture may disrupt the ability of the pre-
implantation embryo to sustain the genomic imprints initiated in the germ 
line, consequently having detrimental effects on future development.  
 
Genomic imprinting is a pre-requisite for normal embryonic development 
as it controls early embryonic gene expression, cleavage and cell 
differentiation (De Rycke et al., 2002). Imprinted genes play key roles in 
the regulation of foetal growth and placental function throughout 
gestation (Stouder et al., 2009). Differential gene expression is 
hypothesised to have evolved to combat the maternal and paternal 
conflict of limiting and increasing foetal size respectively. The paternal 
alleles generally enhance placental development. In contrast maternal 
genes hinder placental growth therefore limiting foetal size (Jurkowska 
and Jeltsch, 2013). 
 
Methylation sites are located in specific regions termed CpG Islands, in or 
near the promoters of genes (Figure 1.5). One function of methylation of 
these regions is to act as binding sites for proteins like methyl CpG 
binding protein (MeCP2) which recruits other proteins such as histone 
deacetylase that modify chromatin structure and histone protein 
acetylation resulting in dosage control of genes (Young and Fairburn, 
2000). DNA methylation generally results in transcriptional repression of 
the methylated allele.  
 
The vast majority of imprinted genes are located in clusters that are 
conserved between the human and murine genomes (Thompson et al., 
2001). Mouse studies demonstrate that disruption in epigenetic imprint 
maintenance results in aberrant embryo development and reduced 
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viability (Thompson et al., 2001;  Reik et al., 1993). Furthermore 
perturbed expression of imprinted genes is associated with four broad 
categories of human disease: cancer, metabolic disorders, 
psychiatric/behavioural disorders and neuron-developmental (Paoloni-
Giacobino, 2007).  
Figure 1.5: Genomic imprinting is established by methylation (transfer of the 
methyl group from S adenosyl L-methionine-ringed in orange, to number 5 
carbon of cytosine pyrimdine ring) of CpG di-nucleotides (cytosine residues 
adjacent to guanidine-ringed in red) by the DNA methyl-transferase enzyme.  
 
There is limited information available in humans on the methylation status 
of imprinted genes, but available data suggests imprint acquisition and 
maintenance during gametogenesis and embryogenesis follows a similar 
pattern to that reported in the mouse (Sato et al., 2007). Currently, there 
are 96 conserved murine and human genes that exhibit parent of origin 
specific methylation patterns identified with more continuously being 
found (Wood and Oakey, 2006). The H19 and IGF2 gene cluster has 
received the most attention due to its sensitivity to in vitro manipulations 
and role in placental development (Doherty et al., 2000). 
 
1.4.1 The role of IGF2 and H19 
IGF2 is a potent foetal mitogen that exerts its effects on the placenta, 
thus inadvertently regulating foetal growth and development (De Rycke et 
al., 2002). It is a critical factor in placental growth and nutrient transfer. 
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Other attributes include oncogene and tumour suppressor gene functions. 
In contrast the 2.5kb H19 transcript does not encode a functional protein, 
instead it is implicated in silencing the maternal IGF2 allele so it is also 
crucial for foetal and placental growth (Young and Fairburn, 2000).  
 
Both imprinted genes IGF2 and H19 are integral components of the 
Imprinted Gene Network (IGN) and are involved in embryonic and 
postnatal growth control (Fauque et al., 2010). They are located 90kb 
apart from each other on the distal end of human chromosome 11p15.5 
and mouse chromosome 7q11-13. Gene expression is controlled by a 
shared DMR upstream of the maternally expressed H19 gene (Leighton et 
al., 1995). Methylation is solely on the paternal allele, which acts as a 
chromatin boundary to the un-methylated maternally expressed H19 
gene, in addition to shielding the maternal IGF2 gene from essential 
enhancer sequences and transcriptional activators such as CGBP, leading 
to repression (Figure 1.7) (Tilghman, 1999;  Voo et al., 2000).  
 
IGF2 receptor (IGF2r) is a transmembrane receptor that transports IGF2 
to the lysosomes. During development, the receptor reduces the amount 
of IGF2, therefore limiting embryonic growth (Wutz et al., 2001). The 
expression of IGF2r is regulated by differential methylation at two 
separate regions, DMR1 and DMR2. The hyper-methylated regions on the 
paternal allele are expressed (Sasaki et al., 1992). DMR2 methylation is 
essential for IGF2r expression (Feil et al., 1994). The maternally 
expressed IGF2r is also epigenetically regulated through expression of the 
anti-sense RNA transcript Air, which regulates its own allele-specific gene 
expression. Anti-sense RNA is defined as messenger RNA (mRNA) 
transcribed from an imprinted allele in the opposite direction to normal 
transcription leading to blockage of further transcription from this allele 
(Young and Fairburn, 2000).   
 
The maternally expressed IGF2r is not translated into a protein but is 
involved in removal of the paternally expressed IGF2 ligand by targeting it 
for degradation in the lysosomes. Deletion of the maternal IGF2r allele in 
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mice results in a 30% increase in birth weight, organ overgrowth and 
polyhydraminios, whilst no phenotypic effect was observed upon deletion 
of the paternal counterpart (Eggenschwiler et al., 1997).  
 
Gene expression of IGF2 and H19 is hypersensitive to disruptions during 
gametogenesis and stresses during in vitro culture, which is why they are 
used as a quasi-sensor for epigenetic perturbations (Nan et al., 1998). 
The maternal un-methylated DMR upstream of H19 contains four DNase-1 
hypersensitive sites that are coated by nuclear proteins such as the zinc 
finger protein binding site CTCF to protect the region against methylation 
development (Figure 1.6) (Feil and Khosla, 1999). Disturbances in 
establishment of imprints as a consequence of superovulation or after in 
vitro manipulation can result in these sites becoming methylated, leading 
to a complete absence of H19 expression and bi-allelic expression of IGF2 
(Thompson et al., 2002). The H19 CTCF1-2 region is more susceptible to 
disruption during ART (Fauque et al., 2007). 
 
 
 
 
 
 
Figure 1.6: (A) IGFII and H19 genes are regulated by methylation of the 
paternal DMR upstream of H19. (B) The maternal DMR upstream of H19 has 
nuclease hypersensitive sites that following ovarian stimulation may become 
methylated (Adapted from Thompson et al 2001). 
 
1.5 Implantation  
1.5.1 Implantation in human 
The implantation site in the human is usually at the uterine fundus (Chen 
et al., 2012). Implantation involves the reciprocal interaction between the 
trophectoderm of the blastocyst and the uterine endometrium resulting in 
B A 
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apposition, adhesion and subsequent trophoblast invasion (Aplin, 2006). 
The development of new blood vessels (angiogenesis) and immunological 
protection from the maternal defence mechanisms is also essential 
(Khamsi et al., 1998). This event is orchestrated by genetic and cellular 
signals but despite its importance in initiating a conception, very little 
information is available about this process. This is partly due to the 
inaccessibility of the uterus during the implantation event and lack of 
suitable models to study its mechanism of function.   
 
Embryo implantation starts with the rapid proliferation and differentiation 
of uterine stromal fibroblasts, in a progesterone dependent manner, into 
large epithelioid-like decidual cells to form a new structure, the decidua. 
Decidua formation is associated with an increase in maternal angiogenesis 
(formation of new vessels from existing vasculature) regulated by 
vascular endothelial growth factor (VEGF) actions through specific VEGF 
receptors (VEGFRs) (Douglas et al., 2009). VEGF is a 40-45 kDa, 
disulphide linked homo-dimeric glycoprotein, that functions as a potent 
mitogen and chemo-attractant for endothelial cells (Neufeld et al., 1994). 
Uterine epitheloid cell proliferation is significantly increased after 
implantation indicating the embryo may provide a stimulus that enhances 
angiogenesis. The extravillous trophoblast can modulate vascularisation 
directly or indirectly via the angiogenic factor VEGF-A (Plaisier et al., 
2007). The decidual vasculature is the primary nutrient exchange 
apparatus for the embryo until the placenta becomes fully functional 
(Kashiwagi et al., 2007).      
 
The human placenta is extremely invasive with trophoblast cells breaching 
the uterine epithelium in order to sequester a blood supply for the 
developing placenta from the spiral arteries. IGF2 is a key mediator of this 
invasion in humans and is expressed by the invasive trophoblast cells 
(Irving and Lala, 1995). In addition to its well documented mitogenic 
actions, IGF2 also promotes differentiation and migration whilst inhibiting 
apoptosis which are all essential for placenta development (Han and 
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Carter, 2000). IGF2 has been demonstrated to induce expression of VEGF 
and coincidently VEGF is primarily located in the vicinity of proliferating 
endothelium in the murine reproductive tract (Shweiki et al., 1993). It has 
therefore been suggested that VEGF forms a gradient of angiogenic 
activity in order to induce angiogenesis in the decidua. Disruption of IGF2 
gene expression results in a marked decrease in foetal and placental 
weight due to impaired trophoblast invasion and insufficient vascular 
remodelling, which reduces maternal blood flow to the placenta, acting as 
a causative factor of IUGR and pre-eclampsia (Pringle and Roberts, 2007).  
 
1.5.2 Mouse implantation 
In poly-ovular mammals such as the mouse, embryos are evenly 
distributed in a spatial temporal pattern in the uterine horn through 
peristaltic movement, termed embryo spacing (Chen et al., 2012). 
Trophoblast invasion in the murine model differs to humans because the 
trophoblast giant cells (TGCs) do not invade the endometrium but rather 
remain in close proximity to the expanding giant cell layer (Pringle and 
Roberts, 2007). In early to mid gestation the maternal vessels undergo 
extensive angiogenesis and are remodelled to form a network of dilated 
vessels that serve to maximise placental blood supply (Pringle and 
Roberts, 2007). The secretion of IGF2 from the TGCs may induce these 
vascular changes and promote early placental growth. Studies 
demonstrate IGF2 and both type 1 and type 2 IGF receptors are co-
localised in developing blood vessels, thus supporting its hypothesised 
role in both decidual angiogenesis and placental differentiation (Pringle 
and Roberts, 2007).  
 
1.5.3 The Renin-angiotensin system 
The renin-angiotensin system (RAS) also plays a pivotal role in 
decidualisation, implantation and placentation through the regulation of 
blood flow, oestradiol secretion and prostaglandin synthesis (Nielsen et 
al., 2000). It is a complex system, which is orchestrated by various 
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peptides and proteins. Proteolytic cleavage of angiotensinogen by renin 
generates the deca-peptide angiotensin (Ang) I which is ultimately 
converted to the biologically active octa-peptide Ang II by the angiotensin 
converting enzyme (ACE), as shown in Figure 1.7. Ang II has two main 
types of cell membrane located receptors, AT1 and AT2 receptors, which 
typically mediate antagonising actions (Matsusaka and Ichikawa, 1997). 
Expression of renin and angiotensinogen mRNA in the human decidua and 
placenta and high activities of ACE in the uterus, placenta and foetal 
tissues support the presence of a functional local RAS in the placenta 
(Nielsen et al., 2000).  
Figure 1.7: Components of the RAS. The majority of angiotensinogen is 
synthesised in the liver and pro-renin is converted to the biologically active rennin 
in the kidney.  
 
AT1 and AT2 receptors are located in placenta and foetal membranes, 
albeit at lower concentrations in the latter (Kalenga et al., 1996). 
Predominantly it is the G-protein coupled AT1 receptors that are localised 
in the extra-villous trophoblast (EVT), cytotrophoblast, 
syncytiotrophoblast and in and surrounding the blood vessels of the 
placental villi (Li et al., 1998). The positive correlation between Ang II 
concentration and AT1 receptor numbers suggests Ang II may directly 
regulate expression of this receptor in the placenta (Kalenga et al., 1996). 
In contrast it is the AT2 receptors that are the predominant Ang II 
receptor type in the endometrium.  
                                               Chapter 1: Literature Review 
29 
 
AT2 receptors are down-regulated during pregnancy, most likely due to 
sex steroids, but the expression of AT1 receptors remains unaltered 
(Matsumoto et al., 1996). This can be explained by the functions of the 
two receptor types following binding with the ligand Ang II. AT1 receptor 
stimulation causes vasoconstriction and promotes growth processes that 
are required throughout pregnancy. AT2 receptors, on the other hand, 
inhibit cell proliferation, apoptosis and potentially vaso-dilation and 
mediate cell differentiation (Nielsen et al., 2000).  These findings led to 
development of the concept that changes in the relative expression of AT1 
and AT2 receptors will determine whether Ang II promotes growth, 
apoptosis or differentiation, but it has yet to be assessed thus far.  
 
Studies indicate the major physiological role of the RAS in the placenta is 
to interact with other systems in order to regulate tissue function. In the 
rat, the RAS is suggested to be involved in the differentiation of stromal 
cells into decidual cells during decidualisation, a pre-requisite for 
implantation of the blastocyst (Squires and Kennedy, 1992). Ang II, 
during implantation and placentation may stimulate angiogenesis, 
increase vascular permeability and regulate growth processes (Nielsen et 
al., 2000). Ang II acts as a vasoconstrictor whilst also promoting 
vasodilatation, by stimulating synthesis of vasodilatating prostaglandins 
and vasorelaxants including nitric oxide (Li et al., 1998). These actions 
will aid regulation of vascular resistance and blood flow in the placenta.   
 
Disruptions in the RAS have been implicated in cases of pre-eclampsia and 
IUGR, specifically down regulation of AT1 receptors in the placenta (Li et 
al., 1998). Ang II has recently been suggested to play a role in early EVTs 
differentiation and entry into the decidua, via actions of the AT1 receptor 
(Tower et al., 2010). Inadequate growth and development of the villous 
tree leads to a reduction in gaseous and nutrient transfer capacity of the 
placenta which can lead to IUGR. Shallow invasion of the EVTs and 
impaired remodelling of the endometrial spiral arteries predisposes to pre-
eclampsia (Tower et al., 2010). Furthermore, decreased placental blood 
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flow and poor placental function may be caused by the decreased effect of 
Ang II in promoting secretion of vasorelaxants, ultimately leading to 
vasoconstriction (Nielsen et al., 2000). In normal pregnancies, vaso-
dilation is mediated by prostaglandin synthesis, decreasing the maternal 
arterial pressure.      
 
1.6 OVARIAN STIMULATION 
1.6.1 Clinical applications in ART 
COS regimes are tailored to individual patients based on their pre-
treatment assessment including but not limited to, ovarian reserve 
inferred through AMH levels or antral follicle counts, age, basal FSH levels, 
past response to exogenous gonadotrophins as well as the current cycle 
response, which is monitored through ultrasound and serum blood 
analyses (Jayaprakasan et al., 2008). It is patient variability which makes 
analyses of the effects of ovarian stimulation in humans problematic. 
Despite the variations in treatment doses given to patients, 
superovulation is composed of two distinct elements, the induction of a 
cohort of follicles to develop to the pre-ovulatory stage, followed by the 
final maturation and rupture of the follicle.  
 
FSH is used to induce multiple follicular growth (Huirne et al., 2004). As 
previously discussed (Section 1.2.6.1), FSH levels rise at the luteo-
follicular transition to recruit a cohort of follicles which develop to the 
tertiary stage. It has been suggested that elevation of FSH concentration 
above basal readings of 10-30% would be sufficient to stimulate the cyclic 
recruitment of follicles, termed the FSH threshold (Brown, 1978). When 
circulating levels decline in the late follicular phase due to negative 
feedback on the hypothalamus, only one dominant follicle has the 
sensitivity to continue growing whilst the rest of the growing cohort 
perishes due to atresia. The duration of elevated FSH levels termed the 
FSH window or FSH gate hypothesis as it was originally known was 
proposed as an addition to the FSH threshold theory  (Figure 1.8) (Baird, 
1987;  Fauser and Van Heusden, 1997). Administration of FSH recruits a 
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variable proportion of gonadotrophin responsive follicles to persist to the 
ovulatory stage (Webb and Campbell, 2007). 
 
 
Figure 1.8: The administration of gonadotrophins extends the window when 
serum levels are above the threshold resulting in more follicles being recruited 
(Taken from (Fauser et al., 2005)).  
 
There is also an LH window hypothesis, based on the observation that low 
doses of LH enhances granulosa cell steroidogenesis in vitro, whereas high 
doses resulted in increased synthesis of progesterone, inhibition of 
aromatase activity and suppression of cell growth (Overes et al., 1992;  
Yong et al., 1992). Premature luteinisation due to high concentrations of 
LH may therefore occur, resulting in compromised oocyte development 
(Chappel and Howles, 1991). In addition, LH has been shown to modulate 
both oestradiol and inhibin A secretion from follicles, which could also via 
negative feedback, lower pituitary FSH levels, which would affect the fate 
of FSH dependant follicles (Webb and Campbell, 2007).  
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1.7 Gonadotrophins 
1.7.1 Gonadotrophin structure 
FSH is a hetero-dimeric glyco-protein belonging to the 
gonadotrophin/thyrotropin hormone family, constituting of two non-
covalently linked subunits, a common α subunit and a hormone specific β 
subunit, as shown in Figure 1.9 (Pierce and Parsons, 1981). All β subunits 
possess 12 cysteines at conserved locations which form 6 intra-chain 
disulphide bonds that aid final conformational stability of the protein (Huth 
et al., 1993). FSH is administered to sustain peripheral gonadotrophin 
levels above the threshold. It has a half-life of approximately 2 hours 
meaning repeated injections are required to sustain FSH levels sufficiently 
high enough to maintain follicular growth.  
 
Follicle development is monitored throughout COS by the aid of ultrasound 
and serum hormone concentration analyses. Upon reaching the desired 
follicular diameter designated by the clinic (commonly 18-20mm as an 
indirect determiner of oocyte maturity), LH or its surrogate human 
chorionic gonadotrophin (hCG) is administered as a trigger to conclude 
maturation of the follicle, 36 hours prior to egg collection (Figure 1.9). 
Both LH and hCG are hetero-dymeric glyco-proteins with molecular 
weights of 30 and 40 kDa respectively (Hill et al., 2012). Both are 
composed of the common α subunit found in all gonadotrophins and a 
hormone specific β subunit.  
 
Despite LH and hCG possessing identical α subunits it is common practice 
to deliver hCG for the ovulation trigger as the modified extension of the β 
subunit increases the preparations half life (Huirne et al., 2004). The long 
half life of 33 hours for hCG is partly due to the presence of four serine O-
linked oligosaccharides on the extended hydrophilic carboxyl-terminus 
(Matzuk et al., 1990).  In addition to hCG having a slower metabolic 
clearance, it also has a stronger LH receptor binding affinity, therefore 
there is a potency ration of hCG to LH of approximately 6:1 (Group, 
2000).  
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Figure 1.9: Structural representation of the hormones used in superovulation, 
including their respective half lives. Black branches indicate glycosylation of the 
protein structure, circles indicate O-linked oligosaccharides (adapted from 
(Macklon et al., 2006b)).  
 
To prevent early ovulation in response to a premature LH surge the 
endogenous hypothalamic pituitary axis must be down-regulated 
(Janssens et al., 2000). Down regulation can be induced either by GnRH 
agonists which bind and stimulate the same type I GnRH receptor as 
native GnRH provoking down-regulation through receptor clustering and 
internalisation, or antagonists that cause an immediate reversible 
suppression (approximately 6 hours) of gonadotrophin secretion from the 
pituitary by competitive inhibition of the GnRH receptor (Conn and 
Crowley, 1994). Immature mice were used in our study to overcome the 
need to induce down regulation.  
 
1.7.2 Purified gonadotrophins 
Over the past three decades pharmaceutical companies have been 
developing more potent and purer drugs with the aim of getting maximal 
number of oocytes developing for ART therapies (Figure 1.10). 
Gonadotrophin hormones were first discovered by Ascheim and Zondek in 
1927 when they isolated human chorionic gonadotrophin (hCG) from the 
blood and urine of pregnant women. hCG was extracted from human 
placenta and released on the market in 1931, under the trade name 
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Pregnyl (Lunenfeld, 2004). Purified urinary preparations of hCG were later 
released in 1940 and have survived until the present day (Huirne et al., 
2004). The international units (IU) of hCG was established in 1939 and 
was defined as the activity contained in 0.1mg of the standard preparation 
as judged by vaginal opening and induction of oestrus in immature rats. 
This ranged from 6000-8500 IU/mg (Lunenfeld, 2004). 
 
Equine chorionic gonadotrophin (eCG) or pregnant mare serum 
gonadotrophin (PMSG) as it later came to be known is secreted from 
endometrial cups in pregnant mares and was discovered by Cole and Hart 
in 1930. In 1938 an international unit of PMSG was defined as 0.25mg of 
the standard preparation, which was defined as the total dose required to 
increase rat ovarian weight fivefold (Lunenfeld, 2004). Commercial 
preparations were released on the market soon after. It is a 60kDA 
glycoprotein and although being similar to hCG, in terms of terminal 
extension and glycosylation of the ǃ-subunit increasing its half life, PMSG 
has both FSH and LH activity, so can function as a stimulator and 
ovulation inducer in most species by stimulating oestrogen production 
which then triggers the LH surge (Chopineau et al., 1997;  Lunenfeld, 
2004). PMSG is excreted in a highly viscous gel from the endometrial cups 
at the point of attachment of the foetus on the surface of the 
endometrium from i.e. 40-130 days gestation, peaking at 50-70days. 
PMSG hormone is released into the peripheral circulation and prepared by 
collecting blood from pregnant mares near the 65th day of gestation.  
 
As early as 1938 David and Koff described the ability of intravenously 
administered PMSG to induce ovulation in humans. However although it 
was shown PMSG produced an ovarian response during the follicular 
phase, attempts to induce ovulation afterwards was inconsistent and 
progesterone changes in the endometrium did not occur, preventing any 
pregnancies (Lunenfeld, 2004). Treatment of women with PMSG was also 
hampered due to the inter species differences resulting in formation of 
antibodies to the gonadotrophins, which in some cases cross reacted with 
their endogenous FSH and LH (Macklon et al., 2006a). Due to reduced 
efficacy and safety of gonadotrophic preparations from animal sources the 
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approval of the use of PMSG in human fertility management was revoked 
in 1972, but its application in rodent stimulation and other mammals is 
still widely utilised, as due to the long half life, only a single injection is 
required (Lunenfeld, 2004). 
 
The first menotrophin, human menopausal gonadotrophin (hMG) was 
isolated in 1949 from crude extracts of large urine pools. 30 litres of urine 
were required to make enough hMG for a single treatment cycle (Macklon 
et al., 2006b). It was first released for clinical use in Italy by Serona in 
1950 and the first pregnancies from this preparation were reported in 
1962.(Lunenfeld, 2004). The original Pergonal 75 hMG preparation 
contained a combination of FSH and LH (75 IU) bioactivity in a 1:1 ratio, 
with an indeterminate amount of urinary protein contamination, estimated 
to be around 95% due to the crude and labour intensive production 
techniques (Lunenfeld, 2004). The original hMG preparation units used 
were referenced to a known standard batch called the international 
reference preparation (IRP-hMG) and judged on the capacity of the 
compound to induce oestrus in 28 day old immature rats. hMG was 
retrospectively standardised to IU of FSH and LH and based on the 
average dose given to patients (55-110IU daily). Pergonal 75 bioactivity 
was measured by the standard in vivo rat ovarian weight gain Steehlman 
and Pohley bioassays. 
 
As protein purification techniques improved, with the application of 
immuno-affinity chromatography, the relative amounts of the active FSH 
ingredient increased leading to the manufacturing of urine derived 
preparations (urofollitrophins) containing only urinary FSH (uFSH) (Huirne 
et al., 2004). By using an immuno-column with monoclonal antibodies for 
FSH, urinary hMG is filtered through with only LH and urinary proteins 
removed, whilst FSH is retained in the column where it can be extracted 
and lyophilised to a biologically pure FSH preparation. This results in an 
FSH product containing <0.1IU LH activity and <5% unknown urinary 
contaminants (Lunenfeld, 2004). This technology led to the development 
of highly purified hMG in the past decade, currently used today, where the 
LH component removed during the purification of FSH is replaced using 
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10IU of hCG (75IU equivalent LH bioactivity) enabling LH activity 
constituents to be better controlled (Wolfenson et al., 2005). Based on 
publications in the literature, this new highly purified preparation was 
potentially released on the market in 2000; however the exact year is not 
disclosed in any publication or the company website to our knowledge.    
 
1.7.3 Recombinant gonadotrophins 
Although improvements in the purity and specific activity of urinary 
gonadotrophins had been achieved, the enormous quantities of urine (20-
30 litres of urine per cycle) required to supply the increasing demand was 
a limitation. The advent of recombinant DNA technology in the 1990s led 
to the production of recombinant gonadotrophins, bypassing this 
requirement for urine and promising unlimited availability of 
gonadotrophins with reduced batch to batch variability (Balen et al., 
1999). Recombinant DNA technology enables novel gonadotrophins to be 
produced with longer or shorter half lives whilst the improved purity 
eliminates the risk of allergic reaction. Furthermore the batch-to-batch 
consistency compared with urinal gonadotrophins may improve the 
outcome of treatment. Due to the improved purity, rFSH, in addition to 
being expressed in IU of bioactivity, can also be expressed as protein 
weight (mass in µg) in so called filled by mass preparations. 
 
Human recombinant FSH (rFSH) was developed in 1988 by stably 
transfecting the α- and β-FSH subunit into Chinese hamster ovary (CHO) 
cells via cloning plasmids (vectors) which also contained promoters so 
that transcription and synthesis of functional glyco-proteins initiated in 
recipient cells (Lunenfeld, 2004). Gonal-F® manufactured by Serono 
laboratories used two separate vectors to transfer the α- and β- subunits 
whereas Puregon® developed by Organon used a single vector containing 
the coding sequences of both subunit (Howles, 1996;  Olijve et al., 1996). 
No differences in clinical performance between the two recombinant 
products has been proven (Lunenfeld, 2004). The first pregnancy from 
rFSH was reported in 1992 from COS for IVF (Devroey et al., 1992). rFSH 
was licensed for clinical use in 1995 and is now available in the form of 
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follitropin-α (Gonal-F) and follitropin-β (Puregon). Pergoveris was 
recently developed which is a composition of rFSH and rLH in a 2:1 ratio 
combination (150 IU of follitropin α and 75 IU of lutropinα) as a mode of 
providing adequate doses of both FSH and LH gonadotrophins to stimulate 
follicle development (Bosch, 2010). Two pharmacodynamic studies have 
been conducted to assess the response of concomitant exposure to FSH 
and LH in a fixed dose. In the mouse model they displayed a synergistic 
effect on follicle development in vitro whilst in the monkey promotion of 
follicle growth and oestrogen production was evident (Liu et al., 2002;  
Karnitis et al., 1994). Recombinant hCG (rhCG) and LH (rLH) have 
additionally been developed in the 21st century (lutropin-α (Luveris) and 
choriogonadotropin-α (ovidrel)). 
 
Figure 1.10: Graphic overview of the main milestones in the development of 
gonadotrophins for clinical application. (Adapted from Macklon et al 2006).  
 
1.7.4 Efficacy of different gonadotrophins for COS 
Large scale multi centre comparative trials were conducted before the 
clinical implementation of rFSH. Initial trials were positive with an early  
meta-analysis of these studies favouring rFSH over uFSH in terms of 
clinical pregnancy rates (Daya and Gunby, 2000). This meta-analysis 
however was withdrawn from the Cochrane database due to a conflict of 
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interest and inclusion of no up to date trials (Daya and Gunby, 2006). 
Many independent comparative trials have been performed since but 
provide variable results and are underpowered due to small sample sizes 
in the single centre studies. Meta-analyses and systematic reviews 
therefore provide the best indicators of differences in pregnancy rates and 
the effectiveness of the different gonadotrophin preparations.  
 
Another meta-analysis of randomised controlled trials from the same 
period found no difference in cumulative ovulation rates, pregnancy rate, 
miscarriage rate, multiple pregnancy rate or ovarian hyper stimulation 
syndrome (OHSS) risk when the stimulatory effects of rFSH were 
compared with its traditional urinary counterpart (Bayram et al., 2001). In 
support of this was an updated analysis which again showed no difference 
in pregnancy rates between hMG, uFSH and rFSH (Al-Inany et al., 2003). 
The same research group, upon inclusion of the new highly purified hMG 
containing hCG as the LH substitution found clinical pregnancy rate and 
live birth rates in favours of hMG compared with rFSH, but only in the IVF 
patients (Al-Inany et al., 2009). Another meta-analysis at the same time 
found this positive trend in favour of highly purified hMG, for both IVF and 
ICSI patients with a pooled increase in pregnancy rate of 4% 
(Coomarasamy et al., 2008).   
 
The debate as to which preparation is more efficaous was concluded to be 
in favour of no differences in terms of clinical success between hMG, uFSH 
and rFSH according to a the latest Cochrane systematic review which 
suggested further research in this area is unwarranted (van Wely et al., 
2011). However this review put all hMG studies together and did not 
distinguish between hMG and the new highly purified hMG which has its 
LH activity from hCG. A more recent review concluded highly purified hMG 
in long GnRH agonist cycles only, led to an increase in live birth rates of 
3-4% (Hill et al., 2012). It has been suggested this is due to the 
preparation containing both FSH and LH activity which is required for 
normal ovulatory follicle development. In support of this, high circulating 
levels of exogenous hCG in the blood of women stimulated with highly 
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purified hMG during mid follicular phase of the cycle has been positively 
associated with live birth rates (Arce and Smitz, 2013).  
 
In normo-gonadotrophic women, supplementation of endogenous LH has 
been considered to be detrimental to follicle growth. The debate has 
resurfaced recently through increased understanding of the role of LH in 
optimising oocyte quality (Filicori and Cognigni, 2001). Excessive 
suppression of LH (<0.5 IU/L) with down regulation may impair oestrogen 
synthesis resulting in low oocyte yield, fertilisation and pregnancy rates 
with an associated increased risk of spontaneous abortion (Westergaard et 
al., 2000;  Fleming et al., 2000). Therefore there may be a requirement 
for LH supplementation in ovarian stimulation to increase androgen 
production for aromatisation into oestrogen, maintaining the natural 
follicular milieu, potentially improving oocyte quality and thus embryo 
quality and implantation rates (Bosch, 2010).  
 
As mentioned in section 1.2.8, LH exerts some of its actions on the 
cumulus cells surrounding the developing oocyte. These cells are involved 
in bi-directional communication with the oocyte which is vital to sustain 
oocyte viability, thus early embryo development. Therefore LH may be an 
essential component absent in some ovarian stimulation regimes in some 
patients, particularly those whose endogenous LH levels are low (Platteau 
et al., 2004). However, as discussed in section 1.6.1, LH at high levels has 
been shown to have detrimental effects on oocyte development, therefore 
it may not be suitable for all. Current evidence suggests LH 
supplementation does not benefit all patients but improves pregnancy 
rates in poor responders and those of advanced maternal age (>35 years) 
(Mochtar et al., 2007). In normo-gonadotrophic patients clinical 
pregnancy rates, implantation rates and embryo quality were comparable 
with traditional hormone preparations, with a slightly elevated risk of 
OHSS in the Pergoveris group (Pacchiarotti et al., 2010).  
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1.7.5 Ovarian stimulation in mice 
Mice reach sexual maturity at approximately 6 weeks of age and are 
spontaneous polyoestrus ovulators that release 8-12 oocytes at ovulation 
depending on the strain (Nagy et al., 2003). This value can be 
substantially increased with the use of exogenous gonadotrophins, 
reducing the number of animals required for experimentation (Nagy et al., 
2003;  Fowler and Edwards, 1957). The established superovulation 
protocol for the laboratory mouse involves the (intra peritoneal) injection 
of PMSG to induce multiple follicle recruitment followed by hCG to induce 
ovulation (Nagy et al., 2003;  Fowler and Edwards, 1957;  Luckett and 
Mukherjee, 1986). These injections are administered 48 hours apart in 
mice due to the short oestrus cycle of 3-4 days (Nagy et al., 2003). 
Ovulation occurs 10-13 hours post hCG injection (Nagy et al., 2003). The 
advantage of PMSG is that it only requires a single injection, however this 
preparation is associated with detrimental effects on the embryo and 
offspring, as discussed in section 1.8.2. 
 
Since their clinical implementation, stimulation of mice with human 
gonadotrophins has been investigated to see whether they would yield 
better quality embryos as observed in humans. Although hMG increased 
the number of oocytes collected compared to uFSH in immature mice, the 
gold standard PMSG was still superior in terms of oocyte yield and 
fertilisation rates (Edirisinghe et al., 1986). In contrast another research 
group proposed uFSH to be superior to PMSG based on comparable in 
vitro and in vivo embryo viability, potentially because this group used 
mature mice of an alternative strain and in addition gave repeated 
injections of uFSH to overcome the short half life of the gonadotrophin 
preparations, whereas the previous study just gave a single high dose 
injection which may not have been sufficient to stimulate follicle 
development (Muñoz et al., 1995). rFSH has been shown to improve the 
number of mature oocytes retrieved from mice compared to uFSH which 
lead to improved fertilisation in the recombinant cohort, but further 
embryo development was not assessed (Calongos et al., 2008). More 
recently, hMG was shown to yield comparable number of oocytes and 
good morphology embryos compared to PMSG but the hMG group resulted 
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in no live births following embryo transfer (ET) (Brooke et al., 2007). This 
study however performed micro-injection for transgenic applications and 
superovulated mature mice which could have confounded the results. 
Comparisons of the different superovulation regimes in mice are difficult, 
due to the various strains and age of mice used, combined with the 
different doses and timing of gonadotrophin injections.  
 
1.8 CONSEQUENCES OF SUPEROVULATION 
ART involves the removal of gametes and embryos from their natural 
environment and subjecting them to artificial in vitro conditions. This 
environment may have profound effects on the physiology and viability of 
the conceptus. As development proceeds the sensitivity of the embryo to 
external stimuli declines as homeostatic regulation mechanisms are 
acquired permitting control of intra-cellular pH, metabolic controls and 
limiting ionic and osmotic stress (Gardner and Lane, 2005). Therefore 
stress inflicted on the oocyte potentially as a result of non-physiological 
hormone levels during COS may have a greater effect on gene function 
and developmental kinetics that might manifest at later stages of 
development (Figure 1.6). The environment the female gametes are 
exposed to during superovulation could impact future embryo 
development by multiple pathways including changes in blastomere 
survival (Hardy and Spanos, 2002), gene expression (Niemann and 
Wrenzycki, 2000) and metabolism, all of which can impede embryo 
development  (Thompson, 1997).  
 
1.8.1 Oocyte yield  
Since the implementation of controlled ovarian stimulation (COS) in ART, 
the pregnancy and delivery rates have significantly improved, however 
the analysis of oocyte utilisation per patient portrays a conflicting story. It 
is estimated that the average live birth rate per oocyte inseminated in 
human IVF is 2-4% (Revelli et al., 2011). Therefore there is significant 
oocyte wastage when large numbers of oocytes are produced with 
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stimulation. To date very few studies have analysed the outcome of the 
various commercial hormone preparations and protocols have on the 
oocyte yield. As discussed in section 1.2 ovarian follicular development is 
hierarchal. At any moment in time, few follicles have comparable somatic 
cell compositions and endocrine environments. Follicles in functionally 
different states will respond to the stimuli of exogenous gonadotrophins 
according to their developmental stage, thus the hierarchal nature of 
folliculogenesis may not be able to be completely overridden.  
 
 
Figure 1.11: A causal model demonstrating the three main pathways that can be 
induced by stress on the oocyte through superovulation that manifests itself in 
abnormal foetal growth (Adapted from Thompson et al 2002). 
 
Consequently, even though superovulation regimes increase the 
proportion of LH responsive follicles and thus the number ovulated, it may 
be that the oocytes subsequently released will have been exposed to 
varying endocrine and nutrient micro-environments and therefore may not 
all be developmentally competent (McNatty et al., 2010). Oocyte quality 
varies widely after COS and this is most evident in high responders as it 
has been shown that the quantity of good quality embryos is inversely 
proportional to the number of oocytes retrieved (Meniru and Craft, 1997).  
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Oocytes recovered after superovulation may originate from immature or 
mildly atrietic follicles that would not have been ovulated if the current 
oestrus cycle was under normal physiological control (Hohmann et al., 
2001). In addition, the use of exogenous gonadotrophins may speed up 
the rate of nuclear maturation, which may prevent sufficient amounts of 
mRNAs to be stored, that are required for development prior to genome 
activation (Mehlmann, 2005). These hypotheses may explain the low 
success rates of ART when the number of oocytes recovered is compared 
to the number of offspring produced (Patrizio and Sakkas, 2009).  
 
1.8.2 Developmental manifestations 
1.8.2.1 Embryo development alterations 
The use of exogenous gonadotrophins on embryo development has been 
particularly characterised in the mouse model stimulated with PMSG and 
hCG. Ovarian stimulation with this drug has been shown to reduce the 
proportion of Day 5 embryos and delay development to the blastocyst 
stage both in vitro (Ertzeid and Storeng, 1992;  Van der Auwera and 
D'Hooghe, 2001) and in vivo (Ertzeid and Storeng, 2001). COS with PMSG 
was shown to increase the frequency of chromosomal abnormalities in 
embryos which is known to impair embryo development which may 
explain altered embryo development post stimulation (Chang, 1977). 
Total cell number of blastocysts and the number of micro villi on the cell 
surface was shown to be decreased following COS (Champlin et al., 1987). 
This may potentially explain the delay observed in implantation (Van der 
Auwera and D'Hooghe, 2001) and the associated increased risks of 
neonatal mortality on mice post-implantation (Beaumont and Smith, 
1975).   
 
The detrimental effects of COS in humans are difficult to define as the 
majority of embryos are produced after COS and therefore have no 
control for comparison. The ethical limitations are also a hindrance. A 
small in vitro study has shown that elevated oestrogen, commonly 
observed after COS, delayed development of cleavage stage embryos and 
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reduced embryo adhesion rates (Valbuena et al., 2001). Deleterious 
effects on oocyte quality and embryo aneuploidy has been shown to occur 
in a dose like manner in young oocyte donors (Rubio et al., 2010). 
However, no differences were observed in a retrospective study assessing 
the capacity of embryos to cleave and their morphological quality grade 
depending on if they were obtained from a natural cycle or a COS cycle 
(Ziebe et al., 2004).   
 
1.8.2.2 Postnatal development alterations 
The detrimental effects of ovarian stimulation with PMSG on embryo 
development in vivo and in vitro, implantation rates, foetal mortality and 
live birth weight have been well categorized in mice (Ertzeid and Storeng, 
2001;  Ertzeid and Storeng, 1992;  Van der Auwera and D'Hooghe, 2001). 
Analogous ailments have also consistently been correlated in human 
pregnancies with singleton conceptions generated through IVF displaying 
more peri-natal complications than their naturally conceived counterparts, 
including but not limited to pre-term birth, low birth weight, intra-uterine 
growth restriction (IUGR) and postnatal health issues requiring hospital 
admission (Jackson et al., 2004;  Helmerhorst et al., 2004;  Basatemur 
and Sutcliffe, 2008).  
 
In ruminants there are numerous well categorised phenotypic anomalies, 
which result as a consequence of alterations to imprinted genes and are 
collectively termed under Large Offspring Syndrome (LOS) (Smith et al., 
2012). Some of these reported abnormalities in foetuses and calves 
following the transfer of in vitro cultured embryos include increased rates 
of early embryonic death and abortion, production of large size foetuses 
and calves, musculoskeletal deformities, disproportionate foetal growth, 
abnormal organ growth, failures in development of the allantois, and 
abnormalities of placental vasculature and development including 
hydrallantois (Farin et al., 2006). However, this large range of 
developmental abnormalities may arise through different mechanisms and 
is not always manifested as excessive foetal and placental growth (Farin 
et al., 2001). The abnormal development may occur at varying degrees, 
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causing heterogeneity of the LOS phenotype, which makes it difficult to 
study the underlying cause (Farin et al., 2006). The same issue is 
apparent in humans. 
 
Although these developmental quandaries have not been accredited to 
imprint or epigenetic disturbances to date, in humans, the known 
involvement of imprinted genes in regulating the nutrient transfer capacity 
of the placenta and the phenotypic similarities displayed by animal models 
(LOS) post superovulation attributed to methylation perturbations, 
suggests errors may account for a wider spectrum of ART related 
complications than is currently recognized (Maher, 2005;  Shi and Haaf, 
2002;  Khosla et al., 2001). In humans, global DNA methylation in 
placenta and cord blood is drastically altered after IVF, with in excess of 
700 genes, including imprinted genes, displaying altered methylation 
statuses compared to naturally conceived children, providing a potential 
source of the developmental and growth abnormalities (Katari et al., 
2009b).  
 
Evidence indicates low birth weight is a superfluous consequence of 
ovarian stimulation (Pelinck et al., 2010;  Kalra et al., 2011). Birth weight 
is improved, when embryos are transferred in a cryopreserved cycle. This 
provides some evidence that the effects of a stimulated cycle on the 
endometrium during a fresh cycle may also have a role in the adverse 
effects on neonatal outcomes (Belva et al., 2008). Low birth weight has 
been suggested to predispose adults to stroke, type 2 diabetes and 
dyslipidemia, collectively referred to as metabolic syndrome as a result of 
low birth weight, termed the Developmental Origins of Health and 
Disease (DOHaD) hypothesis (Barker, 1995). In a Dutch cohort study 
consisting of IVF children aged  8 to 18 years matched to naturally 
conceived controls, greater systolic and diastolic blood pressure was found 
in the IVF children, as well as high fasting blood glucose levels (Ceelen et 
al., 2008). This highlights the paramount importance of monitoring the 
long term consequences of superovulation in ART progeny. 
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1.8.3 Genetic perturbations 
1.8.3.1 ART and imprinted disorders 
In the past decade our understanding of pre-implantation development 
and the role genetics plays has vastly improved. In recent years focus has 
been directed at assessing the correlation of ART procedures with 
imprinting and genetic disorders. Whilst the absolute risk of developing an 
imprinted disorder is low, children born through ART appear to be more 
susceptible than those in the general population (Maher, 2005), as shown 
in Table 1.1. There have been numerous reports correlating genomic 
imprinting errors and disorders with ART, in both animal models (Market-
Velker et al., 2010;  Menezo et al., 2010;  Zhang et al., 2010b;  Mundim 
et al., 2009) and human subjects (Strawn et al., 2010;  Katari et al., 
2009b;  Lawrence and Moley, 2008;  Sato et al., 2007). 
 
The most documented imprint disorders are those that manifest through 
aberrant growth such as Angelman Syndrome (AS), Beckwith-Weidemann 
Syndrome (BWS), and Silver-Russell Syndrome (SRS), as summarised in 
Table 1.1 Analyses of inflicted children consistently detect methylation 
defects at the DMRs of PEG1/MEST (SRS), KCNQ10T1 (BWS) and SNRPN 
(AS) (Fortier et al., 2008). All these genes have been demonstrated to be 
perturbed following ovarian stimulation in a dose dependant manner 
(Market-Velker et al., 2010). Finding the aspect of the ART procedure 
responsible for these risks has remained elusive. Due to the low incidence 
of imprinting disorders after ART it is extremely difficult to explore cause-
effect relationships from clinical data. Therefore precisely defined in vitro 
models are powerful tools in defining mechanisms.  
 
1.8.3.2 The association of methylation and COS 
Imprint disorders however are merely the tip of the iceberg with 
disruption of methylation affecting the oocyte and embryonic genome on a 
global scale after ovarian stimulation (Shi and Haaf, 2002;  Sato et al., 
2007). The occurrence of methylation alterations when COS was the only 
medical intervention to treat the infertility lends support to the hypothesis
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Table 1.1: Summary of current information on imprinted disorders linked with ART.
          
Disorder 
                      
Phenotype 
                
Incidence in 
general population 
                         
Molecular defect in general 
population 
                 
Estimated incidence 
in ART population 
                 
Molecular defect in 
ART cases 
               
References 
 
AS 
 
 
Frequent laughter, severe 
learning handicap, lack of 
verbal communication, 
poor balance, seizures 
 
 
1 in 15,000 
 
Most cases due to deletion of 
15q11.2-15q13 or paternal 
uniparental disomy of 
chromosome 15; 3-4% have 
hypomethylation of maternal 
SNRPN allele 
 
 
Estimation of risk 
has yet to be 
calculated with 5 
documented cases 
following ART 
 
25% cases due to loss 
of methylation at 
maternal DMR 15q11-
13 for the  
SNRPN allele 
 
 
Lawrence and 
Moley 2008, 
Fortier et al 2008, 
Ludwig et al 2005  
BWS Foetal and postnatal 
overgrowth, Macroglossia, 
exomphalos, 
visceromegaly, neonatal 
hypoglycaemia, 
predisposition to 
embryonal childhood 
tumours 
 
1 in 13,700 40-50% have micro-deletions or 
loss of methylation at DMR1 
and DMR2 of 11p15, 20% 
paternal uniparental disomy, 
the remaining maternally 
inherited CDKN1C mutations, 
translocation or inversion of 
maternal chromosome 11  
 
Largest case 
controlled study 
estimates overall 
risk of BWS after 
ART is up to 9 times 
higher than general 
population  
68% of cases due to 
loss of maternal 
methylation imprint at 
KCNQ10T1 locus on 
chromosome 11 
Strawn et al, 
2010, Maher 
2005, Halliday et 
al 2004, DeBaun 
et al 2003, 
Weksberg at al 
2005  
SRS Intra-uterine growth 
restriction, limb 
asymmetry, clinodactyl, 
dimorphic facial features, 
gastrointestinal 
complications 
1 in 100,000 33-67% due to 
hypomethylation of paternal 
11p15 allele, 10% due to 
maternal uniparental disomy 
and the remaining chromosome 
11 duplication and 
translocations or deletions of 
chromosomes 1, 7, 17, X 
 
Estimation of risk 
has yet to be 
calculated with 5 
documented cases 
following ART 
Hypermethylation of 
the maternal 
PEG1/MEST locus and 
hypomethylation of 
the paternal 11p15 
Bliek et al 2006, 
Kagami et al 
2007, Amor and 
Halliday 2008  
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that superovulation is the source of methylation defects which are 
subsequently maintained through pre and post-implantation development 
as evidenced by perturbed imprints still detectable in placenta and foetal 
cord blood (Fauque et al., 2010;  Katari et al., 2009b). Epigenetic marks 
are gained in an asynchronomous manner throughout folliculogenesis in 
correlation with oocyte diameter but the majority of ICRs are methylated 
in the diplotene stage of meiosis in late oogenesis, coincidental with 
antrum formation (Lucifero et al., 2002). The unphysiological hormonal 
milieu as a consequence of exogenous gonadotrophin administration 
during this phase may perturb imprints. 
 
Several studies have highlighted the occurrence of abnormal methylation 
patterns in oocytes or embryos after hormonal stimulation, in mice, as 
well as humans. Gain in methylation at the H19 DMR has been observed 
in superovulated oocytes in a human ART program (Sato et al., 2007). 
Perturbed methylation patterns have also been reported in 2 cell mouse 
embryos after superovulation compared to un-stimulated controls, which 
was associated with embryo loss during implantation (Shi and Haaf, 
2002). Disruption of H19 expression was observed in individual 
blastocysts and bi-allelic expression of H19 and parallel increases of IGF2 
were still detectable in 9.5 day post coitum (dpc) placentas in mice 
conceived after superovulation. This highlights that methylation 
perturbations may be propagated through the cell lines (Fortier et al., 
2008;  Fauque et al., 2007). Quantitative differences in DNA methylation 
patterns have also been found in placental and umbilical blood samples 
taken from children conceived naturally and those born after IVF, again 
demonstrating the potential of aberrant methylation to remain throughout 
development (Katari et al., 2009a).  
 
During folliculogenesis it is the dominant and most competent follicle that 
is selected for ovulation over a period of time. As a result of 
superovulation, oocytes can be recovered from immature or mildly atrietic 
follicles that would not have been ovulated if the current oestrus cycle was 
under endogenous endocrinological control (Hohmann et al., 2001). The 
methylation apparatus in such rescued oocytes may not be fully 
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competent, resulting in incorrectly established methylation imprints which 
are consequently maintained in subsequent cell divisions post fertilisation 
(Baerwald et al., 2009;  Young and Fairburn, 2000). Furthermore, these 
follicles are stimulated to develop at an accelerated pace, which may 
potentially be too rapid for complete oocyte maturation and synthesis of 
maternal factors required for acquisition and maintenance of methylation 
(Li et al., 2010;  Baerwald et al., 2009).  
 
New research supports the idea that follicles are stimulated to develop at 
an accelerated pace, which may potentially be too rapid for complete 
synthesis of maternal factors required for acquisition and maintenance of 
methylation (Li et al., 2010;  Baerwald et al., 2009), by demonstrating it 
is not the initial methylation mechanism that is affected by ovarian 
stimulation but rather the mRNA stores of maternal effect gene products 
(Denomme et al., 2011).  If these stores are not sufficiently accumulated 
during oocyte maturation, due to them developing too quickly or being 
retrieved from atrietic follicles, it may render the developing embryo 
unable to maintain and regulate correct imprinted gene expression 
present in superovulated oocytes (Hohmann et al., 2001). The argument 
that superovulation is the root of imprint and methylation disturbances in 
ART is strengthened by the demonstration that their incidence is increased 
by ovarian stimulation in mice, in a dose dependent manner (Market-
Velker et al., 2010). Mouse embryos obtained after superovulation with 
PMSG displayed twice the frequency of methylation imprint perturbations 
compared with those naturally ovulated which manifested in impeded 
embryo development (Shi and Haaf, 2002). In later gestation this 
aberrant imprinting was confined to the placenta suggesting the 
trophectoderm (TE) cell lineage may be less robust at imprint 
maintenance, possibly due to the exposure of these peripheral cells to the 
external environment of the uterine milieu (Fortier et al., 2008;  Mann et 
al., 2004).   
 
The recent discovery that altered methylation following superovulation can 
trans-generationally affect the germ cells of resulting offspring and further 
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second generations in mice highlights the importance of uncovering the 
origin of the disruption, in order to improve the safety and efficacy of ART 
in humans and prevent propagation of genetic disorders to future 
generations (Stouder et al., 2009). The definitive cause of methylation 
errors is still unclear and evidently requires further investigation with 
longitudinal studies of ART children. A potential resistance to 
reprogramming during oocyte maturation may explain propagation of 
epigenetic defects to future generations but the mechanisms are still 
elusive (Youngson and Whitelaw, 2008). 
 
In addition to disruption of imprinted genes, aneuploidies in the 
developing embryos have also been investigated. Aneuploidy rates are 
high following COS and some clinical data suggests that the incidence of 
aneuploidy and chromosomal abnormalities are increased when higher 
dose ovarian stimulation regimes are used in ART (Polinder et al., 2008) 
(Baart et al., 2007). This dose dependant manner of induction of 
aneuploidy has also been demonstrated in fertile oocyte donors, where 
lower dose protocols significantly increased fertilisation rates and the 
proportion of chromosomally normal blastocysts compared to higher 
doses, in the same patient in separate cycles (Rubio et al., 2010).  
 
1.8.4 Disruption of implantation 
It is evident from the implantation rate data from infertile women 
undergoing IVF that the majority of embryos fail to implant. Implantation 
is a complicated process involving uterine cell adhesion, invasion of the 
endometrium, angiogenesis and immunological shielding from the 
maternal defence system (Khamsi et al., 1998). In mice implantation 
rates in superovulated females are significantly lower than unstimulated 
animals (Ghaemi et al., 2008). Failure to implant could be a consequence 
of endometrial receptivity inadequacy or due to an inherent problem with 
the embryo such as defective genes. Although both plausible, studies 
distinguishing between these two theories are scarce.  
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Blastocysts collected after superovulation with PMSG, which we 
subsequently transferred to non-stimulated mice for in vivo pre-
implantation embryo development, showed reduced numbers of micro-villi 
on their surfaces and were consequently associated with lower chance of 
implantation (Champlin et al., 1987). Flushed blastocysts from 
superovulated mice have been shown to have smaller trophoblastic 
outgrowths which may affect extra-cellular proteolysis required for 
implantation (Ertzeid et al., 1993). Therefore, poor embryo quality may be 
due to COS.  
 
In humans, luteolysis is advanced after the final oocyte maturation trigger 
in superovulation, leading to a reduction in the luteal phase and a 
concomitant reduction in pregnancy rate, possibly due to asynchronicity 
between the embryo and endometrium (Beckers et al., 2003). This can be 
explained by the clearance of hCG levels administered mid-cycle in 
combination with the continued suppression of pituitary LH secretion and 
progesterone levels, resulting in pre-mature regression of the CL. Whist 
oestrogen provides feedback for gonadotrophin synthesis it also plays a 
functional role in stimulating cervical mucus secretion and proliferation of 
the endometrial lining. Reduced oestrogen synthesis as a consequence of 
suppression of LH production during down-regulation may impair 
endometrial receptivity of the embryo leading to failed implantation 
(Bosch, 2010). Furthermore the uterus is a vibrant source of growth 
factors and cytokines in whose secretion, steroids may play a role (Ertzeid 
et al., 1993). Oestrogen has recently been shown to stimulate the 
angiogenic factors, vascular endothelial growth factor (VEGF) and 
endothelial nitric oxide synthase (eNOS) expression in the ovary (Ha et 
al., 2010). Disruption due to exogenous gonadotrophin administration 
may cause imbalances in the uterus inhibiting implantation.  
 
High dosages of exogenous hormones are associated with a decline in 
pregnancy rates (Stadtmauer et al., 1994). Thus increasing hormone 
doses in an effort to increase the number of oocytes obtained may have 
detrimental consequences for embryo development. The non-physiological 
hormonal milieu of the uterus during COS, is detrimental to endometrial 
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receptivity, with the elevation of oestrogen dictating the duration of the 
implantation window (Kolibianakis et al., 2002). Luteal phase 
progesterone supplementation to compensate these effects of down-
regulation on the females ability to sustain a pregnancy is now common 
practice in COS (Macklon et al., 2006a).  
 
1.9 HYPOTHESIS, AIMS AND OBJECTIVES OF 
RESEARCH 
Despite the poor implantation rates after ART and the increased 
prevalence of disorders in resulting children, there is paucity of 
information on the definitive identification of the causal factor. The one 
thing the majority of ART treatments have in common is superovulation, 
therefore with our enhanced appreciation of the importance of genomic 
profiles, particularly imprinted genes, it is pertinent to assess the 
protocols to identify what is responsible for ART consequences. The overall 
objective of this research therefore was to assess the impact of different 
gonadotrophin preparations on oocyte yield, oocyte quality and 
subsequent embryonic and foetal development.  
 
Various commercial preparations of gonadotrophin hormones have been 
developed and are in clinical use today. Adequate investigations into the 
effects of these preparations in superovulation protocols are lacking. It is 
the specific aim of this research to examine 3 different human 
gonadotrophins, hMG, rFSH and combined rFSH and rLH in a 2:1 
combination (Pergoveris) in mouse superovulation on the outcomes of 
oocyte yield, embryo development, number of pregnancies, health of 
offspring and ovarian pathology. The results of this will be compared to 
the un-stimulated negative control and PMSG the COS positive control. 
This will be achieved by completing the following specific objectives: 
1. Assess the impact of the treatments on oocyte quality. Cumulus cell 
morphology will be categorised and after removal will be analysed 
for the angiogenic factors VEGFA, PEDF and MYHII. The maturity 
status of the oocytes will then be assessed and fertilised zygotes 
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will remain in culture. The hypothesis is that ovarian stimulation will 
reduce the quality of oocytes.  
2. Assess the impact of the treatments on embryo quality. Embryos 
will be cultured for 5 days with daily monitoring. Upon reaching the 
blastocyst stage, embryos will be graded and stained to provide 
further information on quality in terms of cell numbers and 
apoptosis rates. The hypothesis is that stimulation with PMSG, will 
be more detrimental than human gonadotrophins.  
3. Assess the impact of the treatments on gene expression. 
Specifically we will look at the expression of imprinted genes H19, 
IGF2 and IGF2r and the RAS genes ATR1, ATR2 and VEGFA in 
blastocysts. The hypothesis is that blastocysts following treatment 
with PMSG will have greater differences in gene expression 
compared to naturally ovulated control, than those stimulated with 
human gonadotrophins.  
4. Assess the impact of the treatment on resulting offspring following 
embryo transfer. After in vitro culture, blastocysts will be 
transferred to pseudo-pregnant females and the pups born will be 
analysed for total body weight and relative organ weights for the 3 
weeks prior to weaning. The hypothesis is that pups born following 
treatment with human gonadotrophins will be more comparable to 
non-treated controls, than those born after PMSG stimulation. 
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CHAPTER 2: MATERIALS AND METHODS 
 
The following chapter describes those methods common to all the in vitro 
trials carried out for this study. Any changes made or additional 
techniques performed for a specific study are detailed in the relevant 
chapter. In order to assess the consequences of superovulation on embryo 
and subsequent development, mouse zygotes were obtained from females 
superovulated with different protocols and cultured in vitro. Pregnant 
mare serum gonadotrophin (PMSG), human menopausal gonadotrophin 
(hMG), recombinant follicle stimulating hormone (rFSH) and rFSH and 
recombinant luteinising hormone (rLH) in a 2:1 ratio were used in the 
superovulation sub-experiments, allowing comparisons to be made 
between the different regimes in terms of embryo yield and quality. 
Zygotes obtained from naturally mated mice were used as negative 
controls for in vitro development rate and gene expression. Following 
collection, the culture and manipulation of embryos were kept constant 
regardless of the experimental group, meaning only the affect of the 
superovulation protocols were being analysed.  
 
2.1 OVARIAN STIMULATION 
All mice and embryos utilised in this research were ethically approved and 
regulated under the Scientific Procedures Act of 1986. All research 
conducted was covered by the Home Office under license numbers 
40/2914 and 40/3480 held by Professor Bruce Campbell. Trained staff 
with their own personal Home Office license euthanized the mice. Four-
five week old (C57BL/6 x CBA)F1 hybrid female mice (Charles River UK 
Ltd, Margate, UK) were ordered throughout the study. Mice were housed 
in groups of 4 in enclosed IVC cages at suitable conditions with food and 
water ad libitum, on a 12 hour light and 12 hour dark cycle within the 
Biomedical Sciences Unit (BMSU) at the University of Nottingham, for a 
minimum of 7 days to synchronise the oestrus cycles (Lee-Boot Effect). 
                                                      Chapter 2: Material and Methods 
55 
 
Upon reaching the desired weight of approximately 17g at 5-6 weeks of 
age, mice were randomly allocated to the superovulation sub-experiments 
to minimise external influences such as genetic background of the donor 
mouse and culture conditions. Eight week old male B6CBAF1 mice were 
also maintained in the animal unit for a maximum of 6 months to ensure 
optimal mating capacity.  
 
2.1.1 PMSG stimulation 
Five-six week old (C57BL/6 x CBA)F1 female mice were superovulated by 
injection with 5IU of Pregnant mare serum gonadotrophin (PMSG) 
(Intervet, Buckinghamshire, UK) into the peritoneal cavity at 11am and 47 
hours later, at 10am, 5IU of human chorionic gonadotrophin (hCG) 
(Chorulon, Intervet) was administered. Females were monogamously 
caged with males of the same genotype (B6CBAF1) and mated overnight.  
 
2.1.2 hMG, rFSH and Pergoveris stimulation 
Five-six week old female mice were superovulated by injection with the 
gonadotrophin preparations summarised in table 2.1 twice daily at 8.30am 
and 5.30pm for two consecutive days. On the third day at 10am, 5IU hCG 
was administered and females were monogamously caged with males and 
mated overnight.  
Table 2.1: Summary of human gonadotrophins used  
     
Preparation 
                         
Manufacturer 
      
Concentration 
           
hMG 
                         
Menopur, Ferring 
Pharmaceuticals 
               
0.5 or 5IU 
Pergoveris Merck Serona 0.5 or 5IU 
rFSH Gonal-F, Merck Serono 0.5 or 2.5 or 5IU 
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2.2 Naturally mated control 
The natural ovulation (negative in vitro control) group of 5-6 week old 
B6CBAF1 females were housed with males of the same genetic stain for 
three consecutive nights. Upon vaginal plug detection each morning 
following mating, females showing evidence of copulation were euthanized 
and embryos and ovaries obtained, whilst unplugged females remained 
with the males until the following morning when evidence of mating was 
investigated again. If on the third morning female mice had failed to plug 
they were not used in the experiments. The majority of female mice 
plugged on the third night of housing with the male, in accordance with 
the literature, known as the Whitten effect (Whitten, 1956).  
 
2.3 EMBRYO COLLECTION AND CULTURE 
The presence of copulation plugs indicating day 1 of pregnancy was 
assessed the following morning and all female mice were euthanized by a 
schedule 1 approved method. Cervical dislocation was the method chosen 
as it has been shown to be an effective technique for obtaining intact 
oocytes (Roustan et al., 2012). 
 
2.3.1 Embryo collection 
All culture media used was purchased from Vitrolife1 and prepared fresh 
on the day of usage. Reagents and consumables were purchased from 
Sigma Aldrich UK unless otherwise specified. All procedures were carried 
out on a heated stage (LINKAM CO102, Surrey, UK) with the temperature 
in the culture medium at 37ûC. After euthanasia embryos were collected 
as quickly as possible to avoid the deleterious effects observed through 
extended handling in GMOPS2. Mice were sprayed with 70% alcohol 
(458600, Sigma Aldrich) and following removal of the dermis and 
dissection of the peritoneal wall with scissors, each ovary and uterine horn 
                                      
1 See Appendix 1 for media compositions 
2 See Appendix 2 for experimental data on GMOPS  
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was teased from the abdomen with the aid of forceps and the ovary and 
oviduct excised (Figure 2.1). Collected tissue was immediately placed in a 
centre well dish (BD Falcon, 353653, Oxford) containing 1ml of warmed 
G-MOPSTM in the well and 3ml in the moat (Vitrolife, Warwick, UK) which 
had previously been supplemented with 5% Human Serum Albumin (HSA) 
and incubated in a non-gassed humidified chamber at 37ûC (PLANER 
BT37GP, Middlesex, UK). Left and right ovaries and oviducts were kept 
separate throughout.  
 
Figure 2.1: A Following cervical dislocation, mice were spread with 70% alcohol. 
B The skin pulled away from the abdominal region. C The peritoneum cut to 
expose the internal abdominal organs. D The bi-cornuate uterus, oviducts and 
ovaries located and oviduct extracted.  
 
The embryo cumulus complex was removed from the oviduct by tearing 
the swollen ampulla region with a sterile needle (BD Microfine, 324899, 
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Oxford, UK) under a stereoscopic dissecting microscope (OLYMPUS SZ40, 
Southend-on-sea, UK) with a heated stage (Figure 2.2). One cell embryos 
collected were denuded in 50µl drops of 80IU bovine testes derived 
hyaluronidase (H4272) under 3ml of mineral oil (M8410) in 35mm cell 
culture dishes (Corning, 430165, Sigma-Aldrich) and washed twice in 50µl 
drops of GMOPS under oil before being put into culture using a 10µl Gilson 
pipette.  
 
 
 
 
Figure 2.2: Schematic diagram depicting the oviduct (Nagy et al., 2003).  
 
2.3.2 In vitro embryo culture 
Throughout all procedures and handling of embryos 0.130-0.133mm 
denudation pipettes (Swemed, 14302, Vitrolife) were used unless stated 
otherwise. All dishes were prepared a minimum of 1½ hours in advance to 
allow equilibration (Doherty and Schultz, 2000). Day 1 pronuclear 
embryos were transferred to 60mm culture dishes (BD Falcon, 353652) 
containing twenty five 5µl micro-drops of G-1 culture medium (Vitrolife) 
supplemented with 5% HSA overlaid by oil pre-equilibrated in a benchtop 
incubator at 37ûC, 6% CO2 (MINCs, COOK). After transferral embryos 
were incubated at 37ûC in a humidified atmosphere with 6% CO2 (Sorvall 
Heraeus BB6220 Incubator, Kendro Laboratory Products, Basingstoke, UK) 
for continued single embryo culture. When embryos reached the 4-8 cell 
stage assisted hatching (Refer to section 2.4.1) was performed before 
transferring them to 60mm culture dishes containing twenty five 5µl drops 
of G-2 medium (Vitrolife) supplemented with 5% HSA overlaid with oil and 
incubated again in a closed incubator system at 37ûC and 6% CO2 and 
atmospheric O2.  
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2.3.2.1 Development monitoring 
Assessment and documentation of cleavage was performed at a pre-fixed 
time daily from embryo collection until the blastocyst stage using image 
capture software (XYCLONE, Hamilton Thorne Biosciences, Beverly, MA). 
The in vitro development of embryos was not affected by the daily 
removal of the embryos from the incubator for analysis as exposure to 
atmospheric conditions was as brief as possible and the temperature was 
maintained by a heated stage.3  
 
Towards the end of the study embryos were also cultured in an 
EmbryoscopeTM Incubator (Parallabs Ltd, UK/Unisens FertiliTech A/S, 
Denmark) which has an integrated inverted microscope and imaging 
system for embryo viewing. Digital images were acquired every 20 
minutes in 7 focal planes, permitting time lapse analysis. Subsequent to 
collection and denudation embryos were loaded individually into the 25ǋl 
drops of G-1 media under 2ml mineral oil in the embryoscope slide. 
Twelve embryos were loaded per slide, and returned to the Embryoscope 
for further culture. Media change was performed by washing out the wells 
with pre-equilibrated G-2 media using a footprint technique. This self 
contained incubator uses a tri-gas mix to control the CO2 and O2 levels at 
5% and 6% (lower than 21% atmospheric utilised by the other incubator). 
 
2.3.2.2 Blastocyst grading  
Blastocysts were classified into different developmental stages: early 
(blatoceal cavity not fully formed), fully expanded (Blastocoel completely 
filling cavity and expanding the zona pellucida), hatching and hatched. 
Blastocysts were further graded according to the detailed grading system 
developed by Gardner and Schoolcraft (Gardner and Schoolcraft, 1999) as 
shown in Table 2.2.  
                                      
3 See Appendix 3 for experimental data on daily monitoring of embryos.  
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Table 2.2: The three separate quality scores assigned in blastocyst grading. 
(Adapted from Gardner and Schoolcraft 1999). 
 
Expansion 
Grade 
 
Blastocyst development and stage status 
 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
 
Blastocoel cavity less than half the volume of the 
embryo 
Blastocoel cavity more than half the volume of the 
embryo 
Full blastocyst, cavity completely filling the embryo 
 
Expanded blastocyst, cavity larger than the embryo, 
with thinning of the shell 
Hatching out of the shell 
 
Hatched out of the shell 
 
 
ICM Grade 
 
Inner cell mass quality 
 
 
A 
B 
C 
 
 
Many cells, tightly packed 
Several cells, loosely grouped 
Very loose cells 
 
TE Grade 
 
 
Trophectoderm quality 
 
A 
B 
C 
 
 
Many cells, forming a cohesive layer 
Few cells, forming a loose epithelium 
Very few large cells 
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2.3.3 DAPI staining of arrested embryos 
Embryos without distinguishable polar bodies or pronuclei that remained 
uncleaved at the time of media change were classed as unfertilised and 
underwent oocyte staining to determine the maturity status. In addition 
embryos which had ceased cleavage at the 2 cell stage onwards were also 
stained to determine the putative cause for the developmental arrest. 
 
Subsequent to 5 minutes wash in Dulbeccos Phosphate Buffered Saline 
(PBS) (D8537, Sigma) supplemented with 2% bovine serum albumin 
(BSA) (Albumin Bovine, A2153, Sigma) (PBS-BSA), oocytes were 
incubated at room temperature in 4% paraformaldehyde (PFA) (43368, 
Alfa Aesar, Lancashire, UK) for 20 minutes and washed again in PBS-BSA 
before incubation in 0.5% Triton-X100 (T-9284, Sigma) mixed in PBS-BSA 
for 15 minutes. After a final wash in PBS-BSA oocytes were grouped in 
10s and transferred onto a slide with drops containing VECTASHIELD 
mounting medium with with 4',6-diamidino-2-phenylindole (DAPI) 
(VECTOR Laboratories, Burlingame, California, USA) and the cover slip 
sealed with nail varnish. Analysis of maturity status was performed using 
fluorescent light microscopy.  
 
2.4 GENE EXPRESSION 
2.4.1 Assisted hatching 
All biopsy procedures were performed using an inverted tissue culture 
microscope (OLYMPUS IX70, Integra TI) with an in-built heated stage 
whilst the embryos were in 5µl drops of G-PGD (Vitrolife) supplemented 
with 5% HSA under oil in 60mm ICSI dishes (BD Falcon, 353665). At the 
4-cell stage an opening in the zona pellucida was drilled with a 260-µs 
pulse from a non-contact laser (XYCLONE, Hamilton Thorne Biosciences, 
Beverly, MA) to promote herniation of the trophectoderm upon further 
development (Figure 2.3). 
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Figure 2.3: A An 8 cell stage embryo suitable for drilling B Laser is directed at 
area with most distance between zona pellucida and oocyte C A single pulse of 
the laser is sufficient to thin the zona. 
 
2.4.2 Trophectoderm biopsy 
Trophectoderm biopsy was only performed on blastocysts hatching a 
sufficient distance away from the (ICM) (Figure 2.4). Trophectoderm 
biopsy was chosen to assess mRNA profiles based on the observation that 
in humans, the trophectoderm mRNA profiles correlated with embryo 
viability (Jones et al., 2008). Differential staining was performed on 
blastocysts hatching at the site of the ICM. Approximately 5 
trophectoderm cells were aspirated with a 25µm sharp, thin walled biopsy 
pipette (Biomedical Instruments, Zöllnitz, Germany) and detachment 
achieved with repeated 300-µs pulses of the laser (staccato), whilst the 
pipette was drawn away from the embryo, which was held stationary with 
a 9-17µm thick walled blunt holding pipette (Swemed, 14317, Vitrolife). A 
video of which is shown on the CD-Rom accompanying this thesis.  
Figure 2.4: A Blastocysts chosen that are hatching away from the inner cell 
mass. B Trophectoderm cells are aspirated and whilst pulled away from the 
embryo are detached with the aid of the laser. C Cell sample for further analysis. 
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2.4.2.1 Viability 3 hours post biopsy 
Biopsied cells were designated for genetic analysis and embryos returned 
to culture in G-2 for 3 hours to check for evidence of re-expansion 
indicating viability (Figure 2.5). Time lapse videos of re-expansion were 
obtained using the aforementioned Embryoscope, in addition to the  Primo 
vision time lapse embryo monitor (Cryo Innovation, UK), which is an 
image capture device placed inside the incubator. Biopsied blastocysts 
were transferred to 16 well, well of the well (WOW) dishes (Cryo 
Innovation) containing 25µl pre-equilibrated G-2 media under mineral oil. 
Embryos that survived the biopsy were re-graded pooled and triple 
stained to assess the biopsy effect on future quality. 
Figure 2.5: Example time lapse images from the Embryoscope A Biopsied 
blastocysts collapse due to loss of blastocoel fluid during the procedure. B 
Re-expansion due to replacement of fluid indicates survival. 
 
2.4.2.2 Triple fluorescence staining-DAPI, PI, Tunel 
Biopsied blastocysts and those blastocysts that were unsuitable for 
trophectoderm biopsy due to location of hatching in the vicinity of the 
ICM, were triple stained to determine the quality of blastocysts expressed 
as total cell numbers (TCN), a ratio of ICM:TE cells and to identify 
apoptotic cells. All staining protocols were conducted in glass embryo 
dishes with lids (Fisher Scientific, SDE90, Leicestershire, UK) and embryos 
were moved through all incubation stages using a 10µl Gilson pipette.  
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Cavitated blastocysts were washed once with PBS-BSA at 37ûC. 
Trophectoderm cells (TE) were permeabilised with PBS-BSA supplemented 
with 0.2% Triton X-100 for 20 seconds. After being thoroughly washed in 
PBS-BSA, TE cells were stained red by incubation in 10µg/ml of Propidium 
Iodide 95% (PI) (P4170, Sigma) in PBS-BSA for 10 minutes in the dark at 
37ûC. Subsequent to this step all remaining incubations were performed 
in the dark.  
 
After three wash steps in PBS-BSA blastocysts were fixed in 4% PFA for 
15 minutes at room temperature. Following two wash steps in PBS-BSA 
blastocysts were further permeabilised in 0.2% Triton X-100 
supplemented with 0.1% sodium citrate for 20 minutes at room 
temperature. Apoptosis was detected using the Click-iT® TUNEL Alexa 
Fluor® 488 reaction kit according to the manufacturers instructions 
(C10245, Invitrogen). DNA strand breaks were induced in the positive 
controls through incubation in 100µl DNase I solution (composed of: 89µl 
deionised water, 10µl DNase I buffer and 1µl DNase I) for 30 minutes.  
 
After blastocysts were washed twice in distilled water apoptosis was 
detected by incubation in 6µl droplets of Terminal deoxynucleotidyl 
Transferase (TdT) reaction buffer under oil for 10 minutes at room 
temperature. Further incubation in 100µl drops of TdT reaction cocktail 
(composed of: 94µl of TdT reaction buffer, 2µl of ethynyl modified 
nucleotide EdUTP and 4µl TdT) for 60 minutes at 37ûC was performed 
following washing of blastocysts in PBS-BSA. Blastocysts were washed 
twice in PBS-BSA and incubated in 100µl drops of Click-iT reaction cocktail 
(composed of: 97.5µl of Click-iT reaction buffer and 2.5µl of Click-iT 
reaction buffer additive) for 30 minutes at room temperature. After a 
further wash in PBS-BSA, blastocysts were left in 100µl drops of 1mg/ml 
solution of Hoechst (BisBenzimide H33258, B1155, Sigma) in PBS for 15 
minutes at room temperature.  
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After being washed once in PBS-BSA and once in a 50:50 solution of PBS-
BSA with VECTASHIELD mounting medium with DAPI, blastocysts were 
finally mounted on a diagnostic microscope slide (Thermoscientific, ER-
308B-CE24, Portsmouth, UK) in drops of VECTASHIELD with DAPI to stain 
the ICM cells blue and the coverslip (cover glass, 8310131, VWR 
International) sealed with nail varnish.  
 
Figure 2.6: Example images from the Volocity of (A) DAPI, (B) PI, (C) Tunel 
and (D) combined stained blastocysts.  
 
2.4.2.3 Fluorescence analysis 
Analysis of fixed and differentially stained blastocysts was performed on a 
fluorescent light microscope (Nikon Eclipse 90i, Nikon Instrument Inc, 
Derby, UK) using Volocity Software, Version 5.2. Analysis of all three 
fluorescence stains was performed separately and then combined in a Z 
stacked image generated of all planes of the blastocysts to enable 
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quantification of cells in all focal planes (Figure 2.6). Cell counts were 
performed using the measurements software on the volocity program to 
count 2D objects and separate touching objects. Cell counts obtained with 
the software were comparable to those counted manually by visual 
analysis (Figure 2.7). 
 
 
 
 
 
 
 
Figure 2.7: Example images from the Volocity software A Cell counts calculated 
automatically by the software. B Cell counts manually counted visually. 
 
2.4.3 Gene expression analyses of trophectoderm 
Biopsied cell samples were analysed for imprinted gene expression and 
expression of components of the RAS system. 
 
2.4.3.1 Snap freezing 
Due to the limited size of the sample material, biopsied cells were 
immediately snap frozen in liquid nitrogen to disable any RNase, 
preventing RNA degradation and aid release of the cells genetic material. 
Gloves and laboratory coats were used and procedures conducted in a 
sterile laboratory cleaned with laboratory disinfectant (Trigene Advance, 
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Medichem International, 023802) to create RNase free conditions. Cells 
were collected in a minimum final volume of approximately 5µl directly 
from the G-PGD drop and placed at the bottom of a 0.5ml sterile 
polymerase chain reaction (PCR) tube (Axygen, California, USA). When all 
cells were in the tube it was immersed in liquid nitrogen and placed in a -
80ûC freezer for storage. 
 
2.4.3.2 Total RNA purification 
Snap frozen samples were removed from the -80ûC freezer and the total 
RNA and DNA was purified according to the AllPrepTM DNA/RNA Micro kit 
manufacturers instructions (Qiagen, 820284, West Sussex, UK). Samples 
were re-suspended in 75µl of Buffer RLT Plus (with added ǃ-
mercaptoethanol) before being made to the final volume of 350µl with 
Buffer RLT Plus and vortexed for 1 minute to homogenise. The lysate was 
pipetted into an AllPrep DNA spin column, which was placed in a 2ml 
collection tube. This was centrifuged for 30 seconds at 10,000 
revolutions per minute (rpm). The AllPrep DNA spin column was discarded 
and the RNA purified from the flow through in the 2ml collection tube. 
 
350µl of 70% ethanol was added to the flow through and mixed by 
repeated pipetting. The sample was transferred to an RNeasy MinElute 
spin column placed in a 2ml collection tube. This was centrifuged for 15 
seconds at 10,000 rpm and the flow through discarded. Next, 700 µl of 
Buffer RW1 was added to the RNeasy MinElute spin column and 
centrifuged at 10,000 rpm for 15 seconds to wash the spin column 
membrane. The flow through was discarded and 500 µl of Buffer RPE was 
added the RNeasy MinElute spin column and centrifuged for 15 seconds at 
10,000 rpm. Then, 500 µl of 80% ethanol was added to the column 
followed by centrifugation at 10,000 for 2 minutes. The RNeasy MinElute 
spin column was then transferred to a new 2 ml collection tube and 
centrifuged at full speed for 5 minutes with the lid open, to allow the 
alcohol to evaporate. The column was finally placed in a 1.5 ml collection 
tube and 14 µl of RNase-free water was pipetted directly into the centre of 
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the column. This was centrifuged for 1 minute at full speed to elute the 
RNA. This was stored on ice if cDNA was being produced straight away or 
stored in a -80ûC freezer. 
 
2.4.3.3 cDNA production  
Subsequent to purification of RNA, cDNA was produced by reverse 
transcription using the High Capacity RNA-to-cDNA Master Mix 
(4390779, Applied Biosystems). Addition of 4µl of 5X RT Reaction mixture 
and total RNA (maximum 1µg) to a tube was performed at room 
temperature and made up to a total volume of 20µl with RNase free 
water. The reaction was performed in a Techne flexcycler (FTGENE5D, 
Techgene) according to the following protocol: incubate at 25ûC for 5 
minutes, 42ûC for 30 minutes, terminate at 85ûC for 5 minutes and keep 
at 4ûC until use in qPCR. 
 
2.4.3.4 Relative real time quantitative PCR 
Quantification of H19, IGF2, IGF2r, ATR1, ATR2, VEGFA gene expression 
in the trophectoderm biospy cDNA samples was performed in singleplex 
reactions and compared against the endogenous control, 18s (selected 
based on the results of the geNorm reference gene selection kit by Primer 
Design)4, to normalise for starting amount differences. Pools of in vivo 
generated blastocysts from 0.5IU hMG superovulated mice were used for 
the serial dilutions and as a calibrator (reference) for the PCR.5 The 
Taqman® PCR reaction mixture (Applied Biosystems) composed of 0.5µl of 
20X Taqman Gene Expression Assay (Table 2.3), 5µl of 2X Taqman® Fast 
Advanced Master Mix (4444963, Applied Biosystems) and 1.5µl of cDNA 
prepared previously made up to the final volume of 10µl with RNase free 
water for each replicate was pipetted into the tubes of a 96-well plate 
(MicroAmp®, 4346906, Applied Biosystems) and subsequently loaded into 
                                      
4 See Appendix 4 for results of the geNorm reference gene selection kit.  
5 See Appendix 5 for in vivo blastocyst collection method. 
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the Biosystems 7500 Fast Real-Time PCR System (Applied Biosystems). 
7500 Software version 2.0.5 (Applied Biosystems) was run on the 
computer attached to the PCR machine to set the thermocycler profile of: 
50ûC for 2 minutes, 95ûC for 20 seconds, followed by 40 cycles of 95ûC 
for 3 seconds and 60ûC for 30 seconds. After completion of the PCR run 
(approximately 40 minutes) the expression levels of the genes were 
calculated according to the standard curve. 
 
Table 2.3: Taqman® gene expression assays for qPCR 
 
Gene Name 
 
 
Gene 
Symbol
 
Assay ID. 
 
Amplicon 
Length 
(bp) 
 
 
Species 
 
18s ribosomal RNA 
 
Rn18s 
 
Mm03928990_g1
 
61 
 
Mus 
Musculus 
 
H19 fetal liver mRNA H19 Mm00469706_g1 76 Mus 
Musculus 
 
Insulin like growth factor 
2 
IGF2 Mm00439565_g1 96 Mus 
Musculus 
 
Insulin-Like Growth 
Factor 2 receptor  
IGF2r Mm00439576_m1 64 Mus 
Musculus 
 
Vascular endothelial 
growth factor A 
Vegfa Mm01281449_m1 81 Mus 
Musculus 
 
Angiotensin II, type 1 
receptor associated 
protein 
ATR1 Mm00507771_m1 59 Mus 
Musculus 
Angiotensin II receptor, 
type 2 
ATR2 Mm01341373_m1 86 Mus 
Musculus 
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2.5 STATISTICAL ANALYSES 
All data was tested for normality using the Kolmogorov-Smirnov and 
Shapiro-Wilk tests using SPSS version 16 (IBM Software Services, 
Hampshire, UK). Normally distributed data was expressed as mean±SEM 
whereas non-parametric data was presented as median (inter-quartile 
range). Statistical relevance was set at P<0.05 for all analyses in this 
thesis. Statistical analyses of development data was performed using a 
non-parametric general analysis of variance (Kruskal-Wallis test) on SPSS 
having confirmed the data was not normally distributed or transformable 
by logarithm or square root. See experimental chapters 3 and 4 for 
descriptions of the statistical variables used. The data was analysed 
according to treatment group and all interactions were included between 
different groups. Statistical analyses of the blastocyst triple staining data 
was performed on SPSS for cell count data and also Graph Pad prism 6 
(GraphPad Software, California, USA) for chi squared test for associations 
for the analysis of proportional data. See the experimental chapters 4 and 
5 for more specific descriptions of the statistical models used. Statistical 
analyses of the ovarian histology data was performed using SPSS. All the 
data was non-parametric so significance was tested using the Kruskal-
Wallis test (Chapter 3). Gene expression data was assessed using a 
general analysis of variance (ANOVA) on SPSS after confirming the data 
was normally distributed or by Kruskal-Wallis test if the data was non-
parametric and not transformable. More details can be found in the 
relevant chapters (5 and 6). To analyse weight and organ trajectory in 
progeny born from the different treatments, a multiple linear regression 
analysis was performed by using the general linear model in SPSS. See 
chapter 6 for more details.  
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CHAPTER 3: THE EFFECT OF OVARIAN STIMULATION ON 
OOCYTE QUALITY  
 
3.1 INTRODUCTION  
The effect of the use of exogenous gonadotrophins on embryo 
development has been particularly well characterised in mice stimulated 
with PMSG and hCG (Ertzeid and Storeng, 1992;  Van der Auwera and 
D'Hooghe, 2001;  Ertzeid and Storeng, 2001). Poor embryo development 
following ovarian stimulation has been attributed to oocyte quality 
(Wassarman and Kinloch, 1992). Maternal mRNA stores are accumulated 
during folliculogenesis and it has been suggested that exogenous 
gonadotrophins speed up nuclear maturation resulting in insufficient 
mRNA stores and consequently poor embryo development (Mehlmann, 
2005). Embryo developmental arrest commonly occurs at the maternal to 
embryonic genome switch which occurs at the two cell stage in the mouse 
(Gardner and Lane, 2005). In Chapter 4 we investigated the efficacy of 
common human gonadotrophin preparations with different half lives and 
LH activity (hMG, rFSH and Pergoveris). Alterations in embryo 
development were evident from the use of different doses of 
gonadotrophin preparations which varied in terms of their biological 
clearance rate, FSH isoforms and level of LH-activity. In this mouse 
model, LH activity was shown to be essential for viable embryo 
development post fertilisation and based on the known roles of LH in 
folliculogenesis and the association of perturbed embryonic viability after 
the different ovarian stimulation regimes, this chapter will address 
whether these alterations were a consequence of altered folliculogenesis 
on oocyte quality.      
 
Unfortunately, assessment of oocyte quality is complicated by the fact 
that its structural integrity must be retained and several alternative 
indirect markers of oocyte quality have been proposed.  In response to 
the LH surge, the cumulus layer surrounding the oocyte undergoes 
expansion as a consequence of the synthesis of the glycosaminoglycan 
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muco-polysaccharide hyaluronan which is excreted by the cumulus cells 
into the ECM (Mandelbaum, 2000). Cumulus expansion ultimately leads to 
a breakdown in communication between the somatic cells and the oocyte 
and through activation of the hyaluronan receptor (CD44) leads to oocyte 
maturation (Krysko et al., 2008). The cumulus cells are vital orchestrators 
of oocyte maturation and development (McKenzie et al., 2004). 
Consequently the cumulus cells may reflect oocyte quality and be used as 
surrogate for direct analysis of the oocyte itself and as they are separated 
and discarded during routine IVF anyway are easily accessible (Fragouli 
and Wells, 2012). As a result of this, analysis of the cumulus cell 
transcriptome has been proposed as a non-invasive method of assessing 
and predicting embryo quality (Assou et al., 2006;  Assou et al., 2010;  
van Montfoort et al., 2008). This is especially important in countries where 
the decision which oocyte should be fertilised and used for treatment 
needs to be made at the metaphase II (MII) stage. Cumulus expansion is 
already used as a predictive morphological marker for oocyte selection 
(Russell and Robker, 2007). 
 
In addition to cumulus markers, markers of follicular health and maturity 
may be used to assess the effects of ovarian stimulates on oocyte quality. 
Vascular endothelial growth factor (VEGF), one of the final products of the 
RAS pathway, is synthesised in theca and granulosa cells and is the main 
pro-angiogenic factor in the ovary (Agrawal et al., 2002). VEGF is a 
heparin binding secreted dimeric glycoprotein which is a vascular 
endothelial cell specific mitogen (Shweiki et al., 1993). VEGF 
concentrations increase according to the stage of follicular development 
and are highest in pre-ovulatory follicles. Greater concentrations in the 
follicular fluid have been associated with oocyte maturity and improved 
fertilisation rates (Bokal et al., 2005). High VEGF concentrations in the 
follicular fluid has been correlated with increased vascularisation of the 
follicle that may translate into better fertilisation rates, improved embryo 
quality and higher pregnancy rates (Monteleone et al., 2008). VEGF 
inhibition by VEGF Trap impaired follicle growth, resulting in small poorly 
vascularised subordinate antral follicles (Herr et al., 2010). 
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In addition, Myosin heavy chain II (MYHII) promotes angiogenesis by 
inducing the synthesis of angiotensin II (AngII). MYHII has been shown to 
be more highly expressed in unstimulated cumulus cells compared to 
those obtained after COS (de los Santos et al., 2012). This suggests 
MYHII is down regulated through exogenous gonadotrophin stimulation. 
AngII has been implemented in oocyte maturation by its stimulatory 
steroidogenic activity and establishment of follicle dominance through the 
augmentation of LH activity on the granulosa cells (Ferreira et al., 2011;  
Siqueira et al., 2012). In the absence of gonadotrophins, AngII can 
stimulate progesterone, oestradiol and prostaglandin synthesis, in addition 
to stimulating ovulation and meiotic maturation of oocytes (Acosta et al., 
1999;  Yoshimura et al., 1992).  
 
The concentration of AngII in the follicular fluid increases immediately 
prior to ovulation and after exposure to LH and hCG (Acosta et al., 2000). 
Inhibition of the angiotensin receptor 2 (ATR2) expressed by theca cells 
with saralasin prevented ovulation (Ferreira et al., 2007). Taken 
altogether it is suggested AngII has an early role in ovulation by 
mediating and enhancing the preovulatory LH surge and a later role in 
luteinisation (Acosta and Miyamoto, 2004). Furthermore AngII has been 
shown to induce VEGF expression and has been hypothesised to function 
as a co-regulator with LH in luteal angiogenesis (Herr et al., 2010).  
 
During the early stages of folliculogenesis, the follicle is avascular and 
receives its nutrients and oxygen through gap junctions (Section 1.2.8). 
In the later stages of folliculogenesis, a vascular sheath forms on the 
basal membrane surrounding the follicle to enable the steroidogenic 
products of the theca cell layer to enter the peripheral blood circulation 
and to enable cells to receive the required oxygen and nutrients 
(Cavender and Murdoch, 1988). The granulosa cell layer remains 
avascular until ovulation, therefore a regulatory mechanism to prevent 
angiogenesis in the follicle is pertinent (Chuderland et al., 2012).  
 
Pigment epithelium derived factor (PEDF), alternatively known as 
SERPINF1, is a 50 kDA secreted glycoprotein belonging to the non-
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inhibitory members of the serine protease inhibitors (serpin) superfamiliy. 
PEDF is a natural angiogenesis inhibitor (Dawson et al., 1999). It exerts 
its anti-angiogenic effect by inhibiting the stimulatory effects of numerous 
pro-angiogenic factors, the most extensively characterised being VEGF 
(Stellmach et al., 2001). The PEDF ligand binds the PEDF-R receptor on 
the cell surface (Notari et al., 2006). PEDF enhances gamma secretase 
activity resulting in the cleavage of the tyrosine kinase receptor VEGF 
receptor 1 (VEGFR-1) transmembrane domain, which interferes with VEGF 
signalling to induce formation of vessels, thus inhibiting angiogenesis (Cai 
et al., 2006). In addition, PEDF competitively binds VEGFR-2, further 
inhibiting the pro-angiogenic VEGF activities by reducing the proliferation 
and migration of proliferative endothelial cells (Zhang et al., 2006). PEDF 
also upregulates thrombospondin, another anti-angiogenic protein (Guan 
et al., 2004). PEDF is secreted by granulosa cells and its expression is 
hormonally regulated.  
 
Increasing doses of oestrogen to mimic its elevated production by 
granulosa cells in the later gonadotrophin-dependant stages of 
folliculogenesis causes a gradual decrease in PEDF secretion. Furthermore, 
exposure to progesterone, mimicking entrance into the luteal phase, 
drastically suppressed PEDF secretion suggesting that this factor modifies 
follicular vasculature (Chuderland et al., 2012). At the time of the LH 
surge, PEDF and VEGF are inversely regulated. High concentrations of hCG 
elevates VEGF levels in a dose response manner, whilst with incremental 
doses of hCG PEDF levels decline (Chuderland et al., 2012). It has been 
proposed that maintaining a balance between these pro and anti-
angiogenic factors is critical for regulating angiogenesis (Gao et al., 
2001). Based on previous correlations between blood flow and embryo 
quality, alterations in the vascularity of the follicle may affect patients 
treatment outcome and may therefore be suitable predictive markers for 
oocyte quality in cumulus cell analyses (Bhal et al., 1999;  Coulam et al., 
1999;  Huey et al., 1999;  Du et al., 2006;  Shrestha et al., 2006).  
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The objective of this experiment was, therefore, to examine the effect of 
common human gonadotrophin preparations with different half lives and 
LH activity (hMG, rFSH and Pergoveris) on the ovarian response to 
stimulation and oocyte quality. The endpoints measured were cumulus cell 
expansion, cumulus cell gene expression (VEGFA, PEDF and MYHII), 
oocyte maturity and ovarian histology.  
 
3.2 METHODS OVERVIEW 
Upon reaching a mean weight of 17g at 5-6 weeks of age, mice were 
randomly allocated to the various treatment groups as described in 
chapter 2 section 2.1:   
 
Table 3.1: Number of mice in each treatment group 
                     
Treatment 
                  
Number of technical 
repeats (n) 
                      
Total Number of         
mice (n) 
 
Un-stimulated 
 
18 
 
72 
5IU PMSG 12 49 
0.5IU hMG 9 36 
5IU hMG 6 23 
0.5IU Pergoveris 9 36 
5IU Pergoveris 10 41 
0.5IU rFSH 4 14 
2.5IU rFSH 4 16 
5IU rFSH 3 12 
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The experimental pathways described in this chapter are schematically 
presented in Figure 3.1. In addition to collecting pronuclear zygotes 
following natural mating, oocytes were also collected to provide a 
cumulus cell sample devoid of sperm contamination for PCR 
analysis.  
 
Figure 3.1: Flow chart summarising the experimental design used in this 
chapter. 
 
3.2.1 Ovarian histology 
Ovaries were collected simultaneously to zygotes and fixed in Bouins 
solution for 24 hours and stored in 70% alcohol until ready to be 
processed using a standardised tissue processing protocol and 
haematoxylin and eosin staining method (Refer to Appendix 7).  
 
3.2.1.1 Ovarian histology analysis 
Twenty ovaries per treatment group were randomly selected for analysis. 
Ovarian sections were analysed for the number of corpora lutea and antral 
follicles per ovary. The average diameter of corpora lutea per ovary was 
estimated by calculating the mean of the two maximum widths as 
depicted in Figure 3.2. 
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Figure 3.2: Regions of the ovary exhibiting differential staining with tightly 
packed steroidogenic cells were classed as corpora lutea. The two longest 
diameters of the corpus luteum were measured and averaged to calculate the 
mean diameter of corpora lutea per ovary. 
 
3.2.2 Cumulus cell morphology 
Upon collection of fertilised zygotes, the cumulus expansion status was 
classified as absent, expanded or dense, as depicted in Figure 3.3. 
Figure 3.3: Representative images of oocytes (A) without cumulus, (B) with 
dense cumulus and (C) with expanded cumulus.  
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3.2.3 Oocyte morphology 
Following embryo collection, all collected zygotes were put into culture 
regardless of maturity status. On Day 2 of in vitro embryo culture, those 
zygotes which had remained un-cleaved were classed as immature or 
unfertilised oocytes. Figure 3.4 depicts the classifications of oocytes. 
 
Figure 3.4: Sample images of collected oocytes. 
 
3.2.4 Oocyte collection and denudation  
Five to six week old female mice were superovulated with PMSG, 0.5IU 
hMG and 5IU Pergoveris (n=4 per group), or remained un-stimulated 
(n=8) and monogamously mated with vasectomised males described in 
section 6.2.2. Oviducts were collected 24 hours post hCG administration 
according to the aforementioned method in section 2.3.1. Individual 
oocytes were separated from the COCs upon release from the oviduct and 
stored in 5µl drops of G-IVF media (Vitrolife)6 supplemented with 10% 
HSA under 5ml mineral oil. Oocytes were exposed to hyaluronidase for 10 
seconds in 5µl drops under oil and those cumulus cells which remained in 
the 5µl GMOPS wash drops under oil were immediately snap frozen for 
later genetic analysis.  
 
                                      
6See Appendix 1 for media compositions.  
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3.2.5 Gene expression analysis of cumulus cells 
Cumulus cell samples from mature oocytes were randomly selected for 
each treatment group (n=12 per group). RNA was extracted using the 
aforementioned AllPrepTM DNA/RNA Micro kit (See section 2.4.3). This was 
converted to cDNA using the SuperScript® Vilo Mastermix according to 
the manufacturers instructions. Addition of 4µl of the superscript reaction 
mixture and 12µl of total RNA to a tube was performed at room 
temperature and made up to a total volume of 20µl with RNase free 
water. The reaction was performed in a Techne flexcycler (FTGENE5D, 
Techgene) according to the following protocol: incubate at 25ûC for 10 
minutes, 42ûC for 60 minutes, terminate at 85ûC for 5 minutes and keep 
at 4ûC until use in qPCR. Quantification of VEGFA, MYHII and PEDF gene 
expression in the cumulus cell cDNA samples was performed in singleplex 
PCR reactions and compared against the endogenous control 18s as 
described in section 2.4.3.4. Pools of cumulus cells from previous studies 
were used for the serial dilutions and as a calibrator (reference) for the 
PCR.  
 
Table 3.2: Taqman® gene expression assays for qPCR 
 
Gene Name 
 
 
Gene 
Symbol
 
Assay ID. 
 
Amplicon 
Length 
(bp) 
 
 
Species 
     
Vascular 
endothelial growth 
factor A 
Vegfa Mm01281449_m1 81 Mus 
Musculus 
Myosin heavy 
chain II 
Myh2 Mm01332564_m1 102 Mus 
Musculus 
 
Pigment 
Epithelium Derived 
Factor 
Serpinf1
 
Mm00441270_m1 
 
84 Mus 
Musculus 
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3.2.6 Statistical analyses 
Data was tested for normality using the Kolmogorov-Smirnov and 
Shapiro-Wilk tests using SPSS version 16 (IBM Software Services, 
Hampshire, UK). Statistical relevance was set at P<0.05 for all analyses. 
Analysis of the oocyte quality proportional data was assessed by Chi 
square test using Graph Pad Prism. The ovarian histology data was not 
normally distributed and could not be successfully transformed by 
logarithm or square root so was assessed by Kruskal-Wallis test in SPSS. 
The difference between antral follicle counts (AFC) and number of 
embryos collected was parametric and analysed by ANOVA. Gene 
expression data for PEDF and MYHII was non-parametric and displayed 
through a box plot. VEGFA expression was normally distributed and the 
means displayed on a bar chart. This data was analysed by Kruskal-Wallis 
and ANOVA tests in SPSS respectively.  
 
3.3 RESULTS 
3.3.1 Ovarian histology analysis 
Naturally cycling mice had an average of 6 corpora lutea (CL) per ovary 
(Table 3.3), which was comparable with ovaries from the positive control 
PMSG group. Compared to the positive control, ovaries from the 0.5IU 
hMG, 5IU hMG, 5IU Pergoveris and 5IU rFSH treated mice had 
significantly more CLs (P<0.001).  Collected ovaries from the 5IU dose of 
hMG treated group had a greater increase in CL numbers (P<0.001). 
Higher doses of Pergoveris also resulted in increased numbers of CLs 
(P<0.001), whereas ovaries following treatment with the lower doses of 
Pergoveris and rFSH were comparable to the controls (P<0.05).  
 
Ovarian stimulation led to an almost 2 fold increase in CL diameter in 
collected ovaries compared to un-stimulated control ovaries (P<0.001) 
and there were no differences between the regimes (P>0.05) except for 
the 2.5IU and 5IU rFSH treated ovaries which had CLs with smaller 
diameters (P<0.01). The mean antral follicle count (AFC) for the un-
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stimulated control was 9 per ovary. This was increased by ovarian 
stimulation with PMSG (P<0.001). Ovarian stimulation with 0.5IU 
Pergoveris, 5IU Pergoveris and 5IU rFSH resulted in a greater AFC 
compared to the positive control (P<0.01).  
 
Table 3.3: Summary of median (inter-quartile range) ovarian histology data for 
the treatment groups (n=20 per group). (* P=<0.05, ** P=<0.01, *** 
P=<0.001 compared to positive control as tested by Mann-Whitney U test).  
 
Figure 3.5 shows representative images of ovarian sections for the 
different treatment groups. Ovaries following treatment with PMSG, 0.5IU 
hMG and 5IU Pergoveris showed freshly ovulated follicles in the histology 
sections. All of the treatment groups demonstrated small follicles within 
the ovarian cortex (centre) except for the 5IU Pergoveris and 5IU hMG 
treatment groups. Un-ovulated COCs are evident in the 0.5IU Pergoveris, 
5IU Pergoveris and 5IU rFSH treated ovaries, which had more AFC 
compared to the positive control (P<0.01).    
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Figure 3.5: Representative images of ovarian histology for (A) natural, (B) PMSG, (C) 0.5IU hMG, (D) 5IU hMG, (E) 0.5IU Pergoveris, 
(F) 5IU Pergoveris, (G) 0.5IU rFSH, (H) 2.5IU rFSH and (I) 5IU rFSH.
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3.3.2 Oocyte quality 
3.3.2.1 Immature oocytes 
The relative proportion of oocyte and zygote classifications, which failed to 
cleave, was calculated for each treatment group (Figure 3.6). Naturally 
ovulated and fertilised zygotes failed to cleave in 10% of cases, whereas 
all other treatment groups had fewer cleaved embryos on Day 2 
(P<0.001, see section 4.3.2.1). Un-cleaved zygotes were found in all 
treatment groups. Seventy seven percent of the natural group oocytes 
which failed to cleave were unfertilised MII oocytes whereas the remaining 
23% had degenerated. Only the ovarian stimulation groups had immature 
oocytes in their ovulated group and germinal vesicle (GV) stage oocytes 
were only observed in the rFSH treated group. All treatment groups had a 
comparable proportion of degenerated zygotes collected compared to the 
positive control (P>0.05), expect for the unstimulated control and 5IU 
Pergoveris groups (P<0.05 and P<0.01 respectively).  
 
All the ovarian stimulation regimes resulted in a significant proportion of 
immature metaphase I (MI) and fragmented oocytes compared to the 
natural control (P<0.001). Fragmentation was only observed following 
treatment with exogenous gonadotrophins (P<0.001). The 0.5IU 
Pergoveris and rFSH groups had less fragmented oocytes compared to the 
positive PMSG control (P<0.001 and P<0.01), however this may be due to 
there being higher proportions of MI oocytes following stimulation with 
these preparations (P<0.001 and P<0.05). Treatment with 5IU Pergoveris 
resulted in the lowest proportion of metaphase I oocytes (P<0.01). 
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Figure 3.6: Proportion of the total number of uncleaved zygotes for the natural (n=112), PMSG (n=478), 0.5IU hMG 
(n=499), 5IU hMG (n=109), 0.5IU Pergoveris (n=289), 5IU Pergoveris (n=47), and combined rFSH (n=206) treatment 
groups classified as degenerated (purple), fragmented (pink), Germinal vesicle (red), metaphase I (orange) and unfertilised 
metaphase II (green). (*** P<0.001, ** P<0.01, * P<0.05 compared to positive PMSG control as tested by chi square test 
for associations).  
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3.3.2.2 DAPI staining of oocytes 
Fragmented oocytes had their DNA dispersed throughout all the visible 
fragments (Figure 3.7A). Both the germinal vesicle and metaphase I 
oocytes displayed the expected DNA appearance of a nucleus and 
chromatids undergoing anaphase respectively. Figure 3.7D-E 
demonstrates oocytes that were unable to extrude the second polar body 
successfully. Furthermore, Figure 3.7F shows an oocyte that was unable 
to complete syngamy after fertilisation.  
Figure 3.7: DAPI stained immature oocytes which were microscopically 
classified as (A) fragmented, (B) germinal vesicle stage, (C) metaphase I 
stage, (D-F) metaphase II stage. 
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3.3.3 Cumulus expansion 
In comparison to the un-stimulated control group, which had 100% of 
ovulated oocytes with expanded cumulus cells, the ovarian stimulation 
groups had fewer oocytes with intact cumulus cells (Figure 3.8, P<0.001). 
Oocytes densely surrounded by cumulus cells were not evident in the 
natural group, but the relative proportions of those ovulated in the 
ovarian stimulation groups were low and comparable to the control 
(P>0.05). Oocytes ovulating without a cumulus were only apparent in the 
ovarian stimulation groups and significantly more so in the 5IU hMG 
treatment group compared to the positive control (P<0.001). Oocytes 
which did not have any cumulus associated with them were associated 
with fragmentation and degenerated morphology. Those with a heavy 
cumulus mass were difficult to denude with hyaluronidase and in the 
majority of cases, were immature oocytes.  
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Figure 3.8: Proportion of oocytes cumulus cells for the natural (n=256), PMSG (n=653), 0.5IU hMG (n=420), 5IU hMG 
(n=184), 0.5IU Pergoveris (n=273), 5IU Pergoveris (n=546), 0.5IU rFSH (n=84), 2.5IU rFSH (n=176) and 5IU rFSH 
(n=185) treatment groups classified as dense (red), absent (orange) and expanded (green) for the entire group ovulated. 
(*** P<0.001, *P<0.05 compared to positive PMSG control as tested by chi square test for associations).   
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3.3.4 Cumulus gene expression data 
3.3.4.1 VEGFA gene expression 
VEGFA expression in cumulus cells removed from naturally ovulated 
oocytes had a relative median fold difference of VEGFA of 1.61±0.26 
(Figure 3.9). Cumulus cells from stimulated mice had nearly a 0.5 fold 
increase in VEGFA mRNA transcripts compared to controls however these 
trends were not statistically significant (P>0.05) and there were no 
differences between regimes (P>0.05).  
Figure 3.9: Mean ± SEM relative expression of VEGFA in natural, PMSG, 0.5IU 
hMG and 5IU Pergoveris treatments (n=11 per group) No statistical significance 
found with ANOVA.  
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3.3.4.2 PEDF gene expression 
The relative median fold difference of PEDF gene expression in the natural 
group was 13.94 with an inter-quartile range of 29.65. The PMSG treated 
group had significantly less mRNA transcripts with a 16 fold decline 
compared to control (P<0.001, Figure 3.10). Treatment with 0.5IU hMG 
resulted in a 6.5 fold reduction in PEDF gene expression levels (P<0.05), 
whereas the 5IU Pergoveris group did not differ (P>0.05).  
 
Figure 3.10: Median relative expression of PEDF in natural, PMSG, 0.5IU hMG 
and 5IU Pergoveris treatments (n=11 per group). Bars show inter-quartile range. 
(* P<0.05, *** P<0.001 compared to natural control as tested by Mann-Whitney 
U test). 
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3.3.4.3 MYHII gene expression 
MYHII gene expression in the natural group was 1.92 with an inter-
quartile range of 2.32. Cumulus cells from mice treated with PMSG had a 
2.5 fold decline in gene expression (P<0.05, Figure 3.11).The 0.5IU hMG 
and 5IU Pergoveris groups demonstrated a 2-fold decrease in gene 
expression compared to the natural group. This trend however was not 
statistically significant (P>0.05).  
Figure 3.11: Median relative expression of MYHII in natural, PMSG, 0.5IU hMG 
and 5IU Pergoveris treatments (n=11 per group). Bars show inter-quartile range. 
(* P<0.05 compared to natural control as tested by Mann-Whitney U test). 
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3.4 DISCUSSION 
In this study, it was hypothesised that ovarian stimulation would result in 
the ovulation of developmentally compromised oocytes due to an effect of 
exogenous gonadotrophins on oocyte development and quality during 
folliculogenesis. The results obtained suggest that superovulation does 
have an impact during folliculogenesis, on oocyte morphology, cumulus 
expansion and cumulus gene expression.  
 
3.4.1 Ovarian stimulation and oocyte quality 
The superovulation groups had a significantly higher proportion of 
ovulated and fertilised zygotes that did not complete the first cell division, 
when compared to un-stimulated controls. Previous studies have provided 
some information regarding the proportion of immature or abnormal 
oocytes recovered, which is in accordance with the  figures in our study 
(Kanter et al., 2004;  Ozgunen et al., 2001;  Muñoz et al., 1995). 
However, the classification of the morphological appearance of these un-
cleaved zygotes has not been previously performed. Degenerated oocytes 
were observed in all treatment groups potentially due to the invasive 
nature of collecting and handling the zygotes, as was previously reported 
(Roustan et al., 2012). Poor embryo development after ovarian 
stimulation has been hypothesised to be due to accelerated development 
of gonadotrophin responsive follicles so that normal meiotic and 
cytoplasmic maturations do not occur. Our results support this hypothesis 
by the observation of immature metaphase I (MI) oocytes only within the 
stimulated ovulated groups. 
 
All ovarian stimulation regimes led to an increase in the number of 
immature MI oocytes at the expense of mature MII oocytes. Germinal 
vesicle stage oocytes were present only in the 0.5IU rFSH treatment 
group, suggesting low doses of rFSH was not sufficient to remain above 
the threshold level required for complete development of the follicle. 
Fragmentation was a phenomenon which was only observed in the ovarian 
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stimulation groups and has previously been shown to not be compatible 
with continued embryo development upon fertilisation (Veeck, 1988). 
Fluorescent analysis of these embryos showed DNA to be dispersed 
throughout the various cytoplasmic clusters of the oocyte, thus leading to 
arrest. The proportion of fragmented oocytes increased parallel to dosage 
in the Pergoveris groups. Furthermore the hMG groups regardless of 
concentration and PMSG had the highest rates of oocytes with 
fragmentation, suggesting that the presence of LH activity is involved in 
this superovulation artefact and occurs at lower doses when long acting 
LH is present. There is clinical evidence which suggests that 
overstimulation with LH has a negative effect on follicular atresia and 
luteinisation and consequently, on oocyte development in a dose 
dependant manner (Hillier, 1994).  In vitro experiments have illustrated 
that low doses of LH enhanced steroidogenesis, whilst higher doses 
enhanced progesterone synthesis but suppressed aromatase activity and 
inhibited granulosa cell growth (Yong et al., 1992;  Shoham, 2002). 
Elevated LH concentrations have also been associated with poor 
fertilisation and implantation rates and adverse pregnancy outcomes 
(Hillier, 1994). The evidence therefore, supports the theory of a LH 
threshold, above which adverse effects on folliculogenesis occur (Tesarik 
and Mendoza, 2002).  
 
3.4.2 Ovarian histology after gonadotrophin stimulation  
Ovarian stimulation resulted in an increase in mean CL diameters in 
ovaries collected for all the treatment groups. This increase is likely to be 
due to the continued mitotic expansion of the follicle in response to 
prolonged exposure to FSH (Oktem and Urman, 2010) and previously 
shown by other through increased bromodeoxyuridine (BrdU) 
incorporation in the ovarian surface epithelium (Burdette et al., 2006). 
The antral follicle count (AFC) was greater than the number of oocytes 
collected for the majority of the treatment groups.  This may potentially 
be due to errors in tissue preparation or analysis. These errors were 
minimised by every 50µm sections being assessed and one individual 
Chapter 3: Effect on oocyte quality 
93 
 
performing all the analyses to insure every CL was investigated once. The 
results may indicate that a proportion of the pre-ovulatory follicles did not 
ovulate Therefore, the observation that a number of antral follicles failed 
to ovulate after superovulation in our study may reflect the functionally 
different states of the follicles, which may have responded differently to 
the exogenous gonadotrophins in accordance with their developmental 
stage (McNatty et al., 2010). 
 
LH and hCG has previously been shown to lead to down regulation of the 
LH receptor on granulosa cells in humans (Jeppesen et al., 2012) and rats 
(Rao et al., 1977;  Peng et al., 1991), in addition to increasing androgen 
and cAMP production (Hillier, 1994). The incorporation of hCG into hMG, 
may potentially at higher doses exacerbate these effects during ovarian 
stimulation. This would explain why high concentrations of hMG resulted 
in basal numbers of oocytes ovulating. Higher doses of hMG also led to 
the largest proportion of ovulated oocytes lacking cumulus cells, which 
has been shown to result in non-viable oocytes due to the inability to 
complete meiosis (Carabatsos et al., 2000). This may explain why the 
high dose hMG group yielded a large proportion of immature and poor 
quality oocytes, which may subsequently effect embryonic development. 
 
3.4.3 Relationship of cumulus factors with embryo quality 
Cumulus expansion is a morphological marker currently used to predict 
oocyte competency for use in ART (Russell and Robker, 2007). Our study 
demonstrated that oocytes which did not have any cumulus associated 
with them were mostly fragmented and of poor quality and those with a 
heavy cumulus mass were difficult to denude with hyaluronidase and 
generally immature. Therefore, neither were compatible with further 
embryonic development as previously reported (Mandelbaum, 2000). All 
oocytes ovulated without stimulation had full cumulus expansion, which 
occurred at varying reduced levels in the stimulation regime groups.  
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Although the expression of the pro-angiogenic factor VEGFA in cumulus 
cells from un-stimulated and superovulated oocytes were comparable, 
levels of PEDF were reduced for both PMSG and 0.5IU hMG treatments. 
PEDF is a natural angiogenesis inhibitor (Dawson et al., 1999) and the 
balance between these pro- and anti- angiogenic factors has been 
hypothesised to be critical for regulating angiogenesis (Gao et al., 2001). 
In vitro studies indicated that elevated levels of oestrogen caused a 
gradual decline in PEDF expression (Chuderland et al., 2012). Both the 
PMSG and hMG preparations contain long acting LH bioactivity. LH in 
combination with FSH stimulates oestrogen production as discussed in 
section 1.2.6.1, which may explain the decline in PEDF expression in these 
regimes. In addition, the ovarian histology data showed the number of 
oocytes ovulated per ovary was significantly elevated for the PMSG and 
hMG group, suggesting that there may have been more oestrogenic 
follicles within these treatment groups. The Pergoveris treatment groups 
may have been unaffected due to the low half life of the recombinant LH 
in this preparation.  
 
Previous reports suggested that increased angiogenesis in the follicle is 
associated with improved embryo development (Bhal et al., 1999;  
Coulam et al., 1999;  Huey et al., 1999;  Du et al., 2006;  Shrestha et al., 
2006). Angiogenesis is controlled by multiple factors and expression of 
MYHII was reduced in cumulus cells from oocytes ovulated after treatment 
with PMSG as indicated in a previous study (de los Santos et al., 2012). 
This factor promotes angiogenesis by inducing synthesis of AngII, which is 
associated with steroidogenesis, meiotic maturation and ovulation 
(Ferreira et al., 2011;  Siqueira et al., 2012); therefore reduced 
expression may impair oocyte quality. Although marginally reduced in all 
ovarian stimulation regimes, MYHII expression is only significantly 
diminished following PMSG treatment which may explain the more 
perturbed embryo development in this treatment group (Chapter 4).   
 
Chapter 3: Effect on oocyte quality 
95 
 
Inadequately vascularised follicles have previously been shown to produce 
oocytes with spindle defects which the authors attributed to the hypoxic 
conditions which may hinder oxidative metabolism and consequently lower 
the intracellular pH (Chui et al., 1997;  Van Blerkom et al., 1997). 
Fluorescent microscopy analysis of the metaphase II oocytes, which failed 
to divide in our study, demonstrated that the majority of the oocytes did 
have some developmental abnormalities. These oocytes showed 
inappropriate division of the genetic material or failure to complete 
syngamy, were the visible causes for developmental arrest and the timing 
of this arrest prior to ZGA suggests it may be an underlying oocyte quality 
issue, potentially spindle related (Pesty et al., 2007). Only un-cleaved 
oocytes from ovarian stimulation regimes exhibited this morphology. 
Visualising the mitotic spindle by immuno-histochemical staining of the 
cytoskeletal structure by injection of fluoroscein-labelled α-tubulin into un-
cleaved metaphase II oocytes may provide more evidence for any spindle 
defects (Paddy et al., 1996). 
3.4.4 Conclusion 
The results of this study indicate that the quality of oocytes obtained 
following ovarian stimulation of mice with human gonadotrophin 
preparations is compromised as has previously been reported for PMSG. 
The evidence suggests in terms of oocyte and cumulus characteristics, 
that there are no differences in oocyte quality between the different 
ovarian stimulation regimes, although this quality is significantly reduced 
in comparison to the unstimulated control. These studies have confirmed 
the observation that ovarian stimulation with gonadotrophins results in 
fragmented oocytes, although the exact mechanism resulting in this 
response remain unclear (Hillier, 1994). Angiogenesis may also be 
involved in determining oocyte quality as demonstrated by reduced 
expression of MYHII in cumulus cells from gonadotrophin treated mice. 
Future studies described in the following chapters of this thesis will 
examine the effects of ovarian stimulation on embryo development, in 
addition to molecular, in vivo and post partum developmental 
consequences of the differences in oocyte and embryo quality induced by 
these different stimulation regimes. 
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CHAPTER 4: THE EFFECT OF OVARIAN STIMULATION ON 
EMBRYO QUALITY 
 
4.1 INTRODUCTION 
Pregnant mares serum gonadotrophin (PMSG) was the first preparation 
used to induce ovarian stimulation and its application in rodents, such as 
the mouse and other mammals is still widely utilised (Lunenfeld, 2004). 
PMSG is derived from the endometrial cups of pregnant mares and 
although similar to hCG in terms of molecular structure, has an extended 
half life. PMSG also has both FSH and LH activity so it can function as a 
stimulator and ovulation inducer (Chopineau et al., 1997). PMSG was 
originally used in humans to recruit multiple follicles (Beall and 
DeCherney, 2012). Attempts to induce ovulation after follicle development 
with PMSG were inconsistent (Lunenfeld, 2004). The use of PMSG was 
further hampered by inter species differences which were causing the 
formation of antibodies to the exogenous gonadotrophin, which is some 
cases led to a cross reaction with endogenous FSH and LH (Macklon et al., 
2006). In addition, the approval of the use of the animal derived PMSG in 
human fertility management was revoked in 1972 (Lunenfeld, 2004). The 
first gonadotrophin of human origin on the market was human 
menopausal gonadotrophin (hMG). Like PMSG, hMG provides both FSH 
and LH bio-activity (Lunenfeld, 2004). Protein purification improved, with 
the application of immuno-affinity chromatography allowing an increase of 
the relative amounts of the active FSH ingredient (Huirne et al., 2004), 
leading to the manufacturing of highly purified hMG (Menopur), which is 
still in use commonly to date. In this preparation the LH component is 
removed during the purification of FSH and replaced by 10IU of hCG 
allowing LH activity constituents to be better controlled (Wolfenson et al., 
2005). Due to the six times longer half life of hCG, 10IU provides the 
equivalent bioactivity of 75IU LH (Huirne et al., 2004). More recently the 
advent of recombinant DNA technology has led to the production of 
recombinant gonadotrophins (Balen et al., 1999).  
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Large scale multi centre comparative trials were conducted in the 1990s 
assessing clinical outcomes with the different pharmaceutical compounds 
and many independent comparative trials have been performed since. A 
meta-analysis of these early studies favoured rFSH over uFSH in terms of 
clinical pregnancy rates (Daya and Gunby, 2000) however this was 
withdrawn from the Cochrane database due to a conflict of interest and 
the inclusion of dated trials (Daya and Gunby, 2006).  Another meta-
analysis from the same period found no difference in cumulative ovulation 
rates, pregnancy rate, miscarriage rate, multiple pregnancy rate or 
ovarian hyper stimulation (OHSS) risk when the stimulatory effects of 
rFSH were compared with its traditional urinary counterpart (Bayram et 
al., 2001). An updated meta-analysis again showed no disparity in 
pregnancy rates between hMG, uFSH and rFSH (Al-Inany et al., 2003). 
The same research group found clinical pregnancy rate and live birth rates 
in favour of hMG compared to rFSH but only in the IVF patients, including 
the new highly purified hMG containing hCG as the LH substitution (Al-
Inany et al., 2009). Another meta-analysis at the same time found this 
positive trend for both IVF and ICSI patients with a pooled increase in 
pregnancy rate of 4% (Coomarasamy et al., 2008).   
 
LH exerts some of its actions on the cumulus cells surrounding the 
developing oocyte which are involved in bi-directional communication with 
the oocyte (Matzuk et al., 1990). This is vital to sustain oocyte viability 
and thus early embryo development. Therefore LH may be an essential 
component absent in most ovarian stimulation regimes in  the 
endogenous LH levels are fully suppressed (Platteau et al., 2004). Current 
evidence suggests LH supplementation only benefits certain patient 
groups such as poor responders and those of advanced maternal age 
(>35 years) (Mochtar et al., 2007). Despite the LH requirement 
controversy, superovulation has consistently been associated with 
numerous disadvantages.   
 
The effect on embryo development with the use of exogenous 
gonadotrophins PMSG and hCG has been particularly well characterised in 
the mouse model. Ovarian stimulation using PMSG has been shown to 
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reduce the proportion of blastocyst formation and a delay in the 
development to the blastocyst stage both in vitro (Ertzeid and Storeng, 
1992;  Van der Auwera and D'Hooghe, 2001) and in vivo (Ertzeid and 
Storeng, 2001) in mouse models. COS has shown to increase the 
frequency of chromosomal abnormalities in embryos (Chang, 1977), 
reduce the total cell number of blastocysts and the number of micro villi 
on the cell surface (Champlin et al., 1987). Providing a potentially 
explanation for poor in vitro embryo development and the delay observed 
in implantation (Van der Auwera and D'Hooghe, 2001). Analogous 
ailments following ovarian stimulation with PMSG have also been reported 
in other mammalian species such as the hamster (McKiernan and 
Bavister, 1998), cow (Gonzalez et al., 1994) and sheep (Ryan et al., 
1991).  
 
The objective of this experiment was to examine the efficacy of common 
human gonadotrophin preparations with different half lives and LH activity 
in mice (hMG, rFSH and Pergoveris). The endpoints measured in this 
experiment were embryo yield, embryo development, blastocyst grade 
and blastocyst quality.  
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4.2 METHODS OVERVIEW 
This chapter provides the embryo development results for the in vivo 
fertilised mice which were randomly allocated to the various treatment 
groups in Chapter 3: 
 
Table 4.1: Number of mice in each treatment group 
                     
Treatment 
                  
Number of technical 
repeats (n) 
                      
Total  number of     
mice (n) 
 
Un-stimulated 
 
18 
 
72 
5IU PMSG 12 49 
0.5IU hMG 9 36 
5IU hMG 6 23 
0.5IU Pergoveris 9 36 
5IU Pergoveris 10 41 
0.5IU rFSH 4 14 
2.5IU rFSH 4 16 
5IU rFSH 3 12 
 
The age (5-6 weeks), strain (B6CBAF1), mean weight (18.375g), source 
(Charles Rivers UK, same breeding colony) and timing of sacrifice and 
experimental procedures were kept constant throughout the study. After 
collection (refer to section 2.3.1) all embryos followed the same 
experimental conditions in this chapter as schematically represented in 
Figure 4.1.  
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Figure 4.1: Flow chart summarising the experimental design used in this 
chapter.  
 
Embryos were cultured to blastocyst using the G-1/G-2 sequential culture 
system described in section 2.3.2. Those embryos which failed to continue 
development were stained with DAPI to visualise the genetic material 
(refer to section 2.3.3). On Day 5, blastocysts were graded according to 
Gardner and Schoolcrafts system (refer to section 2.3.2.2) and triple 
stained as previously described in section 2.4.2.2. One mouse per 
treatment group was designated for time lapse imaging using the 
embryoscope (section 2.3.2.1) to enable comparisons between daily 
developmental monitoring and time lapse microscopy.     
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4.2.1 Statistical analyses 
Data was tested for normality using the Kolmogorov-Smirnov and 
Shapiro-Wilk tests using SPSS version 16 (IBM Software Services, 
Hampshire, UK). Statistical significance was set at P<0.05 for all analyses.  
Statistical analysis of the number of zygotes collected per treatment group 
was performed using the Kruskal-Wallis test having confirmed the data 
was not normally distributed and could not be successfully transformed by 
logarithm or square root. All subsequent statistical analyses in this 
chapter are made relative to the number of embryos initially collected. 
This was done to give an indication of successful embryo development 
based on the initial yield, which in conventional IVF is unknown until post 
fertilisation and removal of the cumulus cells. Kruskal-Wallis test was also 
used to analyse developmental data. The proportion of embryos reaching 
the blastocyst stage was also expressed as actual numbers per mouse and 
tested by ANOVA having confirmed the data was parametric. 
 
Statistical analyses of the blastocyst triple staining data was performed by 
Kruskal-Wallis test for the total cell counts and chi squared test for 
associations to analyse the proportional data. As the number of 
trophectoderm cells in stained blastocysts was not always clearly 
discernible, only those embryos that had clear fluorescent images were 
used for the TE and ICM proportional analysis. Analysis of blastocysts was 
based on the whole group reaching that stage and the Chi square test was 
used to statistically assess the results for both morphological stage and 
grade. 
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4.3 RESULTS 
4.3.1 Embryo yield 
Compared to the naturally cycling control group, treatment with 5IU 
PMSG, 0.5IU hMG, 5IU Pergoveris, 2.5IU and 5IU rFSH significantly 
(P<0.01) increased the yield of ovulated oocytes (Figure 4.2). 
Administration of rFSH at the 0.5IU dose resulted in significantly less 
embryos collected (P<0.001) than naturally ovulating controls, whereas 
embryo yield for the 5IU hMG and 0.5IU Pergoveris groups did not differ 
from controls. 
 
Figure 4.2: Box plot showing median number of zygotes collected for Natural, 
PMSG, 0.5IU hMG, 5IU hMG, 0.5IU Pergoveris, 5IU Pergoveris, 0.5IU rFSH, 2.5IU 
rFSH, 5IU rFSH. Bars represent the inter-quartile range. (Significantly different 
compared to natural *** P<0.001, **P<0.01 as analysed by Mann-Whitney U 
test). 
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4.3.2 Embryo quality 
4.3.2.1 Proportion developing 
Figure 4.3 depicts development as the proportion of embryos reaching the 
two cell stage, those that continued to divide further past this block and 
those reaching the blastocyst stage, based on the total number of zygotes 
collected regardless of maturity. The natural group had 100% cleavage to 
2 cells. This was not observed in any of the ovarian stimulation groups. In 
the natural group all embryos continued developing past the 2 cell block 
and arrest only occurred prior to the blastocyst phase with one embryo 
per mouse on average not forming a blastocoel cavity. In all the ovarian 
stimulation groups significantly less embryos developed to the blastocyst 
stage when compared with the un-stimulated control (Figure 4.3, 
P<0.001).   
 
PMSG treatment resulted in significantly less embryos undergoing the first 
cell division (P<0.001). Furthermore, a larger proportion of the two cell 
embryos arrested at this stage, resulting in statistically less embryos 
continuing development on towards the blastocyst stage (P<0.001). The 
proportion of embryos completing pre-implantation embryo development 
from the 2 cell stage in the PMSG treatment group was comparable to the 
natural group (P>0.05). The 0.5IU hMG ovarian stimulation group 
followed a parallel mode of embryo development as those stimulated with 
PMSG. The 5IU hMG group on the other hand resulted in significant arrest 
at the two cell stage (P<0.001), but as with the 0.5IU hMG and PMSG 
treatments, of those embryos cleaving past the 2 cell stage, a similar 
proportion developed to the blastocyst stage. 
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Figure 4.3: Box plot showing the median proportion of embryos cleaving to the 2 cell stage, continuing cleavage past this stage 
and reaching the blastocyst stage for all the treatment groups relative to number of zygotes collected. All ovarian stimulated 
groups development was impaired compared to natural (*** P<0.001 as analysed by Mann-Whitney U test). Bars represent the 
inter-quartile range.  
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The 0.5IU Pergoveris treatment resulted in less embryos cleaving 
(P<0.05) and as with the other ovarian stimulation groups, resulted in 
significant arrest of embryo development at the two cell stage (P<0.001). 
In contrast this regime also displayed considerable developmental arrest 
prior to blastocyst formation (P<0.001) resulting in very few blastocysts 
for further analysis. In contrast the 5IU Pergoveris group, in which, 
despite having less embryos completing the first cell division (P<0.001), 
development did continue and overcame the two cell block to reach the 
blastocyst stage.  
 
The rFSH stimulation regimes on the other hand did not yield viable 
embryos. Embryos from mice treated with 0.5IU rFSH rarely cleaved 
whereas embryos from mice treated with 2.5IU rFSH had some cleavage 
and further development whilst embryos from mice treated with 5IU rFSH 
all arrested at the two cell stage. Throughout the entire study, the 0.5IU 
and 5 IU rFSH treatments only resulted in 2 and 1 embryos, respectively, 
reaching the blastocyst stage of development. Further, the blastocysts 
produced were very early blastocysts, only acquired through extended 
culture until Day 6. Accordingly, for the remainder of this results section 
the rFSH treatment groups will not be referred to.  
 
4.3.2.2 Rate of development 
On Day 1 of collection zygotes would be expected to be at the one cell 
pro-nuclear stage as observed in the natural group (Figure 4.4A) and this 
was the stage observed in all the stimulation groups, apart from the PMSG 
group, which had already begun to undergo the first cell division at the 
time of embryo collection (Figure 4.4F). The PMSG group therefore 
reached the blastocyst stage either on Day 4 or 5, whereas all the other 
experimental groups reached this milestone on Day 5 (Figure 4.4F).  
Chapter 4: Effect on embryo quality 
106 
 
Figure 4.4: Daily monitoring of embryo development throughout in vitro culture.  
 
On Day 2 of development the naturally mated group had undergone the 
first cell division. This initial cleavage in the 5IU hMG and 0.5IU Pergoveris 
stimulation groups showed some fragmentation. Groups treated with 
0.5IU hMG, 5IU Pergoveris and PMSG on Day 2 had already reached the 4 
cell stage. This accelerated development was still evident on Day 3 where 
the 0.5IU hMG and 5IU Pergoveris groups had already begun the process 
of compaction whereas the natural group was at the 8 cell pre-compaction 
phase. The 0.5IU Pergoveris group had also started to undergo 
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compaction. The PMSG group already had a clearly evident blastocoel 
cavity on Day 3 and some groups on Day 4 had started to hatch out of the 
zona pellucida. On Day 4 embryos from all experimental groups, apart 
from treatment with PMSG, looked morphologically similar, with a clearly 
evident blastocoel cavity and all embryos reaching the blastocyst stage on 
Day 5.  
 
4.3.2.3 Developmental stage at media change 
The developmental stage which embryos had reached on Day 3 at the 
time of media change, are summarised in Figure 4.5. The proportion of 
embryos from naturally mated mice at the morula stage of development 
was comparable to treatment with 0.5IU Pergoveris (P>0.05). In contrast 
stimulation with PMSG, 0.5IU hMG and 5IU Pergoveris as previously 
indicated, resulted in significantly more embryos at the morula stage 
(P<0.001). Treatment with 5IU hMG, on the other hand resulted in a 
decline in the number of embryos reaching compaction (P<0.05) with a 
significant proportion of these embryos remaining at the 2-4 cell stage of 
development compared to natural controls (P<0.001). Treatment with 
0.5IU Pergoveris also resulted in an increase in the number of embryos 
arresting at this early developmental stage (P<0.001). The PMSG, 0.5IU 
hMG and 5IU Pergoveris groups were comparable to embryos from 
naturally cycling animals with regard to the proportion of embryos not 
progressing from the 4 cell stage (P>0.05). The majority of naturally 
derived embryos on Day 3, at the time of media change, were at the 6-8 
cell pre-compaction stage of embryo development. This was significantly 
different in all the ovarian stimulation groups (P<0.001), either because 
embryos in these groups were more advanced, for example the PMSG, 
0.5IU hMG and 5IU Pergoveris groups, or delayed, as was the case for 
treatment with 5IU hMG and 0.5IU Pergoveris.  
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Figure 4.5: Proportion of cleaved embryos on day 3 at 4 cells (red), 6-8 cells  
(orange) and the morula (green) morphological stage of development for the 
Natural, PMSG, 0.5IU hMG, 5IU hMG, 0.5IU Pergoveris, 5IU Pergoveris, 0.5IU 
rFSH, 2.5IU rFSH, 5IU rFSH. (statistical significant of comparison to naturally 
mated mice at same developmental stage; *** P<0.001, *P<0.05 as assessed by 
chi square test for associations). 
 
4.3.2.4 Timing of embryo development by Embryoscope 
Naturally derived embryos cleaved to the 2 cell stage after 37±2.7 
(Median ± inter-quartile range) hours (Figure 4.6, Representative videos 
are also available on the CD Rom accompanying this thesis). The next two 
rounds of cell divisions occurred at 60±5.3 and 71±5.4 hours. Compaction 
of the embryo occurred at 82±4.5 hours with cavitation first observed at 
100±4.3 hours. Embryos became fully expanded blastocysts at 117±10.2 
and eventually began to hatch at 120 hours.  
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The ovarian stimulation groups had significantly different timings of 
development compared to naturally derived embryos (Figures 4.6-4.9). As 
previously indicated, treatment with PMSG resulted in accelerated 
development, with embryos undergoing the first and second cell divisions 
at 32±1 and 56±4.8 hours post hCG injection (P<0.001) and reaching the 
6-8 cell stage at a comparable time as control embryos (72 hours, 
P>0.05, Figure 4.6). However in comparison to other treatment groups 
and the negative control, embryos from PMSG treated mice underwent 
compaction at the 4 cell stage, instead of after reaching 6-8 cells. Only 2 
embryos out of the 12 analysed progressed to the 6-8 cell stage prior to 
morula formations in the PMSG treatment group (P<0.01). Timing of 
cavitation was comparable with control at 105±16.7 hours (P>0.05), 
however further development into a full blastocyst was significantly 
delayed in the PMSG group (132 hours, P<0.05) although blastocysts 
hatching timing was comparable (139 hours, P>0.05).     
Figure 4.6: Median time for embryos following treatment with PMSG (colour box 
plot) to reach developmental milestones compared to embryos derived from 
naturally mated controls (Greyscale box plot, n=12 per group). Error bars show 
inter-quartile range. (*** P<0.001, ** P<0.01 and * P<0.05 compared to control 
as analysed by Mann-Whitney U test).  
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Daily analysis of embryos from mice stimulated with 5IU hMG indicated 
development occurred at a comparable rate to embryos derived from 
naturally cycling mice; however the embryoscope data indicated that this 
treatment also accelerated the speed of development up until compaction 
(Figure 4.7). Thus, the first cell division occurred significantly earlier at 
32±4.8 hours post hCG (P<0.001). Subsequent development to the 4 and 
6-8 cell stage was also advanced, occurring at 53±6.7 and 66±6.3 hours 
respectively (P<0.05). Despite compaction also occurring earlier (74±6.1 
hours, P<0.05), morphological milestones after this developmental stage 
were similar to the un-stimulated group (P>0.05). 
 
Figure 4.7: Median time for embryos following treatment with 5IU hMG (colour 
box plot) to reach developmental milestones compared to embryo derived from 
naturally mated controls (Greyscale box plot, n=12 per group). Error bars show 
inter-quartile range. (*** P<0.001 and * P<0.05 compared to control as 
analysed by Mann-Whitney U test).  
 
Development of embryos following treatment with 0.5IU Pergoveris was 
also significantly accelerated until the time of cavity formation (Figure 
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4.8). Cleavage in this treatment group to the 2, 4 and 6-8 cell stage 
occurred significantly earlier compared to natural controls (P<0.01). Upon 
reaching the 6-8 cell stage, compaction into the morula occurred almost 
instantaneously at 59±19.1 hours, which was slightly less time taken to 
reach the 6-8 cell stage, and significantly earlier than unstimulated 
controls (P<0.001). This consequently meant cavitation also occurred at 
an earlier time (94±5.9, P<0.01). However, as noted with daily 
monitoring of embryo development, the embryoscope data confirmed this 
group reached the full and hatching blastocyst stage at analogous times to 
the natural group at 118±7.3 and 121±12.5 hours (P>0.05).     
Figure 4.8: Median time embryos following treatment with 0.5IU Pergoveris 
(colour box plot) to reach developmental milestones compared to embryo derived 
from naturally mated controls (Greyscale box plot, n=12 per group). Error bars 
show inter-quartile range. (*** P<0.001 and ** P<0.01 compared to control as 
analysed by Mann-Whitney U test).  
 
Daily monitoring of development of embryos derived from the 5IU 
Pergoveris treatment indicated that this group also had accelerated 
development to the hatching blastocyst stage. This finding was further 
supported by the embryoscope data (Figure 4.9). Initial cleavage occurred 
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significantly earlier compared to controls and all other treatment groups at 
only 30±2.4 hours post hCG (P<0.001). Further cleavage to the 4 and 6-8 
cell stages were subsequently earlier at 54±4.8 and 66±4.2 hours 
(P<0.001 and P<0.01 respectively). Unlike the other ovarian stimulation 
groups this pattern of accelerated embryo development continued until 
the full blastocyst stage with compaction, cavity and full blastocoel 
formation all occurring earlier (P<0.001). Although hatching blastocysts 
from this group were observed earlier at 110±6.9 hours post hCG, this 
trend was not statistically significant (P>0.05). 
Figure 4.9: Median time embryos following treatment with 5IU Pergoveris 
(colour box plot) to reach developmental milestones compared to embryo derived 
from naturally mated controls (Greyscale box plot, n=12 per group). Error bars 
show inter-quartile range. (*** P<0.001 and ** P<0.01 compared to control as 
analysed by Mann-Whitney U test).  
 
4.3.2.5 DAPI staining of arrested embryos 
Embryos that had arrested development prior to media change exhibited a 
number of different abnormalities, as illustrated in Figure 4.10. Unequal 
distribution of the cytoplasm and genetic material was evident, as was 
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failure to separate the metaphase plate. This arrested development 
appeared to only be evident in the ovarian stimulation groups and was not 
present in any of the arrested embryos from the un-stimulated controls.  
Figure 4.10: DAPI stained embryos arrested at the (A) 2 cell, (B) 3 cell and (C) 
4 cell stage.  
 
4.3.2.6 Blastocyst development 
Only ovarian stimulation with 0.5IU hMG and 5IU Pergoveris resulted in a 
significant increase in the number of blastocysts obtained relative to the 
un-stimulated control group (Figure 4.11, P<0.001). The positive control 
PMSG stimulation regime did not result in an increase in the number of 
embryos per mouse developing to the blastocyst stage (P>0.05) when 
compared to untreated controls. The 5IU hMG and 0.5IU Pergoveris 
treatment groups actually resulted in less embryos developing to 
blastocyst compared to controls but this trend was not statistically 
significant (P>0.05).  
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Figure 4.11: Mean ± SEM number of embryos developing to the blastocyst stage 
per mouse for Natural, PMSG, 0.5IU hMG, 5IU hMG, 0.5IU Pergoveris and 5IU 
Pergoveris. (*** P<0.001 compared to control as assessed by ANOVA).  
 
4.3.2.7 Blastocyst grade 
The proportion of blastocysts classified as early, fully expanded, hatching 
and hatched (Figure 4.12) were comparable between the ovarian 
stimulation regimes and the natural control (P>0.05), except for 
treatment with 5IU Pergoveris. This treatment group had significantly 
more hatching blastocysts (P<0.001) and a reduced proportion of early 
blastocysts (P<0.05) when compared to untreated controls.    
 
Eighty eight percent of blastocysts derived from naturally cycling animals 
were graded 3BB or better according to Gardner and Schoolcrafts grading 
system, with the majority being classified as 5AA-5BB (Figure 4.13). The 
quality of embryos derived from the PMSG treatment group was 
comparable to controls with most graded as 5AA- 5CC. However, this 
stimulation group also had some poorer 3CC blastocysts; in agreement 
with the embryoscope data which indicated that this treatment resulted in 
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a delay in development of fully expanded blastocysts (see 4.3.2.4). The 
0.5IU hMG treatment resulted in 81% of blastocysts being graded as over 
3BB and although most were graded 5AA- 4BB, below this classification 
the quality varied across the lower grade boundaries. 
Figure 4.12: Proportion of blastocysts in each morphological classification based 
on treatment (Natural (n=72), PMSG (n=49), 0.5IU hMG (n=36), 5IU hMG 
(n=23), 0.5IU Pergoveris (n=36), 5IU Pergoveris (n=41)). (*** P<0.001, * 
P<0.05 compared to control proportions as analysed by chi square test for 
associations). 
 
Treatment with 5IU hMG resulted in 88% good quality blastocysts being 
graded as 3BB or higher, with the majority being graded as 5AA-5CC. 
However, this group also had a noticeable proportion of low quality 1CC 
grades, although this trend was not statistically significant (P>0.05). Both 
the stimulation regimes utilising Pergoveris resulted in higher embryo 
Chapter 4: Effect on embryo quality 
116 
 
grades than unstimulated controls with 93 and 97% graded 3BB or better 
for the 0.5IU and 5IU doses respectively. However, only the 5IU 
Pergoveris treatment resulted in a statistically significant (P<0.05) 
increase in embryo quality with a predominant representation in the grade 
6 category (P<0.001).            
Figure 4.13: Proportion of blastocysts in each grade based on treatment. (*** 
P<0.001 and * P<0.05 compared to natural control as assessed by chi square 
test for associations).   
 
4.3.2.8 Blastocyst triple staining 
The unstimulated control group had a median total cell number (TCN) of 
81 per hatched or hatching blastocyst (Table 4.1). Treatment with PMSG 
resulted in a 20% decrease in TCN compared to controls (P<0.05). In 
contrast blastocysts from the 0.5IU and 5IU Pergoveris treatment groups 
had a 38% and 58% increase in cell number respectively (P<0.001). 
Blastocysts from the remaining stimulation groups contained comparable 
total cell numbers as untreated controls apart from the 0.5IU hMG treated 
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group which also had a  significant increase in TCN (P<0.01). The 
proportion of cells allocated to the ICM or TE was similar within all 
treatments groups (Table 4.1) although embryos from the PMSG group 
tended to distribute more cells to the trophectoderm than the ICM (Table 
4.1; P=0.059).   
 
The proportion of apoptotic cells within the blastocysts from across all 
treatment groups tended to be relatively low with blastocysts from 
nonstimulated controls, 0.5IU hMG, and 0.5IU Pergoveris treatment 
groups having around 5% apoptotic cells. The proportion of apoptotic cells 
was almost doubled when ovarian stimulation was performed with PMSG 
or 5IU hMG (P<0.05). In contrast the 5IU Pergoveris treatment tended to 
reduced the proportion of apoptotic cells and this difference approached 
statistical significance (P=0.068). Figure 4.14 displays representative 
blastocysts for all the treatment groups from which the cell counts were 
obtained.  
 
Table 4.2: Blastocyst triple staining counts for all treatment groups (Natural 
(n=72), PMSG (n=49), 0.5IU hMG (n=36), 5IU hMG (n=23), 0.5IU Pergoveris 
(n=36), 5IU Pergoveris (n=41)). (* P=<0.05, *** P=<0.001 compared to control 
as assessed by chi square and Mann-Whitney U tests). 
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Figure 4.14: Representative DAPI, PI and Tunel triple stained blastocysts for (A) 
Natural, (B) PMSG, (C) 0.5IU hMG, (D) 5IU hMG, (E) 0.5IU Pergoveris and (F) 
5IU Pergoveris groups and (G-H) Positive tunel controls 
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4.4 DISCUSSION 
In this study it was hypothesised that the use of human gonadotrophin 
preparations for ovarian stimulation in mice would not be detrimental to 
embryo development as has been reported for PMSG. The results obtained 
suggest that whilst superovulation with PMSG is detrimental to in vitro 
development to the blastocyst stage, contrary to the initial hypothesis, 
ovarian stimulation with human preparations also had both negative and 
positive effects on both embryo development and embryo quality relative 
to unstimulated controls. This study provides further evidence of the 
effects of ovarian stimulation with different gonadotrophin preparations on 
embryo development, highlighting the complexity of effects resulting from 
the use of different doses of gonadotrophin preparations which vary in 
terms of their biological clearance rate, FSH isoforms and level of LH-
bioactivity, such as hCG in hMG.    
  
4.4.1 PMSG effect on embryo yield and development 
Ovarian stimulation with PMSG is the standard protocol used to induce 
multiple follicular development in the mouse (Nagy et al., 2003). The 
mean zygote yield of 25 observed in this study for COS with PMSG is 
consistent with those reported in the literature ranging from 17-33 across 
the various mouse strains (Martín-Coello et al., 2008;  Edgar et al., 1987;  
Muñoz et al., 1995;  Kanter et al., 2004;  Brooke et al., 2007). In 
agreement with previous studies treatment with PMSG resulted in reduced 
in vitro development, with significant developmental arrest and a 
blastocyst yield of approximately 50%, which is comparable to the 
published rates of 50-54% when the whole ovulated group per mouse is 
taken into account (Edgar et al., 1987;  Muñoz et al., 1994). The 
proportion of hatching blastocysts on Day 5 in the PMSG group is 
comparable to previously reported rates in the literature of 64.9% 
(Ghaemi et al., 2008). Blastocysts obtained after PMSG treatment, despite 
having high rates of developmental arrest, had an accelerated rate of 
development reaching morphological checkpoints in pre-implantation 
development faster than untreated controls.  
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It is possible that this apparent increase in development is an artefact due 
to the LH activity of PMSG resulting in induction of ovulation and thus 
oocyte fertilisation earlier than naturally ovulated counterparts. However, 
this appears unlikely as the COCs were recovered from the same region of 
the oviduct in both PMSG treatment and controls groups. Further,  
flushing of the uterine horns of PMSG stimulated mice has not been shown 
to yield any further zygotes (Ozgunen et al., 2001), suggesting that 
premature ovulation is not occurring in response to stimulation with 
PMSG. Ninety percent of the embryos from the PMSG treated group 
underwent compaction prematurely at the 4 cell stage whereas embryos 
from nonstimulated and other ovarian stimulation groups underwent an 
additional cleavage step to the 6-8 cell stage before morula formation, 
therefore potentially explaining the increased developmental speed of 
embryos from PMSG treated animals. The total cell numbers of un-
stimulated and PMSG blastocysts calculated in our study are analogous 
with previous reports (Ghaemi et al., 2008;  Tarín et al., 2002) with 
blastocysts from PMSG treated animals having significantly fewer cells. 
This decrease in cell number may potentially be a consequence of the 
increased developmental speed and the observed loss of a cleavage step 
during the in vitro development of embryos from PMSG treated groups. 
The negative effects of PMSG may be partly due to the long acting LH 
bioactivity in the preparation. In a previous study increased doses of 
PMSG not only halved the number of oocytes, but reduced the proportion 
of embryos cleaving to the two cell stage and developing to blastocyst 
significantly to only 38% and a mere 7% respectively (Edgar et al., 1987). 
Although not assessed in our study, analogous results were obtained with 
human gonadotrophin preparations containing hCG as discussed in section 
4.4.5. 
 
4.4.2 Ovarian stimulation with human gonadotrophins 
There have been few studies in the literature investigating human 
gonadotrophins in mouse ovarian stimulation. Human menopausal 
gonadotrophin (hMG) like PMSG has approximately equal amounts of  FSH 
and LH bio-activity (Lunenfeld, 2004) although the relative half-lives of 
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these heterologous gonadotrophins in the mouse are unknown. Similarly, 
as the bio-assay used to determine the biological activity of both PMSG 
and hMG differ (Macklon et al., 2006), it is not possible to directly 
compare the doses utilised in this study for ovarian stimulation. Previous 
studies assessing hMG for mouse superovulation used earlier formulations 
of the preparation where the LH activity came from urinary LH as opposed 
to hCG in the preparation used in our study. These studies have reported 
only 15 zygotes obtained after a single dose of 10IU (Edirisinghe et al., 
1986) and a mean of 34 when 2 repeated doses of 1IU 12 hours apart 
were given (Brooke et al., 2007). Although previous reports have 
concluded a comparable number of embryos are achieved by hMG and 
PMSG, no investigations into embryo development was undertaken, as the 
outcome of previous experiments was increasing the yield of oocytes for 
transgenic applications (Brooke et al., 2007). Our results suggest 
repeated injections of 0.5IU hMG increases the number of blastocysts 
compared to both the negative natural control and positive PMSG control 
and the quality of the resulting 0.5IU hMG blastocysts were comparable to 
naturally derived blastocysts in terms of grade and fluorescent analysis 
outcomes. 5IU Pergoveris also showed more favourable results in terms of 
blastocyst rate and quality whereas stimulation with pure rFSH alone did 
not result in any blastocysts being produced. These differences in embryo 
quality and number following ovarian stimulation can be largely attributed 
to differences in the LH activity, FSH activity and half life of the 
gonadotrophic preparations tested.  
 
4.4.3 rFSH alone  
Treatment with rFSH alone in our study did not yield any blastocysts, 
however, these results are in direct conflict compared to the only  
previous study to our knowledge assessing rFSH in the mouse model 
where comparable total doses of rFSH, given 24 hours apart as opposed 
to every 12 hours in our study, resulted in a 72% blastocyst rate in 
mature mice of the same strain (Edwards et al., 2005). In our study we 
utilised immature mice to overcome the need for down regulation, without 
which premature ovulation may occur in mature mice that may potentially 
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provide an explanation for the discrepancy between our results and the 
literature. However after repeating the 2.5IU rFSH protocol with mature 
mice at 8 weeks of age blastocyst formation was still not evident.7 The 
reason for the discrepancy in results between our study and the previous 
published is unclear. This research group used the same CBA X C57Bl/6 
F1 female strain however several sub-strains of CBA X C57Bl/6 F1 do exist 
and genetic drift as a consequence of the isolation of breeding colonies 
over several years may be a factor (Zurita et al., 2011). The use of 
different culture medium and in vitro culture incubator conditions may 
also explain the differences in results. The authors did conclude that 
embryo development after treatment with rFSH was poor and resulting 
blastocysts had reduced cell numbers (Edwards et al., 2005).  
 
Our study also showed that regimes with rFSH alone did not yield 
developmentally competent embryos. This is a surprising result as this 
standard rFSH stimulation regime has been found to be highly effective in 
humans (van Wely et al., 2011). Ovarian stimulation regimes composed of 
high doses of rFSH only work by maintaining FSH above threshold 
concentrations for an extended period so more ovulatory follicles recruited 
from the gonadotrophin-responsive group are maintained as FSH-
dependent until the ovulatory trigger is applied (Campbell et al., 1999;  
Brown, 1978;  Schipper et al., 1998). Mice have a higher metabolic rate 
compared to humans and based on the evidence that rFSH contains a high 
proportion of less acidic iso-forms (Lispi et al., 2006) which show greater 
in vitro bioactivity but have a faster in vivo clearance rate (Vitt et al., 
1998), suggests this preparation may not be sufficient to maintain FSH 
levels above the threshold. Due to home office license restrictions, the 
frequency of the injections could not be increased to assess this theory.  
 
It could be suggested that poor embryo quality associated with rFSH alone 
is an artefact of the mouse model and reflects fluctuations of the FSH 
                                      
7 See Appendix 5 for data.  
Chapter 4: Effect on embryo quality 
123 
 
level above and below the threshold, due to the preparations short half 
life. The observation that identical FSH concentrations following treatment 
with Pergoveris, which has rLH in addition, does yield developmental 
competent embryos indicates that the presence of LH, whether 
endogenous in not fully down regulated patients or  exogenous from 
preparations such as Pergoveris or hMG can act to support the follicles 
when FSH levels fall below the threshold. During the normal follicular 
phase ovulatory follicles transfer their gonadotrophin dependence from 
FSH to LH as part of the normal follicle selection process (Huirne et al., 
2004;  Campbell et al., 1999), explaining why preparations with LH 
produce viable embryos as discussed further in section 4.4.4. 
 
4.4.4 Combined rFSH and rLH (Pergoveris) 
The production of good quality embryos after treatment with Pergoveris 
can be attributed to the ability of the ovulatory follicles to transfer 
dependence from FSH to LH so gonadotrophic support is adequate until 
the ovulatory trigger is applied (Campbell et al., 1999). Of the two doses 
tested only the higher dose resulted in increased embryo yield and 
improved proportions of good quality blastocysts graded 3BB or higher 
according to Gardner and Schoolcrafts system. In particular, there were 
more hatching blastocysts at higher doses of Pergoveris and a trend for 
reduced apoptosis rates which have all been demonstrated as indicators of 
improved quality which translate into better implantation and ongoing 
pregnancy rates (Alper et al., 2001;  Teranishi et al., 2009;  Brinsko et 
al., 1994;  Fong and Bongso, 1999).  
 
The lack of response using the lower dose of Pergoveris and the 
subsequent poor embryo development can probably be attributed to the 
short half life of rFSH as discussed in section 4.4.3. The timing of 
developmental arrest at the two cell stage is coincidental with mouse 
embryonic genome activation, indicating poor oocyte quality as a result of 
the ovarian stimulation regime may be responsible (Gardner and Lane, 
2005; Wassarman and Kinloch, 1992). Fluorescent analysis of these 
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arrested embryos showed unequal division of genetic material which at 
such early stages of development would potentially depend on the oocytes 
potential to modulate these events (Pesty et al., 2007). Higher 
concentrations of rFSH appear to be required in order to produce fully 
competent oocytes capable of continuing embryonic development after 
ZGA.   
 
4.4.5 Urinary FSH with long half life LH activity 
In stark contrast to Pergoveris, the lower dose of hMG resulted in an 
increase in blastocyst yield whereas the higher dose was detrimental. This 
difference in response can most likely again be attributed to the longer 
half lives of the urinary FSH and hCG contained within hMG. Although it is 
also clear that hMG contains more LH activity (1:1) than Pergoveris (2:1).   
Thus lower doses of hMG could have supplied sufficient gonadotrophic 
support to maintain the ovulatory follicles (as per high doses of 
Pergoveris) due to the longer in vivo half life of these preparations (West 
et al., 2002) as a result of the mostly acidic iso-forms in the urinary FSH 
(Lispi et al., 2006). Higher doses of hMG, in contrast, caused a reduction 
in the number of oocytes ovulated and resulted in poor embryo 
development and blastocyst formation with higher levels of apoptosis. This 
could potentially be due to the supply of un-physiologically high levels of 
LH stimulation due to the modified extension of the β subunit of hCG 
extending its half life (Huirne et al., 2004) in a manner analogous to 
PMSG.   
 
Hillier suggested that each follicle has a LH ceiling threshold, above which 
normal maturation of the follicle ceases, proposed to be associated with 
high levels of cAMP stimulation which is known to be major regulator 
oocyte maturation (Hillier, 1994), potentially explaining our alternative 
results for hCG and rLH containing preparations. The mechanistic effect is 
unclear but previous studies have shown that high concentrations of LH 
and hCG may lead to down regulation of the LH receptor on granulosa 
cells in human (Jeppesen et al., 2012) and rats (Rao et al., 1977;  Peng et 
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al., 1991), confirmed by real time PCR, in situ hybridisation and northern 
blots. In vitro studies suggested long term exposure to LH can result in a 
conformational changes of the receptor that reduces the rate of 
phosphorylation on subsequent ligand binding (Minegishi et al., 1989), 
whereas others have suggested loss of receptors through internalisation 
and degradation may be involved or by reduction in LH receptor synthesis 
(Schwall and Erickson, 1984). Regardless of the putative mechanism, hCG 
has consistently been shown to reduce LH receptors by approximately 
80% within 24 hours following a large bolus injection (Jeppesen et al., 
2012;  Rao et al., 1977), after which re-exposure results in a decreased 
response.  
 
Reduced LH receptors may reduce the number of follicles responsive to LH 
during the later stages of folliculogenesis which was shown to be 
beneficial, as per treatment with Pergoveris and in addition provides a 
potential explanation as to why ovulation rates were reduced at higher 
doses of hMG. Therefore in preparations containing hCG, the LH 
bioactivity resulting from increasing the dose may lead to LH levels above 
a hypothesised ceiling level causing detrimental embryo development, 
whereas the low half life of recombinant LH results in the Pergoveris 
preparation being within the theorised LH window, providing beneficial 
effects. It is unclear how these preparations affect follicle development, 
but the manifestation of the preparations influence on subsequent embryo 
development is clear.   
 
4.4.6 Conclusion 
The results of this study show clearly that the quality of embryos obtained 
following ovarian stimulation of mice with human gonadotrophin 
preparations is critically dependent on the dose, half life and LH content of 
the preparations used. Although we were unable to obtain blastocysts 
from regimes utilising rFSH alone, the results strongly indicate that good 
quality embryos can be obtained from low doses of urinary preparations 
containing FSH and LH activity with longer halve lives or higher doses of 
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recombinant preparations containing FSH and LH activity with much 
shorter half lives. Further, these studies have confirmed and extended the 
observation that ovarian stimulation with high doses of gonadotrophins 
with extended LH activity (PMSG, hMG) results in embryos of poor quality, 
although the exact mechanisms resulting in this response remain unclear. 
Future studies described in the following chapters of this thesis will 
examine the molecular and developmental consequences of the 
differences in embryo quality induced by these different stimulation 
regimes. 
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CHAPTER 5: OVARIAN STIMULATION AND GENE 
EXPRESSION IN THE EMBRYO 
5.1 INTRODUCTION 
In recent years, our knowledge of pre-implantation processes and the role 
genetics plays in fine-tuning these events has vastly improved. Focus is 
now being directed at assessing the relationship between ART procedures 
and genetic alterations. One of the main areas of interest has been 
imprinted gene expression. Whilst the absolute risk of developing an 
imprinted disorder is low, children born through ART do appear to be more 
susceptible than those in the general population (Maher, 2005). There 
have been numerous reports correlating genomic imprinting errors and 
disorders with ART, in animal models (Market-Velker et al., 2010;  Menezo 
et al., 2010;  Zhang et al., 2010;  Mundim et al., 2009) and human 
subjects (Strawn et al., 2010;  Katari et al., 2009;  Lawrence and Moley, 
2008;  Sato et al., 2007). Finding the aspect of the ART procedure 
responsible for these risks has remained elusive. Due to the low incidence 
of imprinting disorders after ART, it is extremely difficult to explore cause-
effect relationships from clinical data. Therefore, precisely defined in vitro 
models are powerful tools for identifying mechanisms.  
 
Methylation disturbances have been reported throughout the oocyte and 
embryonic genome after ovarian stimulation (Shi and Haaf, 2002;  Sato et 
al., 2007) suggesting that superovulation may be the source of imprinting 
defects. Epigenetic marks are gained in an asynchronous manner 
throughout folliculogenesis in correlation with oocyte diameter, with most 
of the methylation occurring in the diplotene stage of oocyte meiosis in 
mice and humans (Lucifero et al., 2002). The unphysiological hormonal 
milieu due to exogenous gonadotrophin administration during this phase 
may perturb imprints. It has been demonstrated previously that 
methylation alterations are exacerbated by ovarian stimulation, in a dose 
dependent manner (Market-Velker et al., 2010). 
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There are 96 known conserved murine and human genes that exhibit 
parent-of-origin specific methylation patterns (Wood and Oakey, 2006). 
The H19 and IGF2 gene clusters have received the most attention as their 
expression is hypersensitive to disruptions during gametogenesis. Hence, 
they are frequently used as a quasi-sensor for epigenetic perturbations 
(Nan et al., 1998;  Doherty et al., 2000). IGF2 is a potent foetal mitogen 
that is regulated by H19 through a shared differentially methylated region 
(De Rycke et al., 2002;  Leighton et al., 1995). They exert their effects on 
the placenta regulating nutrient transfer and coincidently foetal growth 
and development (De Rycke et al., 2002).  
 
In addition to imprinted gene expression, in recent years the relationship 
between vascularity of the ovary and follicle with ART outcomes has also 
been investigated. The renin-angiotensin system (RAS) has been shown to 
play a pivitol role in decidualisation, implantation and placentation through 
the regulation of blood flow, oestradiol secretion and prostaglandin 
synthesis (Nielsen et al., 2000). Disruption of the RAS has been 
implicated in cases of pre-eclampsia and IUGR (Li et al., 1998). Binding of 
angiotensin to the AT1 receptor (ATR1), predominately found on EVT, 
promotes growth processes that are required throughout pregnancy. AT2 
receptors (ATR2) on the other hand, inhibit cell proliferation and leads to 
cell apoptosis (Nielsen et al., 2000). Changes in the relative expression of 
ATR1 and ATR2 have been proposed to determine whether angiotensin 
promotes growth, apoptosis or differentiation. The pro-angiogenic factor 
VEGF, is one of the final products of the RAS pathway (Agrawal et al., 
2002). Oestrogen has recently been shown to stimulate VEGF expression 
in the ovary (Ha et al., 2010). Disruption of the RAS due to exogenous 
gonadotrophin administration may cause imbalances in the uterus 
inhibiting implantation. No previous work has focused on how ovarian 
stimulation may alter this complex angiogenic system.  
 
The objective of this experiment was to examine the effect of common 
human gonadotrophin preparations (hMG and Pergoveris) on the 
expression of genes regulating imprinting and angiogenesis. The 
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endpoints measured were H19, IGF2 and IGF2r gene expression for 
epigenetic disturbances and VEGFA, ATR1 and ATR2 expression levels as 
vascularity indexes. Based on previous oocyte and embryo development 
analyses (Chapter 3 and 4) it was hypothesised that the use of human 
gonadotrophin preparations for ovarian stimulation in mice would not be 
as disruptive to imprinted gene expression as preparations containing long 
acting LH (PMSG/hMG). 
 
5.2 METHODS OVERVIEW 
Mice were randomly allocated to the various treatment groups as 
described in chapter 2 section 2.1. On Day 5 on in vitro culture, 
blastocysts hatching away from the ICM underwent trophectoderm biopsy 
(as detailed in chapter 2 section 2.4.2). Hatched blastocysts were not 
biopsied due to difficulty holding them stationary without the zona 
pellucida. Using Garner and Schoolcrafts blastocyst grading system 
(section 2.3.2.2) these are all blastocysts graded between 5AA and 5CC. 
Un-stimulated (n=12), PMSG (n=9), 0.5IU hMG (n=11), 5IU hMG (n=11), 
0.5IU Pergoveris (n=10) and 5IU Pergoveris (n=12) biopsied samples 
were chosen at random for imprinted gene analysis, so as not to introduce 
bias. Randomly chosen trophectoderm biopsies were also selected from 
the un-stimulated, PMSG, 0.5IU hMG and 5IU Pergoveris treatment 
groups to assess RAS gene expression (n=12 samples per group). They 
were designated for polymerase chain reaction (PCR) for gene expression 
analysis (Section 2.4.3). 
 
5.2.1 Statistical analyses 
Data was tested for normality using the Kolmogorov-Smirnov and 
Shapiro-Wilk tests using SPSS version 16 (IBM Software Services, 
Hampshire, UK). Statistical relevance was set at P<0.05 for all analyses. 
Gene expression was not normally distributed and could not be 
successfully transformed so was graphically represented by a box plot and 
analysed using the non-parametric Kruskal-Wallis test on SPSS. Any 
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sample with an 18s Ct value above 26 was omitted due to lack of 
biological significance.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Flow chart summarising the experimental design used in this 
chapter. 
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5.3 RESULTS 
5.3.1 Imprinted gene expression 
5.3.1.1 H19 expression 
H19 gene expression fold differences were detectable in low levels in the 
treatment groups. The median fold difference for all the treatment groups 
was 0. Expression was not evident in blastocysts following treatment with 
5IU hMG and 0.5IU Pergoveris. However, these trends were not significant 
(P>0.05, Figure 5.2).  
Figure 5.2: Median relative fold difference of H19 transcript levels in the 
treatment groups. Error bars depict the inter-quartile range.   
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5.3.1.2 IGF2 expression 
The relative median fold difference of IGF2 gene expression in the un-
stimulated group was 0.56 with an inter-quartile range of 0.7. In contrast, 
treatment with PMSG and 0.5IU hMG resulted in a 2-3 times decrease in 
IGF2 expression which was statistically significant (P<0.05, Figure 5.3). 
The relative fold difference of 5IU hMG, 0.5IU Pergoveris and 5IU 
Pergoveris treatment groups was comparable to control (P>0.05).    
 
Figure 5.3: Median relative fold difference of IGF2 transcript levels in the 
treatment groups. (* P<0.05 compared to natural as assessed by Mann-Whitney 
U test). Error bars depict the inter-quartile range.   
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5.3.1.3 IGF2r expression 
The relative fold differences of the IGF2r mRNA transcripts were 
equivalent between the ovarian stimulation groups when compared to the 
natural control (P>0.05). As graphically represented in Figure 5.4, PMSG 
had the highest inter-quartile range. 
 
Figure 5.4: Median relative fold difference of IGF2r transcript levels in the 
treatment groups. Error bars depict the inter-quartile range.   
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5.3.2 Examination of the RAS system 
5.3.2.1 ATR1 expression 
The relative median fold difference of ATR1 gene expression in the un-
stimulated control group was 1.34 with an inter-quartile range of 5.71 
(Figure 5.5). Blastocysts following treatment with PMSG had comparable 
expression to natural controls (P>0.05) whereas expression in the 0.5IU 
hMG and 5IU Pergoveris groups was 2.5-3 fold greater than the naturally 
ovulated group, however these trends were not statistically significant 
(P>0.05).  
Figure 5.5: Median relative fold difference of ATR1 transcript levels in the 
treatment groups (n=12 for all). Bars show the inter-quartile range.  
 
5.3.2.2 ATR2 expression 
ATR2 was not detected in any of the biopsied samples selected for 
analysis. Furthermore, with reducing concentration on the blastocyst pool 
standards, ATR2 became undetectable. 
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5.3.2.3 VEGFA expression 
The relative median fold difference of VEGFA gene expression in the 
naturally cycling control blastocysts was 4.3±4.13. The number of VEGFA 
mRNA transcripts was diminished 6.5 fold in the following treatment with 
PMSG (P<0.01, Figure 5.6). The relative fold difference of 0.5IU hMG 
treated blastocysts was also reduced 5 fold although this trend was not 
statistically significant (P>0.05). The 3.5 fold decline of mRNA transcript 
levels in the 5IU Pergoveris group was significantly different compared to 
the natural group (P<0.05).  
 
Figure 5.6: Median relative fold difference of VEGFA transcript levels in the 
treatment groups (n=12 for all). (* P<0.05 and ** P<0.01 compared to control 
as assessed by Mann-Whitney U test).  
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5.4 DISCUSSION 
In this study it was hypothesised that the use of human gonadotrophin 
preparations for ovarian stimulation in mice would not be as disruptive to 
imprinted gene expression as preparations containing long acting LH 
(PMSG/hMG), based on previous oocyte and embryo development 
analyses (Chapter 3 and 4). The results obtained suggest that different 
stimulation regimes result in differences in the pattern of expression of 
some imprinted and angiogenic genes, which may be associated with LH 
bioactivity and stimulation dose.  
 
5.4.1 Ovarian stimulation alters IGF2 gene expression 
In this study, ovarian stimulation with PMSG and low doses of hMG 
resulted in a decrease in IGF2 mRNA levels. Previous reports suggested 
IGF2 expression in the mouse may switch at the blastocyst stage from 
being only paternally expressed to being bi-allelically expressed (Szabó 
and Mann, 1995;  Li et al., 2005;  Ohlsson et al., 1993). Therefore it may 
be that blastocysts from the PMSG and low dose hMG groups may have 
their expression reduced relative to this. This may be due to incorrect 
imprint establishment as a consequence of the superovulation protocols. 
In conflict with other methylated imprinted genes, the hyper-methylated 
regions on the paternal IGF2 allele are expressed and the maternal hypo-
methylated DMR repressed (Sasaki et al., 1992). Reduced expression of 
IGF2 may be caused by a loss of methylation at the paternal H19/IGF2 
DMR (Thompson et al., 2001). Treatment with 5IU hMG resulted in 
increased IGF2 expression, however this was not significant. This could be 
due to the low numbers analysed.  
 
The IGF2-H19 gene complex plays a major role in the nutrient transfer 
capacity of the placenta (Tycko and Morison, 2002). IGF2 modulates the 
expression and activity of nutrient transporters, therefore its over- or 
under-expression may have consequences for foetal growth (Constância 
et al., 2002). The association of reduced IGF2 gene expression with intra-
uterine growth retardation (IUGR) (Grandjean et al., 2000) and Wilms 
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tumour, a childhood cancer of the kidney, in addition to other forms of 
benign and malignant cancers (Ravenel et al., 2001;  McCann et al., 
1996;  McMinn et al., 2006), highlights the importance of further research 
to explore the biological consequences of reduced IGF2 expression during 
pregnancy and resulting offspring observed following stimulation with 
PMSG and 0.5IU hMG. 
 
Two cell mouse embryos obtained after superovulation with PMSG have 
been previously shown to display twice the frequency of methylation 
imprint perturbations compared with those naturally ovulated which in 
addition showed impeded embryo development and embryo loss during 
implantation (Shi and Haaf, 2002). Embryo development was also 
adversely affected by superovulation in our studies (Chapter 3). However, 
the observation that not all superovulated blastocysts had aberrant IGF2 
gene expression in our study may be due to the later stage of analysis, at 
the blastocyst stage. As embryos capable of developing to the blastocyst 
stage are considered to have better developmental potential and therefore 
only the better quality embryos out of each treatment group was 
analysed. A previous study reported methylation perturbations in arrested 
embryos of patients following IVF , however cryopreserved blastocysts 
donated for research several years later from the same patients were foud 
to be normal (Ibala-Romdhane et al., 2011). Perturbations in gene 
expression have also been correlated with blastocyst morphology (Fauque 
et al., 2007); therefore selectively only assessing hatching blastocysts for 
trophectoderm biopsy in our study, which Fauque et al suggested had the 
highest proportion of normally methylated embryos, may also have led to 
similar gene expression between the treatment groups. The observations 
suggest that embryos after ART which undergo developmental arrest 
during culture may do so in part due to imprinting defects (van Montfoort 
et al., 2012). Further research will need to be undertaken to confirm this.   
 
Disruption of H19 and IGF2 expression was previously observed in 
individual blastocysts and in later gestation of 9.5 day post coitum (dpc) 
placentas in mice conceived after superovulation with PMSG (Fauque et 
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al., 2007). These findings suggest that methylation perturbations can be 
propagated through the cell lines and indicate that the trophectoderm cell 
lineage may be less robust at imprint maintenance (Fortier et al., 2008). 
Reduced expression of H19 and IGF2 has also been found to be reduced in 
human placental tissue following ART (Turan et al., 2010). This may 
possibly be due to the exposure of these peripheral cells to the external 
environment of either the uterine milieu or embryo culture system (Fortier 
et al., 2008;  Mann et al., 2004). Many embryos after superovulation have 
now been demonstrated to harbour aberrant methylation for two or more 
genes however suboptimal in vitro culture conditions and the invasive 
nature of oocyte collection and embryo transfer could also contribute to 
methylation defects (Fauque et al., 2007).  
 
In our study we only observed differences in IGF2 expression between 
hMG and PMSG compared to the unstimulated control. This could be 
attributed to the low numbers analysed as a result of cost constraints or 
due to the analysis of embryonic gene expression in our study being 
performed on trophectoderm biopsy samples. This may have potentially 
dampened the negative consequences of ovarian stimulation on gene 
expression as embryos capable of developing to the blastocyst stage 
especially hatching are considered to have better developmental potential. 
Perturbations in gene expression have also been correlated with blastocyst 
morphology with hatching blastocysts shown to have the highest of 
proportion of normally methylated embryos (Fauque et al., 2007). 
However these would be the embryos of choice for transfer by the clinical 
embryologist if the patient had them in their developing cohort. In our 
study only the mural trophectoderm cells, i.e. those furthest away from 
the ICM were analyzed. It is these cells which differentiate into primary 
trophoblast giant cells during implantation (Negrón-Pérez et al., 2013), 
therefore we cannot definitively conclude that the gene expression in this 
region is comparable with the rest of the blastocyst, which is what has 
been assessed in previous studies.  
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5.4.2 Ovarian stimulation alters H19 gene expression 
H19 gene expression in the present study was detected at low levels in all 
the treatments groups, including un-stimulated controls. This maternally 
expressed gene has four DNase-1 hypersensitive sites which are coated 
by nuclear proteins to protect the DMR from becoming re-methylated (Feil 
and Khosla, 1999). Methylation of this region results in complete 
absence of H19 expression (Thompson et al., 2002). Abnormal 
methylation of the H19 DMR has previously reported following ovarian 
stimulation with PMSG in a dose dependant manner (Market-Velker et al., 
2010). Blastocysts following treatment with 5IU hMG had a complete 
absence of H19 expression, whereas the lower dose had comparable 
expression to un-stimulated controls (P>0.05). Absence of expression was 
also evident in the 0.5IU Pergoveris treatment group. Both these groups 
had poor embryo development and blastocyst quality (Chapter 4), which 
may provide some support for the theory, that perturbed development 
may be due to imprinted defects (van Montfoort et al., 2012). 
 
New evidence suggests it is not the initial imprints which are affected by 
ovarian stimulation, but insufficient maternal mRNA stores through 
incomplete oocyte maturation (Li et al., 2010). The hypothesis that 
ovarian stimulation results in disruption of maternal effect gene products 
which are required to maintain correct imprinting throughout embryo 
development is based on the observation that MII mouse oocytes 
collected after ovarian stimulation had comparable methylated H19 gene 
expression compared to un-stimulated controls (Denomme et al., 2011), 
however the same research group had previously shown that in vivo 
collected blastocysts after the same regime showed imprint perturbations 
(Market-Velker et al., 2010). It may be that H19 gene expression was not 
significantly different in our study due to all treatment groups only being 
analysed at the hatching blastocyst stage. To remove this potential bias it 
may have been more appropriate to assess gene expression of whole 
blastocysts, either individually or pooled at different classification stages 
for example expanded, hatching and hatched blastocysts or even earlier. 
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The analysis of whole blastocysts would also prevent genetic perturbations 
remaining unidentified as a consequence of differential gene expression 
between the ICM and TE (Ozawa et al., 2012).  
 
5.4.3 Ovarian stimulation alters RAS gene expression 
ATR2 expression was absent in all trophectoderm biopsies as expected 
due to this receptors mediated effects of cell proliferation and 
vasodilatation inhibition (Nielsen et al., 2000). Angiotensin receptor 1 
(AT1) on the other hand causes vasoconstriction and promotes growth 
processes required throughout pregnancy and is the predominate 
angiotensin receptor localised in the extra villous trophoblast (EVT) 
(Kalenga et al., 1996;  Li et al., 1998).  AT1 expression was comparable 
for all the ovarian stimulation regimes and control; however blastocysts 
following treatment with PMSG did show the greatest variation in 
expression levels. In the rat, the RAS system is suggested to be involved 
in differentiation of stromal cells into decidual cells during decidualisation 
which is a pre-requisite for implantation of the blastocyst (Squires and 
Kennedy, 1992), most likely through the actions of the AT1 receptor 
(Tower et al., 2010). Disruptions in the RAS has been implicated in cases 
of pre-eclampsia and IUGR, specifically down regulation of AT1 receptors 
in the placenta (Li et al., 1998). Over-expression of AT1 may in theory 
result in the opposite effect, causing overgrowth of the foetus. 
 
The 5IU PMSG and 5IU Pergoveris groups had lower expression levels of 
VEGFA, compared to control. Blastocysts following treatment with 0.5IU 
hMG had comparable expression. Decidua formation during implantation 
has been associated with an increase in maternal angiogenesis regulated 
by VEGFA (Douglas et al., 2009) and hypothesised to originate from the 
EVT of the embryo (Plaisier et al., 2007). The lower expression levels 
observed in the ovarian stimulation treatment groups may explain why 
less of the transferred blastocysts implanted, resulting in a live birth. 
Lower implantation rates following ovarian stimulation have consistently 
been observed in mice (Van der Auwera and D'Hooghe, 2001;  Ghaemi et 
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al., 2008;  Fossum et al., 1989;  Ertzeid and Storeng, 1992;  Ertzeid and 
Storeng, 2001;  Ertzeid et al., 1993).  
 
5.4.4 Conclusion  
The results of this study show some perturbation in gene expression which 
does support the initial hypothesis that ovarian stimulation does disrupt 
expression of imprinted and angiogenic genes. However, more work is 
needed with a greater number of repeats, different stages of analysis 
throughout embryonic development and a wider range of genes assessed 
(gene array).   
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CHAPTER 6: THE EFFECT OF OVARIAN STIMULATION ON 
PREGNANCY AND DEVELOPMENT OF LIVE YOUNG 
6.1 INTRODUCTION  
Adverse effects of ovarian stimulation using urinary and recombinant 
preparations in humans have been reported. Singleton conceptions 
generated through IVF have been associated with more peri-natal 
complications than naturally conceived counterparts, such as pre-term 
birth, low birth weight, intra-uterine growth restriction (IUGR) and 
postnatal health issues requiring hospital admission (Jackson et al., 2004;  
Helmerhorst et al., 2004;  Basatemur and Sutcliffe, 2008). However these 
studies analysed the effects of superovulation as a whole and did not 
distinguish between the uses of different gonadotrophins.  
 
It is evident from the HFEA implantation data that approximately 80% of 
embryos transferred fail to implant in infertile women undergoing IVF, 
potentially due to the use of ovarian stimulation (Martínez-Conejero et al., 
2007). Implantation failure can be a consequence of poor endometrial 
receptivity or to inherent problems with the embryo (Ertzeid and Storeng, 
2001). Studies distinguishing between these two causes are scarce and 
require further clarification. No previous work has focused on how ovarian 
stimulation with human gonadotrophins with different FSH and LH half 
lives has on implantation and subsequent progeny.   
 
This objective of this experiment was to assess the effect of embryo 
transfer and ovarian stimulation with different gonadotrophins compared 
with unstimulated cycles, on pregnancy and development of live young. 
The end points measured were live birth rate and offspring development.  
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6.2 METHODS OVERVIEW 
Mice were randomly allocated to the various treatment groups as 
described in chapter 2 section 2.1 and following in vitro culture, 
blastocysts were transferred to pseudo-pregnant recipients: 
 
Table 6.1: Number of mice in each treatment group from which zygotes were 
collected from and blastocysts transferred to. (The technical number of repeats 
for each group was n=2). 
                   
Treatment 
                       
Collection numbers (n) 
                                
Transfer numbers (n) 
Un-stimulated 20 5 
5IU PMSG 12 8 
0.5IU hMG 12 8 
5IU Pergoveris 12 5 
 
The experimental pathways in this chapter are schematically represented 
in Figure 6.1.  
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Figure 6.1: Flow chart summarising the experimental design used in this 
chapter, giving details of the different pathways.  
 
6.2.1 Embryo transfer 
Twenty blastocysts per surrogate were transferred between 2-4pm on the 
5th day of in vitro embryo culture. All blastocysts were randomly 
transferred to the CD1 embryo recipients to avoid selection bias. A 
nonsurgical embryo transfer (NSET) device was used. Blastocysts were 
transferred into 2.5dpc nine week old CD1 pseudo pregnant mice as it has 
been shown to be an effective method in generating live pups (Green et 
al., 2009).  
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6.2.2 Preparation of pseudo-pregnant surrogates 
Eight week old CD1 female mice were group housed for one week to 
synchronise oestrus cycles and then exposed to soiled male bedding to 
induce ovulation (whittened) for two nights prior to monogamously caging 
with nine week old vasectomised CD1 males on the third night. CD1 males 
had been vasectomised at 6 weeks post birth and allowed to recover for 3 
weeks to ensure no residual sperm remained. Vaginal plug detection was 
classed as 0.5dpc of pseudo pregnancy and female mice were housed for 
two more nights prior to embryo transfer (ET) to reach 2.5dpc.  
 
6.2.3 Non-surgical blastocyst transfer 
Blastocysts were transferred to a 15µl drop of pre-equilibrated G-2 media. 
The number of blastocysts transferred was kept constant at 20 per 
surrogate. The NSET device was placed on a P2 Gilson pipette and set to 
1.8µl. After blastocysts were loaded into the device the volume was 
adjusted to 2µl to create a small air bubble at the tip to prevent the 
embryos wicking on insertion. The female was permitted to grasp the bars 
of a new cage and angled in a vertical position by grasping the base of the 
tail. The small speculum was first inserted into the vagina to stretch it 
before inserting the larger speculum. After visualisation of the cervix, the 
NSET device was inserted all the way into the cervix, parallel to the spine, 
until the NSET hub made contact with the speculum. The blastocysts were 
expelled and the NSET device removed from the animal without releasing 
the plunger. The device was subsequently checked under a microscope to 
ensure expulsion of all the blastocysts. If blastocysts remained in the 
device, these were discarded and the actual number of blastocysts 
transferred documented. The NSET device directly deposits the blastocysts 
into the uterine horn, near the oviduct as demonstrated by the injection of 
Coomassie blue during training (Figure 6.2). 
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Figure 6.2: Location of blue dye in a single uterine horn following use of the 
NSET device. 
 
6.2.4 Assessment of live offspring 
Females were housed in pairs and after 15 days post transfer, females 
which showed outwards signs of pregnancy were separated. The 
pregnancy rate per treatment was calculated. A selection of plugged 
B6CBAF1 females were allowed to deliver young for use as in vivo controls 
for the offspring analyses.   
 
6.2.4.1 Number of days gestation 
Mice were checked morning and evening for litters and the number of 
days to parturition was calculated to the nearest 0.5 day as: 
Date of birth  Date of transfer (+4 days) = Gestation length 
Only 4 days for culture was added as in vitro culture is delayed by 
approximately one day compared to embryos developing in vivo.  
   
6.2.4.2 Number of live offspring per treatment 
All females were allowed to develop to term to permit assessment of 
offspring. The number of progeny per surrogate was noted and used to 
calculate the mean number of offspring obtained per ET and the 
percentage of offspring per ET, calculated as: 
Number of offspring per ET (%) = mean number of offspring obtained per 
ET / Mean number of embryos transfered 
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6.2.4.3 Weight trajectory 3 weeks post birth 
A selection of male and female pups from each treatment group were 
randomly selected on Day 10 postpartum, culled by CO2 inhalation and 
weighed individually to calculate total body mass. This was repeated at 
Day 17 and Day 24 to enable a weight trajectory prior to weaning to be 
generated.  
 
6.2.4.4 Organ morphometry 
Euthanized mice were analysed for body composition. Heart, lung, liver, 
kidney, spleen and pancreas were dissected out of individual mice over a 
3 week period. Internal organs were individually placed into pre-weighed 
sterile 1.5ml centrifuge tubes and kept on ice until weighed using a fine 
balance scale. Organ weights were made relative to total body mass using 
the following calculation: 
Relative organ weight = Weight of organ / Total body weight  
 
6.2.5 Statistical analyses  
Data was plotted for histogram and tested for normality using the 
Kolmogorov-Smirnov and Shapiro-Wilk tests using SPSS version 16 (IBM 
Software Services, Hampshire, UK). Statistical relevance was set at 
P<0.05 for all analyses. Pseudo-pregnant mice which had an off centre 
cervix, making embryo transfer difficult were excluded from the analyses, 
as no pregnancy resulted in these females. Dichotomous data such as 
pregnancy rates were analysed by chi-squared on Graph Pad prism. 
Weight trajectory and organ growth analyses of offspring were performed 
by ANOVA using SPSS. 
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6.3 RESULTS 
6.3.1 Live birth rate and offspring analyses 
6.3.1.1 Pregnancy rate 
On Day 15 post transfer, 60% of surrogates transferred with natural 
blastocysts showed outward signs of pregnancy. Surrogates carrying 
embryos derived from PMSG and 0.5IU hMG treated mice all showed 
noticeable abdominal swelling (P<0.001). Only half of 5IU Pergoveris 
surrogates became pregnant. However, there were too few replicates in 
order to do any statistical analyses for this treatment group.  
 
 
Figure 6.3: Mean pregnancy rates on day 17 gestation for the natural (n=4), 
PMSG (n=6), 0.5IU hMG (n=4) and 5IU Pergoveris (n=2) treatment surrogates. 
(*** P<0.001 compared to natural control).  
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6.3.1.2 Live birth rate  
As shown in Table 6.2, the natural cohort had the highest mean live 
offspring rate with 33%. This was lower following treatment with PMSG, 
although the trend was not significant (P>0.05).  Both the 0.5IU hMG and 
5IU Pergoveris ovarian stimulation groups had a lower proportion of the 
embryos transferred resulting in  live offspring (P<0.05). The average 
litter size was equivalent for all treatment groups (P>0.05).  
 
6.3.1.3 Length of gestation 
B6CBAF1 females are reported to take 18.5-21 days to complete 
gestation. Length of pregnancy for the embryo transfer groups was a day 
shorter than those naturally pregnant (Table 6.3). When the time of 
gestation was corrected for the time spent in embryo culture, the total 
time from fertilisation to delivery of live young was significantly longer for 
all ET groups in comparison to in vivo controls from the day of copulation 
plug detection (P<0.05).  
 
Table 6.2: Overview of embryo development and pregnancy for the treatment 
groups. (* P<0.05 and *** P<0.001 compared to natural control). Data is 
expressed as actual number (% of total).  
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Table 6.3: Overview of gestation length for the treatment groups.  
 
 
6.3.1.4 Weekly weight trajectory 
There was an expected increase in weight in all treatment groups over the 
neonatal period of 3 weeks analysed (P<0.001, Figure 6.4). Ten day old 
progeny from the 0.5IU hMG and 5IU Pergoveris treatment groups had a 
significantly larger total body mass compared to unstimulated (P<0.001) 
and in vivo controls (P<0.001 and P<0.01 respectfully). All embryo 
transfer group progeny, on day 17, had significantly larger body mass 
compared to in vivo controls, regardless of treatment group (P<0.001). 
When progeny were analysed on day 24, only the 5IU Pergoveris 
treatment group had significantly larger total body mass compared to 
unstimulated controls (P<0.001).  
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Figure 6.4: Total body mass 3 weeks post birth for in vivo (n=31) natural (n=8), 
PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris progeny (n=6). *** 
P<0.001 compared to in vivo controls. a P<0.001 and b P<0.01 compared to 
unstimulated controls as assessed by ANOVA.   
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6.3.1.5 Mean organ weight trajectories 
6.3.1.5.1 Heart 
Ten day old progeny from the PMSG treatment group had a significantly 
heavier relative heart mass compared to in vivo controls (P<0.05, Figure 
6.5). On day 17, PMSG progeny had a lighter relative heart mass 
(P<0.001), as did the 0.5IU hMG treatment group, compared to in vivo 
controls. When progeny were analysed on day 24, there was no significant 
difference in relative heart mass between any of the treatment groups and 
controls (P>0.05). For all weeks analysed there was no significant 
difference between gonadotrophin treatment groups and unstimulated 
controls (P>0.05).  
 
6.3.1.5.2 Lungs 
The first week analysis showed no difference in relative lung mass 
between any of the treatment groups and controls (P>0.05, Figure 6.6). 
Progeny derived following treatment with PMSG showed a reduced relative 
lung mass in the second week compared to in vivo control progeny 
(P<0.001). In the third week, the relative lung mass was significantly 
increased for the PMSG and 0.5IU hMG treatment groups (P<0.01 for 
both). For all weeks analysed there was no significant difference between 
gonadotrophin treatment groups and unstimulated controls (P>0.05).  
 
6.3.1.5.3 Liver 
There was no significant difference in relative liver weight between any of 
the treatment groups and controls, for all of the time points analysed 
(P>0.05, Figure 6.7).  
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Figure 6.5: Mean relative heart weight 3 weeks post birth for in vivo (n=31) 
natural (n=8), PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris 
progeny (n=6). *** P<0.001 and * P<0.05 compared to in vivo controls as 
assessed by ANOVA. 
Chapter 6: Effect on pregnancy and offspring 
154 
 
Figure 6.6: Mean relative lung weight 3 weeks post birth for in vivo (n=31) 
natural (n=8), PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris 
progeny (n=6). *** P<0.001 and ** P<0.01 compared to in vivo controls as 
assessed by ANOVA. 
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Figure 6.7: Mean relative liver weight 3 weeks post birth for in vivo (n=31) 
natural (n=8), PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris 
progeny (n=6). 
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6.3.1.5.4 Kidneys 
Ten day old progeny from the PMSG and 0.5IU hMG treatment groups had 
a significantly heavier relative kidney mass compared to in vivo controls 
(P<0.05 and P<0.01 respectively, Figure 6.8). On day 17, PMSG progeny 
had a lighter relative kidney mass (P<0.05), compared to unstimulated 
controls. When progeny were analysed on day 24, there was no significant 
difference in relative kidney mass between any of the treatment groups 
and controls (P>0.05).  
 
6.3.1.5.5 Spleen 
The first week analysis showed no difference in relative spleen mass 
between any of the treatment groups and controls (P>0.05, Figure 6.9). 
Progeny derived following treatment with 0.5IU hMG and unstimulated 
controls showed an increased relative spleen mass in the second week 
compared to in vivo control progeny (P<0.01 and <0.001 respectively). 
Offspring from the PMSG treatment group had lighter kidney mass 
compared to unstimulated controls (P<0.05). In the third week, the 
relative kidney mass was significantly increased for the unstimulated 
treatment group compared to the in vivo control (P<0.01). All ovarian 
stimulation treatment groups had a reduced relative spleen mass 
compared to the unstimulated control offspring as shown in Figure 6.9. 
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Figure 6.8: Mean relative kidney weight 3 weeks post birth in vivo (n=31) 
natural (n=8), PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris 
progeny (n=6). ** P<0.01 and * P<0.05 compared to in vivo controls and c 
P<0.05 compared to unstimulated controls as assessed by ANOVA. 
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Figure 6.9: Mean relative spleen weight 3 weeks post birth for in vivo (n=31) 
natural (n=8), PMSG (n=14) 0.5IU hMG litters (n=17) and 5IU Pergoveris 
progeny (n=6). *** P<0.001 and ** P<0.01 compared to in vivo controls. b 
P<0.01 and c P<0.05 compared to unstimulated controls as assessed by ANOVA. 
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6.4 DISCUSSION 
In this study it was hypothesised that the use of human gonadotrophin 
preparations for ovarian stimulation in mice, based on previously obtained 
oocyte and embryo development data, would not be as detrimental to 
pregnancy rates and offspring generated as has been reported for PMSG 
in the literature. The results obtained suggest that there were more 
offspring following ET of blastocysts from non-stimulated mice, than for 
those which were treated with gonadotrophins. In addition, developmental 
alterations for ovarian stimulated transferred blastocysts were observed, 
in terms of total body mass and internal organ relative weights. However 
in some instances the effects observed could have been due to in vitro 
handling. This study provides further information on the effects of ovarian 
stimulation with different gonadotrophin preparations on disruption of 
pregnancy and post natal growth.   
 
6.4.1 Superovulation effects pregnancy and live birth rate 
The majority of previous studies investigating the effect of ovarian 
stimulation on subsequent post-implantation development used 
spontaneously conceiving mouse models.  Adverse outcomes for the 
superovulatory mice may therefore reflect nutritional deficiency as a 
consequence of overcrowded uteri (Edgar et al., 1987;  Evans et al., 
1981). This was taken into account in our study by matching the number 
of embryos transferred in the different treatment cohorts. Reported 
pregnancy rates post transfer of 80% are comparable to the pregnancy 
and live birth rates per embryo transfer achieved in our study using the 
NSET device (Muñoz et al., 1995) and the average litter size reported for 
spontaneously pregnant PMSG stimulated mice was three (Ertzeid et al., 
1993) analogous to our embryo transfer result.   
 
In agreement with previous reports, the live birth rate per embryo 
transferred of PMSG stimulated embryos was reduced by 44% in 
comparison to control embryos (Zhang et al., 2010;  Ertzeid and Storeng, 
2001). Our results surprisingly indicated however, that the human 
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gonadotrophin preparations, despite having improved embryo 
development compared to PMSG, had reduced numbers of live pups per 
embryo transferred (mean live offspring rate). The cause for this is 
uncertain, but one potential theory is blastocysts at a more advanced 
developmental stage, observed more so following treatment with human 
gonadotrophins, may miss the implantation window in the mouse, but 
further research will be required to confirm this.   
 
6.4.2 Ovarian stimulation alters post natal growth 
Previous studies reporting the effect of ovarian stimulation on offspring 
have focused primarily on the foetal stages of development and not 
monitored growth abnormalities post partum. It has previously been 
reported that Day 18 mouse foetuses following treatment with PMSG 
showed a 9% reduction in foetal weight compared to un-stimulated 
blastocysts which were transferred to the adjacent uterine horn of the un-
stimulated surrogate (Zhang et al., 2010). This discrepancy was 
exacerbated following spontaneous pregnancy to rates as high as 45-
48%, supporting the theory that ovarian stimulation also has effects on 
the endometrium, in addition to the embryo (Ertzeid et al., 1993;  Ertzeid 
and Storeng, 1992). The transfer of embryos to a superovulated 
surrogate, resulted in a 72% decline in implantation rate compared to 
transfer to females mated with vasectomised males (Ertzeid and Storeng, 
2001), therefore in our study, blastocyst transfer was only performed on 
females mated to sterile males to specifically assess the influence of 
ovarian stimulation during folliculogenesis on oocyte quality.   
 
Foetal weight after ovarian stimulation has consistently been reported to 
be lower than un-stimulated controls (Ertzeid et al., 1993;  Ertzeid and 
Storeng, 2001;  Van der Auwera and D'Hooghe, 2001). Although foetal 
weight was not directly assessed in our study, post natal overgrowth, 
termed catch up growth has been suggested to be an indicator of IUGR 
(Ceelen et al., 2009). There was an effect of ovarian stimulation on post 
natal total body weight for the human gonadotrophin preparations when 
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compared to the transfer of un-stimulated blastocysts. In comparison to in 
vivo controls, all embryo transfers resulted in offspring with higher body 
mass, including gonadotrophin treated and unstimulated blastocysts. This 
may indicate that abnormal post natal growth may be due to in vitro 
culture and/or the embryo transfer procedure itself, which potentially 
could be further confounded by ovarian stimulation.  
 
Day 17 neonates derived following ovarian stimulation with PMSG and 
0.5IU hMG had reduced relative heart weight compared to in vivo 
counterparts, indicating superovulation combined with in vitro culture and 
embryo transfer may affect development of the cardio-vascular system. 
Low birth weight and the association with coronary heart disease and 
hyper-tension in later life has been previously indicated, although not well 
defined (Ceelen et al., 2008;  Barker, 2002). Low birth weight has been 
suggested to be associated with ovarian stimulation in humans (Pelinck et 
al., 2010), however other have not found this trend (Griesinger et al., 
2008). Comparison of clinical data is confounded by patient demographic, 
different fertility aetiologies and duration of infertility which some authors 
argue may predispose sub-fertile patients to the reported adverse peri-
natal risks, regardless of whether ART treatment was undertaken 
(Kondapalli and Perales-Puchalt, 2013). The evidence of reduced heart 
mass relative to total body weight only in neonates from ovarian 
stimulated regimes in fertile mice, offers some support to the theory that 
ovarian stimulation may be the putative origin of cardiovascular disease in 
early childhood (Yeung and Druschel, 2013).      
 
Our study also showed ovarian stimulation caused a reduction in relative 
lung mass. Some authors have suggested infants conceived through ART 
have a higher incidence of childhood illness requiring healthcare 
utilisation, in particular for respiratory complaints (Koivurova et al., 
2003). The smaller lung mass in progeny from blastocysts transferred 
following superovulation may lead to an alteration in lung function in 
adulthood, however further histological and epidemiological studies are 
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required to confirm this theory. It is important to note that correlations 
between childhood illnesses and ovarian stimulation is not found by all 
authors (Bonduelle et al., 2005), however the results of this study does 
indicate there may be some underlying developmental abnormalities for 
the adverse neo-natal risks some authors have attributed to ART. 
Disproportionate foetal and organ growth, in addition to large offspring is 
well studied in ruminants (see section 1.8.2.2 on LOS). The results of this 
study may show some mild phenotypes of this condition in mice, as a 
result of the ovarian stimulation regimes or the procedures themselves, as 
discussed in the next section.  
 
6.4.3 ART alters pregnancy rates and post natal growth 
Previous transfers of blastocysts treated with PMSG to un-stimulated 
pseudo-pregnant mice reported implantation rates of 50-67.5% (Fossum 
et al., 1989;  Zhang et al., 2010;  Van der Auwera and D'Hooghe, 2001), 
much lower than the 19% live offspring rate reported in our study. 
However, these research groups did not perform in vitro culture, but 
rather collected blastocysts and transferred them directly to the pseudo-
pregnant recipients. The transfer of pronuclear embryos immediately after 
collection resulted in a 63% implantation rate on day 15, compared to 
only 47% when embryos were cultured for 29 hours (Van der Auwera et 
al., 1999). To the best of our knowledge, only one other research group 
performed blastocyst culture followed by embryo transfer and reported an 
implantation rate on day 18 of only 12% for embryos treated with PMSG 
and 25% for un-stimulated control embryos (Ertzeid and Storeng, 2001), 
comparable to our live offspring data. These results indicate that in vitro 
culture may be a confounding factor for post-natal growth abnormalities 
following ART. In vitro culture and embryo transfer alone in this study 
caused additional adverse effects including larger kidneys and heavier 
spleens in both stimulated and un-stimulated treatment groups. The 
observation that unstimulated controls had some statistically different 
organ weight compositions compared to in vivo controls supports this 
hypothesis.  
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6.4.4 Conclusion 
The results of this study suggest that superovulation may alter 
development in vivo which may result in long term consequences for 
offspring born following ART procedures. In vitro culture resulted in 
adverse effects on offspring growth and this was shown to be further 
exacerbated by ovarian stimulation. This may provide a possible 
mechanism for the Developmental Origins of Health and Disease 
hypothesis and highlights the paramount importance of monitoring the 
long term consequences of superovulation in ART progeny (Barker, 1995).  
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CHAPTER 7: THE EFFECT OF OVARIAN STIMULATION ON 
THE ABILITY OF THE EMBRYO TO WITHSTAND IN VITRO 
MANIPULATIONS 
 
7.1 INTRODUCTION 
The use of transgenic mice to study human disease models accounts for a 
third of all experimental animal usage. The generation of transgenic 
animals requires micro-injection of either DNA or a gene transfer 
construct. Transgenic zygote production rates however are suboptimal 
and rely heavily on the use of superovulated animals, commonly using 
PMSG. It is therefore essential that the quality of embryos retrieved after 
ovarian stimulation is high in order to survive both in vitro culture and 
micro-manipulation stresses (Brooke et al., 2007). Our results like others 
in the literature show ovarian stimulation with PMSG reduces the 
proportion of blastocysts and delays development both in vitro (Ertzeid 
and Storeng, 1992;  Van der Auwera and D'Hooghe, 2001) and in vivo 
(Ertzeid and Storeng, 2001). Comparisons of human gonadotrophin 
superovulation regimes in mice are conflicting, due to the various strains 
and age of mice used, combined with the different doses and timing of 
gonadotrophin injections (Brooke et al., 2007;  Edirisinghe et al., 1986;  
Calongos et al., 2008;  Muñoz et al., 1994). Different culture media used 
by research groups may also influence their in vitro embryo development 
data. There is no direct comparison in the literature of the most clinically 
used human gonadotrophin preparations in a single mouse strain, which 
may be more suitable for transgenic applications.  
 
Pre-implantation genetic diagnosis (PGD) for couples at risk of 
transmitting an inheritable chromosomal or genetic disorder (Handyside et 
al., 1990), is gaining in popularity, with 383 cycles performed in 2010 
(Harper et al., 2012). It permits detection of affected embryos prior to 
transfer back to the uterus. Aneuploidy screening (detection of abnormal 
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chromosome number) termed pre-implantation genetic screening (PGS) is 
a sub-type of PGD used for females of advanced maternal age or couples 
that have had repeated IVF failure or recurrent miscarriages previously 
(Gianaroli et al., 2005). As 40% of transferred embryos after IVF 
demonstrate some form of chromosomal abnormality it is thus 
hypothesised that genetic screening of embryos will mainly increase the 
pregnancy rate in this selected group of patients (Kahraman et al., 2004). 
Currently there is insufficient data to either confirm or dispute these 
claims (Twisk et al., 2006). In both PGD and PGS, controlled ovarian 
stimulation is employed to increase the number of embryos available to be 
tested. How stimulation with different regimes affects the ability of 
embryos to recover following a biopsy has not previously been assessed.  
 
As more cells can be successfully retrieved following blastocyst biopsy, 
more clinics are adopting this technique to test for monogenic heritable 
diseases (Chang et al., 2013). The 1.48µm diode non contact infra-red 
laser has previously been shown, when utilised to drill the zona pellucida 
of oocytes, to have no adverse effects on the ability of subsequently 
fertilised mouse embryos to develop (Germond et al., 1995). Implantation 
rates following use of the laser was also unaffected, resulting in 
comparable offspring numbers compared to oocytes that were undrilled 
(Germond et al., 1996). The laser, which works by a local thermal effect 
through the adsorption of the energy by water and/or macromolecules 
leading to a confined thermolysis (Rink et al., 1996), has also been shown 
to be safe to drill human embryos for cleavage stage biopsy (Boada et al., 
1998). Accumulating clinical evidence now suggests its use for blastocyst 
biopsy has no adverse effect on the embryo, implantation or development 
to term (Kokkali et al., 2005;  McArthur et al., 2008;  McArthur et al., 
2005). There have been no in depth studies into how the blastocyst 
responds to the biopsy procedure in a research setting.  
 
The objective of this experiment was to examine the efficacy of common 
human gonadotrophin preparations with different half lives and LH activity 
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in mice (hMG and Pergoveris) on the ability of blastocysts to respond to 
stress in terms of micromanipulation. The endpoints measured in this 
experiment were blastocyst grade pre and post biopsy and the effect of 
biopsy on recovery and imprinted gene expression, which are 
hypersensitive to disruptions during micromanipulation.  
 
7.2 METHODS OVERVIEW 
Mice were randomly allocated to the various treatment groups as 
described in chapter 2 section 2.1: 
 
Table 7.1: Number of mice in each treatment group 
                      
Treatment 
                   
Number of technical 
repeats (n) 
                      
Total number of         
mice (n) 
 
Un-stimulated 
 
18 
 
72 
5IU PMSG 12 49 
0.5IU hMG 9 36 
5IU hMG 6 23 
0.5IU Pergoveris 9 36 
5IU Pergoveris 10 41 
 
After blastocyst grading, those hatching at the site of the ICM were triple 
stained (Results section 4.3.2.8), whereas those hatching away from the 
vicinity of the ICM underwent trophectoderm biopsy (as detailed in 
chapter 2 section 2.4.2). Hatched blastocysts were not biopsied due to 
difficulty holding them stationary without the zona pellucida. Using Garner 
and Schoolcrafts blastocyst grading system (section 2.3.2.2) these are  
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all blastocysts graded between 5AA and 5CC. Un-stimulated (n=12), 
PMSG (n=9), 0.5IU hMG (n=11), 5IU hMG (n=11), 0.5IU Pergoveris 
(n=10) and 5IU Pergoveris (n=12) biopsied samples were chosen at 
random so as not to introduce bias. They were designated for polymerase 
chain reaction (PCR) for gene expression analysis (Section 2.4.3).  
 
After re-incubation for 3 hours, blastocysts were re-graded and those with 
sufficient hatching to permit a second biopsy were re-biopsied and re-
analysed for imprinted gene expression. Only the natural (n=11), PMSG 
(n=9) and 0.5IU hMG (n=11) groups were re-biopsied and analysed for 
H19, IGF2 and IGF2r gene expression, as detailed in section 2.4.3. Those 
that were not, were triple stained to analyse any effects of the biopsy 
procedure on apoptosis rates. After the second biopsy, blastocysts were 
also triple stained to check for viability. Non-biopsied and biopsied 
blastocysts from the natural, PMSG and 0.5IU hMG groups (n=20 per 
group) underwent electron microscopy using an environmental scanning 
electron micrograph (eSEM) in order to view the response to 
trophectoderm biopsy under high magnification and resolution. The 
experimental pathways in this chapter are schematically represented in 
Figure 7.1.  
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Figure 7.1: Flow chart summarising the experimental design used in this 
chapter. 
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7.2.1 Environmental SEM 
Environmental scanning electron micrography (eSEM) was used to analyse 
the surface structure of blastocysts pre and post trophectoderm biopsy to 
see the morphological consequences of the laser at high power and 
resolution. This was used over conventional SEM to permit the observation 
of the blastocysts in their natural state without the need for de-hydrating, 
critical point drying and coating which may alter the shape of the cells and 
introduce artefacts. 
 
7.2.1.1 Sample fixation and preparation 
Non-biopsied and biopsied blastocysts were allowed to recover for 3 
hours, and subsequently were fixed in 4% PFA in glass embryo dishes 
overnight to prevent damage to the blastocysts cell integrity from the 
chamber conditions during the initial de-hydration step. On the following 
day, blastocysts were transferred to PBS drops under oil and the zona 
pellucida was removed using the Integra micromanipulators. Whilst the 
blastocyst was held stationary with a 9-17µm thick walled blunt holding 
pipette on the zona pellucida, PBS media was gently expelled inside the 
cavity using a Swemed pipette. Eventually the blastocyst would flow out 
of its protein cocoon with minimal disruption to its surface structures.  
 
7.2.1.2 eSEM  
Fixed blastocysts were washed several times in distilled water to avoid 
salt contamination from the PBS interfering with the eSEM. Blastocysts 
were individually transferred using a Swemed to the centre of a 5 micron 
nuclepore poly-carbonate filter (Nuclepore Track Etch membrane, 
Whatman, Kent, UK) previously mounted onto a stub. Two extra droplets 
of water were added to the centre of the filter to maintain hydration 
during wet mode imaging of the blastocyst. The stub was then transferred 
to the chamber of the eSEM (Gaseous secondary electron imagery XL30 
eSEM-FEG-FEI) and the conditions set at 3ûC for the cooling stage, 2X 
flood, -10kV, WD 8.1-8.6, 3.5-4 Torr, corresponding to 72-79% relative 
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humidity. This allowed gradual evaporation of the surface layer of liquid 
from the cells and the blastocyst sample images were recorded.    
 
7.2.2 Statistical analyses 
Data was tested for normality using the Kolmogorov-Smirnov and 
Shapiro-Wilk tests using SPSS version 16 (IBM Software Services, 
Hampshire, UK). Statistical relevance was set at P<0.05 for all analyses. 
Statistical analyses of the blastocyst triple staining data were performed 
on SPSS for cell count data and also on Graph Pad prism 6 using chi 
squared test for associations for the analysis of dichotomous proportional 
data. All continuous cell count data was normally distributed and analysed 
by ANOVA. Gene expression was not normally distributed and could not be 
successfully transformed by logarithm or square root so was graphically 
represented by a box plot and analysed using the non-parametric Kruskal-
Wallis test on SPSS. Any sample with an 18s Ct value above 26 was 
omitted due to lack of biological significance. Categorical blastocyst grade 
classifications were assessed using chi squared test on Graph Pad.  
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7.3 RESULTS 
7.3.1 Evidence of stress 
7.3.1.1 Blastocyst quality prior to biopsy 
Figure 7.2 gives the proportion of blastocysts within each grade category 
that underwent trophectoderm biopsy in the Natural (n=105), PMSG 
(n=143), 0.5IU hMG (n=112), 5IU hMG (n=21), 0.5IU Pergoveris (n=21) 
and 5IU Pergoveris (n=42) treatment groups. Treatment with PMSG, 
0.5IU hMG and 5IU hMG resulted in less top quality 5AA grade blastocysts 
compared to naturally derived controls and a higher proportion of lower 
graded 5CC blastocysts.  
 
Figure 7.2: Graph showing the proportion of blastocyst grades prior to biopsy in 
the treatment groups.  (* P<0.05, ** P<0.01 and *** P<0.001 compared to 
natural as assessed by chi squared test).   
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7.3.2 Response to stress 
7.3.2.1 Blastocyst survival 
Biopsied blastocysts derived from unstimulated controls had a 93±3% re-
expansion rate 3 hours after re-incubation (Figure 7.3). Treatment with 
PMSG however resulted in significantly less blastocysts recovering from 
the biopsy procedure (P<0.01). The 0.5IU hMG, 5IU hMG, 0.5IU 
Pergoveris and 5IU Pergoveris treatment groups had comparable recovery 
rates to the unstimulated control (P>0.05).  
 
 
Figure 7.3: Mean ± SEM re-expansion rates 3 hours post biopsy for the natural 
(n=72), PMSG (n=49), 0.5IU hMG (n=36), 5IU hMG (n=23), 0.5IU Pergoveris 
(n=36) and 5IU Pergoveris (n=41) treatment groups. (** P<0.01 compared to 
natural as assessed by chi squared test). 
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7.3.2.2 Post biopsy blastocyst grade 
The proportion of blastocysts re-graded 3BB or better 3 hours post biopsy 
in the natural group was 76%. This was comparable to those treated with 
5IU hMG where 82% were reclassified in this morphological range. 
Biopsied blastocysts after treatment with PMSG however only had 51% 
good quality blastocysts (P<0.001). In contrast to this, the 0.5IU hMG and 
both Pergoveris treatment groups had improved blastocyst recovery after 
the biopsy procedure (91% P<0.01 and 100% P<0.001 respectively). The 
majority of the biopsied blastocysts from natural controls were re-graded 
as 5AA and 4AA (Figure 7.4). However, there were significantly more 
blastocysts with poor grades following treatment with PMSG (P<0.001), 
with nearly half of the group being re-graded as 3CC or 2CC due to limited 
re-expansion of the blastocoel cavity.  
 
The 0.5IU hMG group had better recovery rates (P<0.01) with most 
biopsied blastocysts re-graded as 5AA. Treatment with 5IU hMG has 
resulted in comparable re-expansion rates to the natural group with most 
blastocysts 3 hours post biopsy graded 5BB and 4BB (P>0.05). The 
Pergoveris treatment groups recovered faster than the natural group post 
biopsy (P<0.001) with the majority of blastocysts graded 5AA and 
surprisingly these stimulation groups were the only groups to have any 
blastocysts to continue to hatch fully within the 3 hour post biopsy window 
(Videos of re-expansion can be viewed on the CD Rom accompanying this 
thesis). Representative examples of blastocyst appearance 3 hours post 
biopsy for the different treatment groups are shown in Figure 7.5. 
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Figure 7.4: Blastocyst grade of embryos 3 hours post biopsy for the treatment 
groups. (* P<0.05, ** P<0.01, *** P<0.001 compared to natural as assessed by 
chi squared test). 
 
Figure 7.5: Representative images of re-expanded blastocysts 3 hours post 
biopsy for the (A) Natural, (B) PMSG, (C) 0.5IU hMG, (D) 5IU hMG, (E) 0.5IU 
Pergoveris and (F) 5IU Pergoveris groups.  
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7.3.2.3 Re-biopsy gene expression profiles 
7.3.2.3.1 Unstimulated blastocysts gene expression 
The relative median fold difference of H19 gene expression was similar for 
the first and second biopsied samples for blastocysts derived from 
naturally cycling controls (P>0.05, Figure 7.6). IGF2 expression showed a 
trend for diminished expression in the second biopsy, with two thirds the 
amount of mRNA transcripts being detected compared to the first biopsy 
(P=0.051). The relative fold difference of IGF2r was comparable between 
the two biopsies (P>0.05).    
 
Figure 7.6: Median relative expression of H19, IGF2 and IGF2r in the natural 
treatment group (n=11) within the 1st and 2nd biopsy. Error bars depict the inter-
quartile range.   
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7.3.2.3.2 PMSG treatment group gene expression 
The relative median fold difference of H19 gene expression was 
comparable for the first and second biopsied samples in the PMSG treated 
group (P>0.05, Figure 7.7). IGF2 expression was ten-fold lower in the 
second biopsy sample compared to the initial biopsy, however this trend 
was not significant (P>0.05). The relative fold difference of IGF2r was 
comparable between the two biopsies (P>0.05).    
 
Figure 7.7: Median relative expression of H19, IGF2 and IGF2r in the PMSG 
treatment group (n=9) within the 1st and 2nd biopsy. Error bars depict the inter-
quartile range.   
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7.3.2.3.3 0.5IU hMG stimulated blastocyst gene expression 
The relative median fold difference of H19 gene expression was similar for 
the first and second biopsied samples in the 0.5IU hMG group (P>0.05, 
Figure 7.8). IGF2 and IGF2r expression was also not significantly different 
between the biopsy samples (P>0.05). The 0.5IU hMG stimulation group 
had the most analogous results between the initial and re-biopsied cell 
samples.    
 
Figure 7.8: Median relative expression of H19, IGF2 and IGF2r in the 0.5IU hMG 
treatment group (n=11) within the 1st and 2nd biopsy. Error bars depict the inter-
quartile range.  
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7.3.3 Morphological response 
7.3.3.1 Biopsied blastocysts triple staining 
The findings of the non-biopsied blastocysts triple staining count have 
previously been presented in section 4.3.2.8, but have also been 
incorporated in Table 7.2 to allow comparison of the data. The total cell 
number (TCN) of biopsied blastocysts for the natural, PMSG and 0.5IU 
hMG treatment groups were significantly reduced compared to non-
biopsied counterparts (P<0.01) but re-biopsied blastocysts following 
treatment with PMSG were equivalent to non-biopsied controls (P>0.05). 
Non-biopsied and biopsied blastocysts from the 5IU hMG group were 
comparable in terms of cell number (P>0.05) and the 0.5IU Pergoveris 
group had more cell numbers in the biopsied blastocysts than non-
biopsied, although this trend was not statistically significant (P>0.05). 
Conversely, the TCN of biopsied blastocysts following treatment with 5IU 
Pergoveris was significantly reduced after the biopsy procedure 
(P<0.001). Overall as would be expected, blastocyst biopsy reduced the 
cell number of blastocysts, regardless of treatment group. 
 
The ICM and TE proportion was unaffected by the initial biopsy procedure 
(P>0.05). The TE proportion was reduced after the biopsy, though this 
trend was not significant (P>0.05). Re-biopsies of blastocysts from the 
PMSG treated group had significantly less TE proportion compared to non-
biopsied and biopsied blastocysts (P<0.01) whereas re-biopsied 0.5IU 
hMG treated blastocysts had a comparable TE proportion (P>0.05). There 
was no significant elevation of apoptosis in any of the treatment groups 
for the initial biopsy procedure (P>0.05), however biopsied blastocysts 
following treatment with 0.5IU Pergoveris displayed a trend for higher 
prevalence of apoptosis compared to non-biopsied blastocysts of the same 
group (P=0.0513). Re-biopsied blastocysts from naturally cycling controls 
had comparable apoptosis rates to their non-biopsied and biopsied 
counterparts (P>0.05). In converse, PMSG treated re-biopsied blastocysts 
had a significant increase in proportion of apoptosis compared with non-
biopsied and biopsied (P<0.05). The re-biopsied blastocysts following 
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treatment with 0.5IU hMG also showed a trend for increased proportion of 
apoptosis compared to non-biopsied counterparts (P=0.051). In 
summary, ovarian stimulation did not alter the TCN, ICM, TE or apoptosis 
counts following biopsy.             
Table 7.2: Summary of fluorescent blastocyst triple staining count for non-
biopsied, biopsied and re-biopsied. (* P=<0.05, ** P=<0.01, *** P=<0.001 for 
biopsied and re-biopsied compared to non-biopsied in the same treatment) (a 
P=<0.05, b P=<0.01 for re-biopsied compared to biopsied as assessed by ANOVA 
and chi squared test). 
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Representative fluorescent triple stained biopsied and re-biopsied 
blastocysts can be found in Figure 7.9 for the unstimulated, PMSG, 0.5IU 
hMG, 5IU hMG, 0.5IU Pergoveris and 5IU Pergoveris treatment groups. 
Unlike non-biopsied blastocysts where apoptotic cells were randomly 
dispersed throughout the embryo (See Figure 4.14 in section 4.3.2.8), the 
location of the apoptotic cells within the biopsied and re-biopsied 
blastocysts were located mainly at the site of laser contact and where the 
embryos were held stationary by mild suction.  
 
7.3.3.2 SEM of blastocysts 
Both natural cycling controls and 0.5IU hMG treated blastocysts have 
clearly discernible cells with their structures resembling cobble-stones. 
Blastocysts following treatment with PMSG however appear smooth, with 
individual cells harder to distinguish.  Post biopsy, the area exposed to the 
laser has a different morphology compared to the rest of the blastocyst at 
1000X magnification. At 4000X magnification it is clearer that this region 
of the blastocyst has more cells in tighter apposition. Cells within the rest 
of the embryo have a few noticeable perforations and appear transparent, 
whereas those at the site of biopsy look less porous and more opaque. 
Upon closer examination at 8000X magnification, the cells which were 
pulled apart for the final stage of the biopsy have, in some cases formed 
fringed structures which have sealed (Figure 7.10D). Others such as those 
shown in Figure 7.10L have a rough surface, which appear to have cells 
adhered to each other with what looks to be a protein coat on top.    
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Figure 7.9: Representative examples of biopsied (A) natural, (B) PMSG, (C) 
0.5IU hMG, (D) 5IU hMG, (E) 0.5IU Pergoveris and (F) 5IU Pergoveris 
blastocysts and re-biopsied (G) natural, (H) PMSG and (I) 0.5IU hMG 
blastocysts and a (J) positive tunel control.   
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Figure 7.10: Representative eSEM images of non-biopsied blastocysts (1000X), biopsied blastocysts (1000X) and biopsied area at 
4000X and 8000X magnification for blastocysts derived from (A-D) natural, (E-H) PMSG and (I-L) 0.5IU hMG blastocysts. 
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7.4 DISCUSSION 
In this study it was hypothesised that based on the previously reported 
detrimental embryo development following treatment with PMSG (Chapter 
3), blastocysts treated with human gonadotrophins will be less effected by 
stress. The results obtained suggest that trophectoderm biopsy on PMSG 
treated blastocysts, results in reduced recovery rates and poor blastocyst 
quality. Blastocysts following treatment with human gonadotrophins, on 
the other hand, had better recovery rates and higher graded blastocysts 
post biopsy. Ovarian stimulation can affect the ability of embryos to 
respond to stress but these effects were not apparent with the human 
preparations. This also has implications for the widespread use of PMSG to 
produce embryos for research, such as for transgenic studies.  
 
7.4.1 Ovarian stimulation alters blastocyst response to stress 
Blastocysts following treatment with PMSG were more sensitive to in vitro 
biopsy manipulations than the other treatment groups and un-stimulated 
control, based on their poor recovery following trophectoderm biopsy. 
Although the initial morphological blastocyst grades of embryos from the 
PMSG treatment group were poor, therefore potentially already reducing 
the chance of survival, alternative ovarian stimulation groups with 
comparable grades of blastocysts were not impaired, implying that it is 
the use of PMSG which is responsible for poor survival following biopsy. 
Furthermore, although PMSG appeared to have a large number of cells 
removed at the time of biopsy, as indicated by the TCN data (Table 7.2), 
which may have increased the detrimental impact of the biopsy, other 
treatments had analogous cell number declines following biopsy, 
indicating it may be the stimulation regime responsible for poor survival. 
In addition to poor recovery rates, re-grading of the blastocysts indicated 
half of them were less than 3BB, the grade above which has been shown 
to have better implantation potential and improved pregnancy rates 
(Teranishi et al., 2009). This implies that after biopsy, blastocysts 
following treatment with PMSG may not recover sufficiently to instigate a 
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pregnancy. This is an important finding, as PMSG is commonly used to 
produce numerous embryos for transgenic studies.   This negative effect 
was not observed following ovarian stimulation with human 
gonadotrophins, suggesting stimulation of mice with these preparations 
may be more suitable for transgenic applications and in addition provides 
some reassurance of the safety of this procedure on human embryos 
following ovarian stimulation with human gonadotrophins.  
 
Treatment with Pergoveris was previously shown to increase the 
developmental speed of embryos resulting in more hatched blastocysts 
after in vitro culture (Chapter 3). Recovery rates following trophectoderm 
biopsy were also faster than other groups with over 90% of blastocysts 3 
hours post biopsy graded 3BB or better. Significantly this group was the 
only treatment that had fully hatched blastocysts post biopsy, indicating 
blastocysts following treatment with 5IU Pergoveris are more capable of 
continuing development following micromanipulation stresses. This 
observation should be further tested with other stressors, such as cell 
injections because embryos which are more resilient to environmental 
stress may be more suitable for transgenic applications than PMSG 
retrieved embryos which in our study we showed to be the most sensitive 
to external influences.   
 
7.4.2 Safety of trophectoderm biopsy 
The trophectoderm biopsy work carried out indicated the micro-
manipulation procedure had no adverse effects on blastocyst recovery, 
apoptosis or imprinted gene expression providing evidence for the safety 
of the 1.48µm diode non contact infra-red laser used in this study. Our 
study demonstrates the safety of trophectoderm biopsy in a research 
setting, based on large numbers of mouse blastocysts following ovarian 
stimulation with multiple regimes which complements the few reports of 
clinical data in the literature. Furthermore our results also showed re-
biopsy of blastocysts did not have any effects on apoptosis except for 
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those following treatment with PMSG, which do not recover well after the 
initial biopsy. This observation suggests that it is safe to re-biopsy 
embryos if a null result is received first time, a practice which is deemed 
acceptable by the ESHRE PGD consortium (Harper et al., 2012). This has 
previously only been reported when a blastocyst was re-biopsied after no 
result was obtained following a cleavage stage biopsy (Wininger et al., 
2011). We show it may be possible to safely re-biopsy a blastocyst staged 
embryo with a failed result, which depending on the speed of the clinics 
output would enable embryo transfer the same day, the following day 
(Day 6 transfer) or cryo-preservation until a result is received (Chang et 
al., 2013).  
 
Although apoptosis was not increased by trophectoderm biopsy, the 
location of these damaged cells was focused at the site of analysis. 
Environmental scanning electron micrography was used to attempt to 
visualise the repaired area of the expanded blastocysts. Regardless of 
treatment, the site of biopsy had a greater number of cells, which is also 
apparent on fluorescent images and is consistent with the idea that 
mitosis occurs in response to cell damage. Under high magnification, cells 
within this region appeared denser and looked to be coated with a 
substance resembling plaque. This may be the putative mechanism by 
which the blastocyst recovers from trophectoderm biopsy, sealing the 
blastocoel cavity, allowing re-expansion. Further analysis into the 
potential substance of this embryo scab would be interesting and 
perhaps may be similar to wound healing mechanisms documented in 
adult tissues (Hotary et al., 2002). Alternatively increased tight junction 
expression may enable sealing of the blastocoel cavity post biopsy, which 
may explain the lower recovery rate of PMSG blastocysts, which have a 
smoother appearance than other treatment groups under the eSEM. Gene 
expression analyses of this region are required to support these 
speculations. 
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7.4.3 Biopsy does not alter imprinted gene expression 
Gene expression of IGF2 and H19 have been shown to be hypersensitive 
to stresses during in vitro culture and been suggested to be useful as a 
quasi-sensor for epigenetic perturbations (Nan et al., 1998). In our study 
we re-analysed the second trophectoderm biopsy cell sample to check for 
any alterations in expression of these imprinted genes which could 
potentially cause long term consequences in subsequent offspring (Tycko 
and Morison, 2002). Re-biopsied samples from un-stimulated and 
superovulated blastocysts showed comparable H19 and IGF2 gene 
expression profiles in comparison to their initial result. Even PMSG treated 
blastocysts showed similar results despite poorer recovery rates. This 
observation provides further support for the safety and clinical 
implementation of this blastocyst biopsy for PGD purposes.  
 
7.5 Conclusion 
The results of this study provide evidence that ovarian stimulation with 
PMSG can affect the response of blastocysts to stress, such as 
trophectoderm biopsy. The negative effects of the micromanipulation on 
blastocyst recovery and apoptosis rates were not evident when human 
gonadotrophins were used. This provides some reassurance for the safety 
of this procedure when applied to patient treatment in a clinical setting, 
whilst also indicating superovulation with PMSG may not be optimum for 
generating embryos for use in transgenic mice applications.    
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CHAPTER 8: GENERAL DISCUSSION 
 
 
8.1 Justification and summary of work 
The objectives of the work undertaken in this thesis were to assess the 
impact of different gonadotrophin treatments on oocyte and embryo 
quality, gene expression and the effects on resulting progeny. The main 
findings of this thesis is as follows: 
1. Ovarian stimulation with PMSG and human gonadotrophins 
negatively impacts oocyte quality in terms of morphology and 
developmental potential.   
2. Embryo development following ovarian stimulation with PMSG was 
significantly impeded compared to natural controls. Embryo 
development following the use of human gonadotrophins was not as 
severely impacted compared to PMSG, however the quality of 
resulting embryos appeared to be dependent on the dose, half life 
and LH content of the preparations used. 
3. Although our results showed some alterations in mRNA expression 
levels of imprinted genes and angiogenic factors, only a subset of 
genes were analysed. More work is needed with a greater number 
of repeats at different stages of analysis throughout embryonic 
development and a wider range of genes assessed (gene array).   
4. Ovarian stimulation did alter the growth of progeny post birth in 
terms of body mass and growth. However, aberrations were 
apparent in unstimulated controls compared to naturally conceived 
offspring, suggesting in vitro culture and/or the embryo transfer 
procedure itself may be having an impact.  
 
The research in Chapters 3 and 4 of this thesis assessed whether reports 
that ovarian stimulation negatively effects in vitro embryo development. 
Ovarian stimulation with PMSG and human gonadotrophins had some 
negative effects on both embryo development and blastocyst quality, 
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indicating that ovarian stimulation in general does impact on the 
developmental competence of oocytes and embryos. This study 
highlighted two key issues regarding human gonadotrophin preparations 
which influenced embryo yield and viability. Firstly, preparations 
composed of recombinant FSH were required at higher concentrations to 
yield comparable number of embryos compared to preparations with a 
urinary FSH constitution. Although the more basic FSH iso-forms found in 
rFSH show greater in vitro bioactivity, they have a faster in vivo clearance 
rate compared to the non-basic iso-forms found in uFSH (Vitt et al., 
1998). This may potentially explain why lower concentrations of hMG are 
needed to achieve increased numbers of oocytes as opposed to the low 
half life recombinant Pergoveris which requires significantly more to 
achieve a comparable response. 
 
Another significant finding was the apparent negative effect of the long 
acting LH surrogate, human chorionic gonadotrophin (hCG) within the 
hMG preparation. Increasing the concentration of hMG led to a decrease in 
the number of ovulated oocytes and impeded subsequent embryo 
development and blastocyst quality. This may be due to down regulation 
of the LH receptor previously shown to occur in the presence of hCG 
(Jeppesen et al., 2012;  Rao et al., 1977;  Peng et al., 1991), therefore 
providing a putative mechanism to why ovarian follicles did not respond to 
the ovulatory signal and why embryos derived were of poor quality 
(Bosch, 2010;  Platteau et al., 2004). This effect was not replicated by 
increasing the concentration of recombinant LH which has a shorter half 
life, implying the long half life of hCG may be responsible. hCG takes 66 
times longer than LH to be cleared from the peripheral circulation due  to 
the modified extension of the β subunit (Huirne et al., 2004). The 
evidence suggests a ceiling level for LH exists above which is detrimental 
for embryo development (Hillier, 1994). The long half life of hCG explains 
why at higher concentrations this ceiling is exceeded whereas the lower 
half life of LH, means it is quicker cleared from the circulation and remains 
within a previously theorised LH window (Tesarik and Mendoza, 2002). 
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Oocyte quality is known to directly impact embryo development (Bosch, 
2010). Fragmentation of the oocyte was a phenomenon only found in the 
ovarian stimulation groups and has been shown previously not to be 
compatible with continued embryo development (Veeck, 1988). 
Fragmentation appeared to be worsened by the presence of LH, 
supporting previous clinical evidence which suggested that overstimulation 
with LH had negative effects on follicular atresia and luteinisation and 
consequently oocyte development in a dose dependant manner (Hillier, 
1994). Cumulus cells were analysed for angiogenic factors, the presence 
of which has previously been correlated with increased retrieval rate of 
mature oocytes, improved fertilisation and embryo quality and 
consequently greater pregnancy rates (Nargund et al., 1996;  Bhal et al., 
1999;  Coulam et al., 1999;  Huey et al., 1999;  Du et al., 2006;  
Shrestha et al., 2006;  Chui et al., 1997;  Van Blerkom et al., 1997;  
Borini et al., 2005). Our results suggest angiogenesis may be reduced 
following ovarian stimulation based on reduced expression of MYHII, a  
factor which promotes angiogenesis by inducing synthesis of AngII which 
is associated with steroidogenesis, meiotic maturation and ovulation 
(Ferreira et al., 2011;  Siqueira et al., 2012); therefore reduced 
expression may impair oocyte quality. Treatment with PMSG caused a 
greater decrease in MYHII which may explain why embryo development 
was more perturbed in this treatment group.  
 
The genetic experiments in Chapter 5 attempted to address whether the 
observed reports of imprinting and methylation errors following ART in 
animal models (Market-Velker et al., 2010;  Menezo et al., 2010;  Zhang 
et al., 2010;  Mundim et al., 2009) and human subjects (Strawn et al., 
2010;  Katari et al., 2009;  Lawrence and Moley, 2008;  Sato et al., 2007) 
were altered by ovarian stimulation using different commercial 
preparations of exogenous gonadotrophins. In our study, ovarian 
stimulation with PMSG and 0.5IU hMG resulted in a decrease of IGF2, 
which modulates the expression and activity of nutrient transporters in 
the placenta (Constância et al., 2002). Reduced IGF2 gene expression has 
been associated with intra uterine growth retardation (IUGR) (Grandjean 
et al., 2000) and Wilms tumour, a childhood cancer of the kidney, in 
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addition to other forms of benign and malignant cancers (Ravenel et al., 
2001;  McCann et al., 1996;  McMinn et al., 2006). Alterations of 
imprinted genes has previsouly been shown to result in impeded embryo 
development (Shi and Haaf, 2002), which was also apparent in the 
ovarian stimulation regimes in our study. Loss of H19 expression was 
evident in blastocysts from the 5IU hMG and 0.5IU Pergoveris treatment 
groups, which had the highest levels of developmental arrest and the 
poorest blastocyst quality grades. This may be a consequence of 
insufficient maternal mRNA stores through acceleration of oocyte 
maturation, reducing the ability of the embryo to maintain imprints (Li et 
al., 2010).  
 
The expression of important genes in the RAS system were also analysed, 
which have been shown to play a pivitol role in decidualisation, 
implantation and placentation by regulating blood flow, oestradiol 
secretion and prostaglandin synthesis (Nielsen et al., 2000). Disruptions in 
the RAS has been implicated in cases of pre-eclampsia and IUGR, 
specifically down regulation of AT1 receptors in the placenta (Li et al., 
1998) therefore over-expression of AT1 may cause overgrowth of the 
foetus (Tower et al., 2010) and indeed progeny following ovarian 
stimulation had heavier body mass compared to in vivo controls. 
Furthermore all ovarian stimulation groups had lower expression levels of 
VEGFA which has been associated with deciduas formation during 
implantation (Douglas et al., 2009;  Plaisier et al., 2007) potentially 
explaining why less of the transferred blastocysts in the ovarian 
stimulation groups resulted in live birth. 
 
All experimental chapters in this thesis indicated ovarian stimulation may 
cause detrimental effects which could potentially affect the long term 
health of offspring born following ART. Therefore the embryo transfer 
studies in chapter 6 were performed to confirm or refute previous 
hypotheses that poor embryo development and altered gene expression 
would have adverse effects on pregnancy and live pups generated. In 
accord with previous reports, ovarian stimulation caused a decrease in the 
number of live pups born (Zhang et al., 2010;  Ertzeid and Storeng, 
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2001). In this study we used sterile mated control females as surrogates 
for all the treatment and control groups and transferred the same number 
of blastocysts to the recipients. This allowed us to control for any 
endometrial effects which could have resulted if ovarian stimulation was 
used and allowed us to only assess the effects of the embryo on 
implantation and progeny. Surprisingly, the human gonadotrophin 
preparations, despite having improved embryo development compared to 
PMSG, had reduced live pups per embryo transferred, which was 
exacerbated in stimulation groups such as Pergoveris where the 
blastocysts were more developmentally advanced. The results suggest 
there may be asynchronicity between the stage of embryos transferred 
and the endometrium receptivity.  
 
Some authors have suggested infants conceived through ART have a 
higher incidence of childhood illness requiring healthcare utilisation, in 
particular for respiratory complaints (Koivurova et al., 2003) and 
cardiovascular disease in later life (Yeung and Druschel, 2013). Our 
results showed ovarian stimulation caused alterations in internal organ 
relative body weight. The results of our study do indicate there may be 
some underlying developmental abnormalities for the adverse neo-natal 
risks some authors have attributed to superovulation, although how this 
affects the function of the organ was not assessed in this work. In vitro 
culture in our study appeared to be the main cause for the organ growth 
effects on resulting progeny. This suggests that altered in vitro culture 
conditions may be the initial cause for the alterations and ovarian 
stimulation a further catalyst.  
 
8.2 Potential limitations of work conducted 
The aim of this work was to assess the consequences of ovarian 
stimulation with different gonadotrophin preparations on oocyte 
development, embryo quality, gene expression and ultimately the health 
of offspring.  We chose to conduct this work in the murine model as it is 
the most widely utilised analogue model for pre-implantation embryo 
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development (Taft, 2008). However, mice are poly-ovulaters that release 
8-12 oocytes depending on the strain, therefore the observed responses 
may not be similar to mono-ovulatory species such as humans (Nagy et 
al., 2003). In addition human patients undergoing ART have fertility 
issues that may potentially predispose their gametes and subsequent 
embryos to heightened sensitivity to the superovulation and manipulation 
procedures required in those processes (Gardner and Lane, 2005). 
However, this fact enables the assessment of whether complications 
associated with ART are a consequence of the procedures themselves or 
the infertility.  
 
Throughout this study we used quantitative PCR to assess the effect of 
ovarian stimulation of gene expression both in the cumulus cells and 
embryo itself. However there are many post translational modifications 
required after synthesis of mRNA which makes it difficult to directly 
translate mRNA expression levels detected in this study to protein levels 
with biological activities (Greenbaum et al., 2003). Furthermore only a 
selection of genes were assessed in each case therefore despite gene 
expression data correlating with expected phenotypic outcomes, the 
influence of alternative factors cannot be ruled out. The use of global gene 
expression arrays and an increase in repetitions will provide more 
evidence on how ovarian stimulation alters gene expression.  
 
The analysis of embryonic gene expression in our study was always 
performed by trophectoderm biopsy of blastocyst hatching away from the 
ICM. This may have potentially dampened the negative consequences of 
ovarian stimulation on gene expression as embryos capable of developing 
to the blastocyst stage especially hatching are considered to have better 
developmental potential. Perturbations in gene expression have also been 
correlated with blastocyst morphology with hatching blastocysts shown to 
have the highest of proportion of normally methylated embryos (Fauque 
et al., 2007). In our study only the mural trophectoderm cells, i.e. those 
furthest away from the ICM were analyzed. It is these cells which 
differentiate into primary trophoblast giant cells during implantation 
(Negrón-Pérez et al., 2013), therefore we cannot definitively conclude that 
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the gene expression in this region is comparable with the rest of the 
blastocyst. The analysis of whole blastocysts may have provided different 
results due to the proposed differential gene expression between the ICM 
and TE (Ozawa et al., 2012). The analysis of complete blastocysts would 
also enable the assessment of embryos at different developmental stages, 
which may have genetic pertubations and were not analysed in our study 
due to not meeting the requirements for biopsy.  
 
8.3 Applications of this work 
Ovarian stimulation regimes are tailored to individual patients based on 
their pre-treatment assessment and monitored throughout using 
ultrasound and serum blood concentration analyses (Jayaprakasan et al., 
2008). It is general practice that if a woman is under responding (e.g. has 
3 or fewer follicles developing) (Ferraretti et al., 2011), the dose of the 
exogenous gonadotrophin preparation in use is increased, in an attempt to 
recruit more follicles to develop. Our study indicated that increasing hMG 
high enough led to a reduction in the number of oocytes ovulated. What is 
significant is the severe retardation of embryo development and reduced 
blastocyst quality following high hMG treatment. We postulated based on 
previous studies which have shown that hCG leads to down regulation of 
the LH receptor on granulosa cells (Jeppesen et al., 2012;  Rao et al., 
1977;  Peng et al., 1991) that these consequences may have been due to 
disruption of ovulation and impaired steroidogenesis (Westergaard et al., 
2000;  Fleming et al., 2000). Contrary to our results, systematic reviews 
on clinical data indicates that the use of this preparation increases live 
birth rates by 3-4% (Hill et al., 2012). The results in our study highlight 
the requirement for exogenous gonadotrophins to stay within the LH 
window, which may be different between mice and human patients, 
particularly if down regulation is used.  
 
8.4 Future work 
There were a few areas in our research where we relied on previous 
studies to confer observations with mechanistic actions. For example, 
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although it has been shown that hCG can lead to down regulation of the 
LH receptor on granulosa cells in human (Jeppesen et al., 2012) and rats 
(Rao et al., 1977;  Peng et al., 1991), it was not confirmed in our study. 
In addition we hypothesised that the reduced vascularity of ovarian 
follicles after superovulation inferred from cumulus cell analyses may have 
resulted in spindle defects (Chui et al., 1997;  Van Blerkom et al., 1997) 
explaining the inappropriate division of genetic material and failure to 
complete syngamy in developmentally arrested metaphase II zygotes 
from the ovarian stimulation regimes (Pesty et al., 2007). This hypothesis 
could be confirmed by visualising the mitotic spindle in un-cleaved 
metaphase II oocytes by immuno-histochemical staining of the 
cytoskeletal structure  through injection of fluoroscein-labelled α-tubulin 
(Paddy et al., 1996). Finally, our results provided support for the theory 
that ovarian stimulation may result in disruption of maternal effect gene 
products which are required to maintain correct imprinting throughout 
embryo development (Li et al., 2010;  Rivera et al., 2008). Potentially the 
analysis for altered gene expression of the oocyte specific Dnmt1o iso-
form which has been demonstrated to maintain methylation imprints until 
the embryonic genome is activated would provide further evidence 
(Mertineit et al., 1998).   
 
Although our study indicated organ growth discrepancies in progeny 
following ovarian stimulation and in vitro culture, these conclusions were 
based solely on the weight of the organs made relative to the total body 
mass of the mouse. More in depth offspring analyses are required to 
generate more data and provide further support for the hypotheses made. 
For example, reduced heart mass and enlarged kidneys are indicators of 
hypertension and cardiovascular disease (Yeung and Druschel, 2013;  
Ziakas et al., 2005;  Päivänsalo et al., 1998). Monitoring of blood pressure 
by telemetry using a digital recording device on the mouses tail would 
provide long term undisturbed data readings for the developing offspring 
to monitor fluctuations in cardiac function throughout post natal 
development (Van Vliet et al., 2006). Enlarged kidneys are also an 
indication of diabetes. The quantification of glucose and insulin in tail 
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bleeds of mouse progeny would provide further evidence into the 
adverse effects of ART on metabolic syndromes (Geutskens et al., 
2004). Finally our results showed reduced lung mass of ovarian 
stimulation progeny which may indicate a physical impairment of 
the lungs. Histological analysis of the lung tissue collected for 
alterations in bronchi tree structure or arteriole structure may 
provide some indications. Alternatively a lung function test can be 
performed on live mice to measure airway responsiveness (Glaab et 
al., 2007). There are numerous methods but barometric whole body 
plethysmography is the easiest to perform whereby conscious mice 
are put into an enclosed chamber and pressure fluctuations during 
the breathing cycle are recorded. This method provides continual 
monitoring of lung function throughout development with mammal 
disturbance to the animal (Hamelmann et al., 1997).  
 
8.5 Final Summary  
In summary, it has been observed throughout this thesis, that 
ovarian stimulation causes perturbed embryo development, gene 
expression alterations and postnatal growth aberrations. The 
observations of these adverse effects in a fertile mouse model, 
suggest underlying fertility pathology is not the main cause for 
adverse peri natal outcomes following ART. In vitro culture alone 
did appear to have an effect on progeny growth, suggesting 
suboptimal culture environment may be the cause for some of the 
observed consequences, which were worsened by ovarian 
stimulation. Comparison of human gonadotrophin preparations 
highlighted the complexity of effects resulting from the use of 
different doses of gonadotrophin preparations which vary in terms 
of their biological clearance rate, FSH isoforms and level of LH-
activity. Of significant importance was the demonstration 
continuous administration of high levels of hCG impaired ovulation 
Chapter 8: General Discussion 
196 
 
and subsequent embryo development, which indicates caution 
should be taken not to exceed the LH window when delivering 
exogenous gonadotrophins. The main area for improvement of this 
work is to consolidate the correlations drawn between phenotypic 
observations and mechanistic biological process with further 
evidence, to provide more sound data on the adverse effects of 
ovarian stimulation.  
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APPENDIX 
 
 
Appendix 1: Media Compositions 
A.1.1 G-MOPS 
A handling medium designed to support manipulation of oocytes and 
embryos outside the incubator (ambient environment). It is supplemented 
with 5% HSA and warmed to 37°C prior to use. 
 
 
Amino acids 
 
Buffer 
 
Antibiotics
 
Sugars 
 
Ionic 
Compounds 
 
Other 
 
 
 
Alanine, 
Alanyl-
glutamine, 
Aspargine, 
Aspartate, 
Glutamate, 
Glycine, 
Proline, Serine, 
Taurine 
 
 
MOPS 
 
Penicillin G 
 
 
Sodium 
Lactate 
 
Sodium 
Pyruvate 
 
Low Glucose 
 
CaCl2 
MgSO4 
KCl 
NaHCO3 
NaCl 
NaH2PO4 
 
Water 
 
Table A.1: The Components of G-MOPS 
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A.1.2 G-1TM 
Supports development of cleavage stage embryos from the pro-nucleate 
to 8-cell stage. It is equilibrated at 37°C, 6% CO2 prior to use.  
 
Amino 
acids 
 
Buffer 
 
Antibiotics
 
Sugars 
 
Ionic 
Compounds 
 
Other 
 
 
 
Alanine, 
Alanyl-
glutamine, 
Aspargine, 
Aspartate, 
Glutamate, 
Glycine, 
Methionine, 
Proline, 
Serine, 
Taurine 
 
 
Bicarbonate 
 
Gentamicin
 
 
Sodium 
Lactate 
 
Sodium 
Pyruvate 
 
Low 
Glucose 
 
CaCl2 
MgSO4 
KCl 
NaHCO3 
NaCl 
NaH2PO4 
Sodium 
Citrate 
 
EDTA 
Hyaluronan
Lipoic acid 
Water 
 
Table A.2: The Components of G-1TM 
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A.1.3 G-2TM  
Supports development of 8-cell stage embryo until the blastocyst stage. It 
is equilibrated at 37°C, 6% CO2 prior to use. 
 
Amino acids
 
Buffer 
 
Antibiotic
s 
 
Sugars
 
Ionic 
Compound
s 
 
Other 
 
 
 
Alanine, 
Alanyl-
glutamine, 
Arginine, 
Aspargine, 
Aspartate, 
Cystine,  
Glutamate, 
Glycine, 
Histidine, 
Isoleucine, 
Leucine, 
Lysine, 
Phenylalanine, 
Proline, 
Serine, 
Threonine, 
Tryptophan, 
Tyrosine, 
Valine 
 
 
Bicarbonate
 
Gentamicin
 
 
Sodium 
Lactate 
 
Sodium 
Pyruvat
e 
 
Low 
Glucose 
 
CaCl2 
KCl 
NaHCO3 
NaCl 
NaH2PO4 
Sodium Citrate 
Sodium 
Pantothenate 
 
Hyaluron
an 
Pyridoxin
e 
Riboflavi
n 
Thiamine
Water 
 
Table A.3: The Components of G-2TM  
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 A.1.4 G-PGD 
The calcium and magnesium free media facilitates embryo biopsy and 
maintains pH. 
 
Amino acids 
 
Buffer 
 
Antibiotics
 
Sugars 
 
Ionic 
Compounds 
 
Other 
 
 
 
Alanine, 
Alanyl-
glutamine, 
Aspargine, 
Aspartate, 
Glutamate, 
Glycine, 
Proline, Serine
 
 
MOPS 
 
Penicillin G 
 
Glucose 
 
Sodium 
lactate 
 
Sodium 
pyruvate 
 
KCl 
NaHCO3 
NaCl 
NaH2PO4 
 
 
Water 
 
Table A.4: The Components of G-PGD  
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Appendix 2: GMOPS- Good media or poor substitute 
Initially oviducts were excised from mice subsequent to cervical 
dislocation and stored in centre wells filled with GMOPS in a non-gassed 
incubator until ready to collect one cell pro-nuclear embryos. Longer 
exposure times to GMOPS manifested in delayed embryonic growth as 
evidenced by degenerated single celled embryos on day 2 of development 
(Figure A.1). This morphological discrepancy was detectable after 
exposure times of just 15 minutes.  
 
 
 
Figure A.1: Morphological microscopic photographs day 2 of development after 
initial exposure times to GMOPS for <1 (A), 15 (B), 30 (C) and 45 (D) minutes. 
Prolonged exposure times resulted in a higher proportion of fragmented, 
degenerated and arrested one cell embryos, compared to the control 
where GMOPS exposure was less than 1 minute and achieved a 100% 
cleavage rate on day 2 of development. GMOPS exposure for 15, 30 and 
45 minutes achieved cleavage rates of 66, 70, 25% respectively. 
Assessment of the nuclear maturity of the degenerating one cell embryos 
confirmed they were arrested fertilised embryos (Figure A.2). 
 
 
 
 
Figure A.2: DAPI stained one cell degenerated embryo exhibiting the presence of 
two pronuclei in the cytoplasm, indicating a fertilised status. 
 
D C B A 
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Perturbed embryonic development was documented throughout in vitro 
culture and was clearly evident at media change on day 3 (Figure A.3). 
Reduced proportions of the expected 4-8 cell and morulas in the GMOPS 
exposure groups compared to the control were clear with only 63%, 21% 
and 16% of embryos progressed to this stage in the 15 minute, 30 minute 
and 45 minute exposure groups respectively, compared to 98% in the 
control. Analysis of these proportional differences using the Fishers Exact 
test showed significant (P<0.001) differences as early as 15 minutes 
exposure to GMOPS. 
Figure A.3: Embryo development at day 3 of culture for control, 15 minute, 30 
minute and 45 minute GMOPS exposure groups. All values are a percentage of 
zygotes collected and cultured in vitro.  
 
The detrimental effect of GMOPS on development significantly impaired 
the ability of embryos to progress to the blastocyst stage (Figure A.4). 
Comparative blastocyst developmental rate (BDR) was observed between 
oviducts exposed to GMOPS for 30 minutes with the control (P>0.05). 
Exposure for 15 and 45 minutes demonstrated a significant decrease in 
BDR, P=0.0042 and P=0.00002066 respectively. There was no difference 
in the morphological appearance of viable blastocysts in each exposure 
group with expanded blastocysts observed in all groups on day 5 of 
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culture. The quantity of degenerated collapsed blastocysts was however 
exasperated in the groups of embryos exposed to GMOPS for longer than 
1 minute, in a time dependent manner (Figure A.5).  
 
 
Figure A.4: Mean (%) blastocyst developmental rate (BDR) ± Standard error of 
the mean (SEM) for control, 15 minutes, 30 minutes and 45 minutes GMOPS 
exposure groups. N=total number of embryos t. **=P<0.01 and ***=P<0.001 
compared with control.  
 
Due to these observed deleterious effects observed with exposure to 
GMOPS the embryo collection protocols were refined so that exposure was 
as transient as possible. This involves the euthanasia of a single mouse 
whose embryos are then immediately harvested without being pooled in 
GMOPS until ready for collection.  
 
 
 
 
Figure A.5: Embryo morphology on day 5 after exposure of oviducts to GMOPS 
for <1 (A), 15 (B), 30 (C) and 45 (D) minutes. 
D C B A 
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Appendix 3: Daily monitoring of embryos does not impair 
development 
Embryos were monitored daily for their developmental progress by taking 
them out of the incubator and assessing them under the microscope. This 
was not detrimental to embryo development as shown in Figure A.6, 
whereby the proportion of embryos continuing development to the 
blastocyst after un-disturbed in vitro culture (colour), was comparable to 
embryos removed daily from the incubator to monitor progress 
(greyscale, P>0.05). The proportion of embryos at each stage was 
inferred at the time of media change and blastocyst analysis for the un-
disturbed group. This may explain why there is an un-significant reduction 
in the number of embryos developing for some cohorts, as the cleavage 
status of degenerated embryos would not have been available.  
 
Figure A.6: Proportion of embryos at each developmental stage with (greyscale) 
or without (colour) daily monitoring outside the incubator.   
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Appendix 4: Endogenous control selection for PCR by geNorm  
The geNorm reference gene selection kit by Primer design was used to 
select the most stable constitutively expressed reference (housekeeping) 
gene for our experimental conditions, to normalise the quantitative real 
time experiments. A panel of 6 genes were selected to assess the ideal 
reference gene for our experimental study to increase the accuracy and 
sensitivity of our PCR experiments. Using the geNorm software qBasePLUS 
by Biogazelle, the genes were ranked according to their expression 
stability.  
 
Both cumulus cell and trophectoderm biopsy cDNA samples were assessed 
with a panel of 6 genes:  
- 18s ribosomal RNA (18s) 
- eukaryotic translation initiation factor 4A2 (EIF4A2) 
- succinate dehydrogenase complex, subunit A (SDHA) 
- glyceraldehyde-3-phosphate dehydrogenase (GADPH) 
- ATP synthase subunit (ATP5B) 
- Actin beta cytoplasmic (ACTB) 
Each 10µl reaction was composed of 0.5µl lyophilised primer and probe 
mix, 5µl of fast advance master mix, 2µl nuclease free water and 2.5µl of 
the cDNA sample.  The plates were run at the following cycling conditions 
for 50 cycles: 10 minutes at 95ûC, 15 seconds at 95ûC, 30 seconds at 
50ûC and 15 seconds for 72ûC. The data file was then exported to 
qBasePLUS software for analysis.  
 
 
The software generates graphs depicting average expression stability (M) 
of reference genes with the least stable gene at the left leading to the 
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most stable gene on the right. An M value less than 1 shows suitability of 
the reference gene for use in the experimental conditions. All reference 
genes were less than 1 for the cumulus cell samples (Figure A.7A), 
however none of them were for the biopsy cell samples (Figure A.7B). 
This can be explained by the low and variable sample sizes for this 
experiment.  
 
 
 
Figure A.7: qBasePLUS average expression stability curves for (A) cumulus cell 
samples and (B) trophectoderm biopsy cell samples.  
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A combined analysis of the reference genes to function equally well in 
both experimental conditions ranked ACTB as the most suitable, closely 
followed by 18s (Figure A.8). 18s was chosen as the endogenous control 
for our PCR experiments based on its stability and also its earlier detection 
(CT value) at approximately the 25th PCR cycle as opposed to the 33rd for 
ACTB in the biopsy cell samples. It was hypothesised therefore that 18s 
would be more capable of detecting the lower starting differences for this 
cell sample.  
 
 
Figure A.8: qBasePLUS average expression stability curve for combined analysis of 
cumulus cell and trophectoderm biopsy cell samples.  
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Appendix 5: In vivo blastocyst control method 
Five to six week old B6CBAF1 female mice were superovulated with the 
0.5IU hMG protocol and remained in the animal house until developmental 
day 4 to collect in vivo blastocysts to be used as standards and calibrator 
in the PCR experiments.  Blastocysts were flushed from the uterine horns 
of the mouse using a 5ml syringe with a 30 Gauge needle containing 
warmed G-MOPSTM medium (Figure A.9). 
 
 
 
 
 
 
 
 
 
 
Figure A.9: 30-G needle inserted inside oviduct and blastocysts flushed out of 
uterus through cervical opening by injection of G-MOPSTM medium. (Sakai and 
Onodera, 2008).  
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Appendix 6: Embryo development for treatment with 2.5IU rFSH 
in mature mice 
Ovarian stimulation with rFSH in immature mice did not yield any 
blastocysts. An alternative research group reported a 72% blastocyst rate 
in mature mice of the same strain (Edwards et al., 2005). Therefore we 
repeated the 2.5IU rFSH treatment dose in 8 week old females to assess 
whether the use of immature mice were the reason for embryo 
developmental arrest in our study. Blastocysts still did not develop 
however, indicating an alternative reason is behind the failure to reach 
blastocysts when rFSH alone is used for ovarian stimulation.   
 
Figure A.10: Box plot showing the median proportion of embryos cleaving to the 
2 cell stage, continuing cleavage past this stage and reaching the blastocyst stage 
for the 8 week old female 2.5IU rFSH treatment groups relative to number of 
zygotes collected. Bars represent the inter-quartile range.  
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Appendix 7: Ovarian histology methods 
Collection and fixation of ovarian tissue 
Ovaries were collected simultaneously to zygotes and fixed in Bouins 
solution [(made in house; 25ml of 37% Formaldehyde solution (F1635, 
Sigma-Aldrich), 75ml of 1.3% Picric acid solution (P6744, Sigma-Aldrich) 
and 5ml glacial Acetic acid (A/0400/PB17, Fisher Scientific, Leicestershire, 
UK)] for 24 hours and stored in 70% alcohol until ready to be processed 
using a standardised tissue processing protocol.  
 
Paraffin wax embedding 
Fixed ovaries were dehydrated with a graded series of ethanol (70%, 90% 
and 95% alcohol for 60 minutes in each concentration, and 100% alcohol 
3X, 60 minutes each change) (458600, Aldrich Chemistry), cleared with 
xylene treatment (4X, 60 minutes each change) (X/0250/PB17, Fisher 
Scientific) and embedded in molten paraffin wax (3X, 1 hour 20 minutes 
each change) in an automatic tissue processor (Shandon Excelsior, 
Thermo Scientific, ELECTRON CORPORATION). 
 
Mounting of sections 
Once the tissue was embedded in paraffin blocks (Tissue Embedder, 
TISSUE-TEK III), 5µm thick sections were cut using a rotary microtome 
(Leitz, 1512). Every tenth section was floated on a plate with 50% IMS on 
its surface before being added to a heated water bath set at 45ûC 
(Paraffin Section Mounting Bath, MH8515, Barnstead Electrothermal). 
Multiple sections were subsequently captured by a glass slide (Superfrost® 
Plus, Thermo Scientific). After air drying at room temperature for at least 
1 hour on a slide drying bench, the slides were baked for a minimum of 16 
hours in an oven set at 50ûC (Genlab, Widnes England). 
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Haematoxylin and Eosin staining 
After baking, the sections were deparaffinised by incubation in xylene for 
5 and 2 minutes followed by ethanol (100% ethanol, 2X for 2 minutes, 
90% ethanol, once for 2 minutes and 70% ethanol once for 2 minutes) 
and rehydrated with distilled water (once for 5 minutes). Subsequently, 
sections were stained with haematoxylin by placing the slide holder in 
Harris haematoxylin (3519455S, BDH) for 5 minutes, rinsing with tap 
water until the water ran clear and dipping three times in acid alcohol 
[10ml concentrated hydrochloric acid (HCl, 37%, H/1200PB17, Fisher 
Scientific) was added to 1 litre 70% ethanol]. The stain was developed for 
5 minutes in Scotts tap water [3.5g sodium bicarbonate (S-8875, Sigma) 
and 20g magnesium sulphate (M/1050/53, Fisher Chemicals, 
Leicestershire, UK) added to 1 litre of distilled water] and rinsed again in 
tap water before eosin staining. The slide holder was added to 0.1% Eosin 
yellowish (341972Q, BDH) for 5 minutes before being washed in tap water 
until the water ran clear. This was followed by dehydration in 70% ethanol 
for 2 dips, 90% ethanol for 2 minutes and 100% ethanol 2X for 2 
minutes. Finally, slides were placed in xylene 2X for 2 minutes and cover 
slipped with DPX mounting medium (D/5319/05, Fisher Scientific). After 
overnight drying, the total number of surface CLs for each mouse ovary 
was quantified using bright field light microscopic analysis (Nikon Eclipse 
90i, Nikon Instrument Inc, Derby, UK).      
 
